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As African countries continue to bear the largest global burden of HIV-AIDS, the use 
of Highly Active Antiviral Treatment (HAART) for suppression of viral multiplication is the 
best available treatment option in which one is advised to take a dose at least once a day for 
the rest of his or her life. Of the HIV-infected number people globally, some are well into their 
second decade of treatment with these antiretroviral drugs. Although the survival rates and the 
quality of life for HIV-AIDS patients have been significantly improved by the intervention, 
missing the pills for a number of days unleashes a rapid viral replication. Additionally, some 
patients experience adverse effects which may interfere with their usual daily activities or 
lifestyles, leading to poor adherence for some, thereby posing risks of treatment failure of the 
drugs in use. In other words, with continued treatment interruptions, resistance to these drugs 
may occur. This means there is still no cure for HIV-AIDS, hence the need to consider 
alternatives that may become available through emerging technologies such as genetic 
therapies. 
This research titled “A Utilitarian Assessment of the Relevance of Genetic Therapies 
for HIV-AIDS in Africa, with Special Reference to the Situation in Kenya,” seeks to establish 
if genetic therapies would be suitable for treating HIV-AIDS which affects millions of patients 
in the world, 70% of whom are in Africa. Kenya is among the ten leading countries in Africa 
in the prevalence of HIV-AIDS, hence a review of the country’s healthcare system, especially 
in relation to the problem of HIV-AIDS, including some on-going research. A comprehensive 
review of genetic therapies shows a distinction between somatic and germline genetic therapies 
as different but potentially effective cures for the illness. Special attention has been given to 
CRISPR Cas9 because, so far, it is the only technology close to providing real treatment for 
HIV-AIDS although there is need for caution and further development.  
Based on the ethics theory of utilitarianism, the dissertation concludes that genetic 
therapies are the most appropriate solution to the HIV-AIDS scourge that will have justifiable 
benefit-sharing for the people, with minimum negative consequences. The therapies are most 
likely to turn misery into good health, pain into happiness, and shame into dignity. From a 
utilitarian perspective, when genetic therapies will be made available for the treatment of HIV-
AIDS, the patient will be cured, the descendants of the patient will be prevented from inheriting 
the disease, and future societies will be saved from a deadly disease. Therefore, there is 
sufficient utilitarian justification in investing both technologically and scientifically in the on-
going research into genetic therapies. 
The dissertation recommends that there be 
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 collaborative effort in supporting on-going research into genetic therapies,
 propagating a positive understanding of genetic therapies,
 commitment to using the therapies once fully developed, and
 governments agreeing to take final responsibility with regard to results, whether
negative or positive.
In view of the discussions, findings and recommendations of this research, genetic therapies 




Aangesien Afrika steeds die grootste wêreldwye las van MIV-vigs dra, is die gebruik 
van Hoogs Aktiewe Antiretrovirale Terapie (HAART) vir die onderdrukking van virale 
vermenigvuldiging die beste beskikbare behandelingsopsie, waarin ‘n mens aanbeveel word 
om minstens een maal per dag ‘n dosis te neem vir die res van sy of haar lewe. Van die mense 
wat wêreldwyd met MIV geïnfekteer is, is sommige reeds in hul tweede dekade van die 
behandeling met hierdie antiretrovirale medisyne. Alhoewel die oorlewingsyfers en die 
lewensgehalte van MIV-vigs-pasiënte aansienlik verbeter is deur die ingryping, word ‘n 
vinnige virusreplikasie veroorsaak wanneer die pasiënt die pille vir ‘n aantal dae nie gebruik 
nie. Boonop ervaar sommige pasiënte nadelige gevolge wat hul gewone daaglikse aktiwiteite 
of lewenstyl kan beïnvloed, wat vir sommige tot ‘n slegte nakoming daarvan kan lei, wat die 
risiko vir behandelingsmislukking van die medisyne in gebruik, kan inhou. Met ander woorde, 
met voortgesette behandelingsonderbrekings kan weerstand teen hierdie middels opgebou 
word. Dit beteken dat daar nog steeds geen geneesmiddel vir MIV-vigs is nie, en dus moet daar 
gekyk word na alternatiewe wat beskikbaar mag word deur opkomende tegnologieë soos 
genetiese terapieë. 
Hierdie navorsing, met die titel “’n Utilitêre Beoordeling van die Toepaslikheid van 
Genetiese Terapieë vir MIV-vigs in Afrika, met Spesiale Verwysing na die Situasie in Kenia,” 
wil vasstel of genetiese terapieë geskik is vir die behandeling van MIV-vigs wat miljoene 
pasiënte regoor die wêreld affekteer, waarvan 70% in Afrika is. Kenia is een van die tien 
voorste lande in Afrika in die voorkoming van MIV-vigs. ‘n Oorsig word gebied van die land 
se gesondheidsorgstelsel, veral met betrekking tot die probleem van MIV-vigs, insluitend 
deurlopende navorsing. ‘n Uitgebreide oorsig van genetiese terapieë toon ‘n onderskeid tussen 
somatiese en kiemsel genetiese terapieë as verskillende, maar potensieel effektiewe 
geneesmiddels vir die siekte. Spesiale aandag word gevestig op CRISPR Cas9 omdat dit tot 
dusver die enigste tegnologie is wat naby kom aan die behandeling van MIV-vigs, hoewel 
versigtigheid en verdere ontwikkeling nodig is.  
Deur middel van die aanwending van die etiek-teorie van utilitarisme, kom die 
proefskrif tot die gevolgtrekking dat die genetiese terapieë die mees geskikte oplossing vir die 
MIV-vigs-plaag is wat regverdige bevoordeeldeling vir die mense sal inhou, met die minimum
negatiewe gevolge. Dit is waarskynlik dat die terapieë ellende in goeie gesondheid, pyn in 
geluk en skande in waardigheid kan verander. Vanuit ‘n utilitaristiese perspektief, wanneer 
genetiese terapieë beskikbaar gestel sal word vir die behandeling van MIV-vigs, sal die pasiënt 




samelewings sal gered word van ‘n dodelike siekte. Daar is dus voldoende utilitaristiese 
regverdiging om te belê in die deurlopende navorsing, beide tegnologies en wetenskaplik, van 
genetiese terapieë. 
Die proefskrif beveel aan  
 dat daar gesamentlike pogings aangewend word om deurlopende navorsing oor 
genetiese terapieë te ondersteun,  
 ‘n positiewe begrip van genetiese terapieë bevorder word,  
 ‘n verbintenis tot die gebruik van die terapieë sodra dit volledig ontwikkel is aangegaan 
word en  
 dat regerings instem om finale verantwoordelikheid te neem ten opsigte van resultate, 
hetsy negatief of positief.  
In die lig van die besprekings, bevindings en aanbevelings van hierdie navorsing, word 
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CHAPTER 1: BACKGROUND INFORMATION 
 INTRODUCTION 
The first chapter of the dissertation provides detailed background information on HIV-
AIDS, especially in the context of the African countries where the impact of the disease is 
greatest. The first section gives a brief general background. The second section provides 
statistics about HIV-AIDS in Africa in order to show the effect of the disease on the continent. 
The third section gives information on the infectious disease burden of Africa in general in 
order to set the stage for the gravity of the health situation with HIV-AIDS in focus. The chapter 
also gives the statement of the problem under study, outlines the research methodology, and 
explains the choice and application of the philosophical theory of utilitarianism. The rest of the 
dissertation is built on the issues raised in this chapter. 
 INTRODUCTION TO HIV-AIDS IN AFRICA 
 One of the most devastating attacks on human health in recent decades is HIV-AIDS, 
with consequences not just evident on physical health of an infected person, but also crossing 
over into the socio-economic fabric of societies in the world in general and Africa in particular. 
The stigma and rejection that patients have experienced upon being confirmed to have been 
infected with the virus has caused much psychological and physical damage. HIV-AIDS is 
known to have attacked humanity through its most intimate facet of life, that is, sexuality, 
thereby ensuring total vulnerability. HIV-AIDS is primarily a sexually-transmitted disease that 
attacks the infected person’s immune system and renders it useless for the purposes of fighting 
disease invasions. It is also a generally known fact that, despite the best efforts in scientific 
research, no cure has been developed against the disease. So, whereas remedies, including Anti-
Retroviral Treatments (ARTs), have been developed that suppress the impact on the virus on 
an individual person, and whereas such treatments have become available across the world, 
Africa continues to bear the greatest burden of HIV-AIDS. It is, therefore, of interest for a 
study such as this one to seek to provide, not only an understanding of the disease, but also 
propose alternative scientific solutions to alleviate human suffering on the continent. 
 As part of the background information, a summary of the history of HIV-AIDS is 
relevant. According to the AIDS Institute, “…the earliest known case of infection with HIV-1 
in a human was detected in a blood sample collected in 1959 from a man in Kinshasa, 
Democratic Republic of the Congo. How he became infected is not known. Genetic analysis 




1940s or early 1950s” (The AIDS Institute, 2011). Since then, HIV-AIDS has grown to become 
“…one of the most devastating infectious diseases to have emerged in recent history” (Sharp 
& Hahn, 2011). In an attempt to establish the exact origins of this pandemic, some scientists in 
1999 “…identified a type of chimpanzee in West Africa as the source of HIV infection in 
humans. They believe that the chimpanzee version of the immunodeficiency virus (called 
simian immunodeficiency virus or SIV) most likely was transmitted to humans and mutated 
into HIV when humans hunted these chimpanzees for meat and came into contact with their 
infected blood. Over decades, the virus slowly spread across Africa and later into other parts 
of the world” (The AIDS Institute, 2011). 
 The history of HIV-AIDS in Kenya is as long as that of the illness itself. It has been 
reported that “…in 1982 AIDS was named and vertical (mother to child) and heterosexual 
transmission were scientifically recognised. The following year 1983 a retrovirus was 
identified that was suspected to be the cause of AIDS. The virus was named HIV and World 
Health Organisation (WHO) HIV surveillance started” (Simon, 2014). The first case in Kenya 
was identified in 1984; in 1985 the government established the National AIDS Committee 
(Ibid.). In 1988 “…the Ministry of Health issued guidelines stating that patients should be told 
their HIV status. In 1989, President Moi is said to have ordered the quarantining of people with 
HIV-AIDS but the order was quietly ignored” (Ibid.). The Kenya National AIDS Control 
Council (KNACC) report of 2014 says that by the mid-1990s, HIV-AIDS was one of the major 
causes of mortality in the country, putting huge demands on the healthcare system as well as 
the economy (Kenya National AIDS Control Council, 2014). According to Bruhns, “HIV-
AIDS was declared a national disaster in Kenya in 1999”; this was “15 years after the first 
HIV-AIDS case had been reported in the country… By that time, more than half a million 
Kenyans were estimated to have died of the disease, and some 2.5 million adults were infected” 
(Bruhns, 2006). “HIV prevalence peaked at 10.5% in 1996, and had fallen to 5.9% by 2015. 
This is mainly due to the rapid scaling up of HIV treatment and care” (AVERT, 2017).  
 According to a UNAIDS Report of 2016, “Kenya has the joint fourth-largest HIV 
epidemic in the world (alongside Mozambique and Uganda), in terms of the number of people 
living with HIV, which was 1.5 million people in 2015. Roughly 36,000 people died from 
AIDS-related illnesses in the same year, although this figure is steadily declining from its total 
of 51,000 in 2010” (UNAIDS, 2016). In the same year, there were “660,000 children orphaned 
by AIDS” (Ibid.). It was estimated that “…30% of new annual HIV infections in Kenya are 
among people from key populations such as men who have sex with men, people who inject 




adolescents. This is disproportionate to how many people from these groups exist within the 
population” (AVERT, 2017)). A report of the Ministry of Health says that “geographic location 
is also a factor, with 65% of all new infections occurring in the western regions of Kenya, 
consisting of nine out of the country’s 47 counties” (Ministry of Health, 2014). 
A research focusing on HIV-AIDS may face the unintended risk of HIV 
exceptionalism, also known as AIDS exceptionalism, which refers to the deliberate treatment 
of HIV-AIDS differently from other diseases in both law and policy (Oppenheimer & Bayer, 
2009, p. 988).  
HIV exceptionalists emphasize the human rights of people living with HIV-AIDS, particularly 
their rights to privacy, confidentiality, and autonomy. They also believe that all people seeking 
an HIV test always require special services, such as counseling with every HIV test, special 
informed consent paperwork, and guaranteed anonymity in public health reporting. In many 
places, it is illegal to disclose HIV test results over the phone or over the internet (Veatch, 1997, 
p. 399).  
It is based on the idea that the disease (HIV-AIDS) requires a response above and beyond 
“normal” health interventions.  
It began as a Western response to the originally terrifying and lethal nature of the virus. More 
recently, AIDS exceptionalism came to refer to the disease specific global response and the 
resources dedicated to addressing the epidemic. There has been a backlash against this 
exceptionalism, with critics claiming that HIV-AIDS receives a disproportionate amount of 
international aid and health funding (Smith & Whiteside, 2010, p. 1). 
Despite the criticism against AIDS exceptionalism, the global community must not lose sight 
of the fact that AIDS continues to kill millions of people, the majority of whom live in Africa, 
of which Kenya is a leading host country. It remains without cure and the scientific research 
community must not forget to seek its possible permanent resolution, including and especially 
genetic therapies. In any case, problem solving, especially of global scale, normally requires 
that special attention be given to the specific problem at hand. This applies to widespread 
calamities, emergency rescue, and relief work, and should apply in serious cases such as HIV-
AIDS. When attention is given to a specific problem, even when resources are 
disproportionately allocated to it, the attempt is to solve an issues which, if not given such 
attention, would threaten humanity in a significant way.  
 THE IMPACT OF HIV-AIDS ON AFRICAN SOCIETIES 
 This study reviews the problem of HIV-AIDS in African societies in light of the 
persistent lack of a cure, and assesses whether genetic therapies, which are currently part of 
on-going scientific research, may be a permanent solution to the people of the continent of 
Africa. Besides TB and malaria, HIV-AIDS is the most seriously devastating infectious disease 




of available literature about its impact on African societies. A recent UNAIDS report regarding 
HIV-AIDS in Africa shows that in the year 2013 “…an estimated 24.7 million people were 
living with HIV, accounting for 71% of the global total. In the same year, there were an 
estimated 1.5 million new HIV infections and 1.1 million AIDS-related deaths” (UNAIDS, 
2014). The same report indicates that Southern Africa is the worst affected region “and is 
widely regarded as the epicentre of the global HIV epidemic,” with Swaziland standing at 
27.4% of the country’s total population -- the highest rate in the world -- and South Africa 
having “5.9 million people living with HIV.” It is reported that “…the majority of new HIV 
infections in sub-Saharan Africa occur in adults over the age of 25 years, and that more than 4 
in 10 new infections among women are in young women aged between 15 and 24 years” (Ibid.). 
It is further reported that since 2009 “…there has been a 43% decline in new HIV infections 
among children… from 350,000 to 200,000 in 2013…” (AVERT, 2017) although actual 
decline figures are significantly different when checked per country. According to UNAIDS 
the average “…HIV infection in sex workers in sub-Saharan Africa is 20·5% compared with 
the global median of 3·9%...” (UNAIDS, 2014) of the estimated total number of sex workers. 
Men who have sex with men have an infection rate range of 15% in the countries with lower 
infection rates, all the way to 57% for the countries with higher infection rates like Mauritania 
and Guinea (Ibid.). 
  The HIV infection rates seem not to have changed much in Africa despite treatment 
efforts and prevention campaigns. Between 1981 and 2005, 23 million people had been 
documented to have died from AIDS, out of whom 17 million were Africans (Van Niekerk & 
Kopelman, 2005). By 2005, 39.4 million people lived with HIV, and 25.4 million of them 
(64%) lived in sub-Saharan Africa (Ibid.). Whiteside has outlined many ways through which 
HIV-AIDS affects Africa, noting that 
There is no cure and treatment is inaccessible for the majority of infected Africans due to both 
the cost and lack of health care staff. Impact is felt through the illness (morbidity) and deaths 
(mortality). Most of those who die will be young adults who have completed education, started 
families, and begun working careers (Whiteside, 2005). 
The effects realised in the population are “increased mortality and decreased fertility” (Ibid.). 
The impact on fertility is realised due to the fact that “…infected women are less likely to fall 
pregnant and carry a child to term, and premature mortality means there will be fewer women 
of childbearing age” (Whiteside, 2005). 
 Economics experts have observed that HIV-AIDS negatively affects economic growth 
through its reduction of human capital (Bell, et al., 2003). There is need for properly 




that, apart from their need for medical care, “people living with HIV-AIDS will be unable to 
work” (Greener, 2002). He further reports (Ibid.) that, where infection rates are higher, “the 
epidemic has left behind many orphans cared for by elderly grandparents.” When adult parents 
lose income, or when they die, age profiling becomes difficult in countries, leading to 
difficulties in human resource capacity. As Greener says, AIDS seriously weakens the taxable 
population, thereby putting a strain on government finances and slowing down economic 
development (Greener, 2002). UNAIDS report of 2010 has it that in 2009, “…1.3 million 
Africans lost their lives as a result of AIDS.” In the same year, “…an estimated 14.8 million 
children in Africa were estimated to have lost one or both parents to become ‘AIDS orphans’” 
(Ibid.). Since AIDS is not normally indicated on the death certificates as the cause of someone’s 
death, the numbers here could be seriously underestimated. As Whiteside has observed, 
children orphaned due to HIV-AIDS “…face severe stress, they are less likely to attend school, 
more likely to be exploited and experience premature mortality, and they also have a more 
pessimistic outlook on life” (Whiteside, 2005).  
 Various sub-Saharan countries have experienced the negative effects of the disease in 
various ways and at various levels. By 2015 Botswana had an adult HIV prevalence of 22.2%, 
which was the third highest “…in the world after Lesotho and Swaziland” (UNAIDS, 2016). 
Given that in 2005 the rate had been 25.4%, it may be concluded that Botswana’s commitment 
in responding to HIV-AIDS has borne some fruit. As a result of the country’s treatment 
programme, 
…new infections have decreased significantly, from 15,000 in 2005 to 9,100 in 2013, although 
in recent years they have begun to rise again, with 9,700 reported in 2015. AIDS-related deaths 
have dramatically decreased from the 14,000 recorded in 2005. They fell to 3,200 in 2015 
(UNAIDS, 2016). 
It is worthy of note that “Botswana was the first country in sub-Saharan Africa to provide 
universal free antiretroviral treatment to people living with HIV” (UNAIDS, 2016), thereby 
setting an example to other countries in the region. According to reports in The Guardian 
(Wednesday, 26th November 2008), the scale-up of treatment programmes in both Botswana 
and Namibia between 2000 and 2005 led to the saving of lives, unlike in South Africa where 
“…more than 330,000 people died unnecessarily in South Africa over the period and that 
35,000 HIV-infected babies were born who could have been protected from the virus and would 
probably have a limited life.”1  By comparison, Botswana achieved 85% treatment coverage, 
while Namibia achieved 71% by 2005, and both countries had 70% coverage with mother-to-
                                                          
1 This occurrence in South Africa was really unnecessary, but it happened because of the dire denialism of the 




child transmission programme. “In the case of South Africa, many lives were lost because of a 
failure to accept the use of available ARVs to prevent and treat HIV-AIDS in a timely manner." 
South Africa’s rejection -- of ARVs that came through a donation from the Bill & Melinda 
Gates Foundation -- was informed by the country’s policy of denialism at the time. President 
Mbeki promoted the notion that AIDS was not directly caused by HIV but by economic factors 
such as poverty, arguing that AIDS was not as serious as people thought (Whiteside, 2005). 
This approach in South Africa relegated to the periphery any possible national action on the 
HIV-AIDS scourge, and left it in the hands of a few Non-Governmental Organisations. Lesotho 
seems to have had a similar experience, having the second highest HIV prevalence rate after 
Swaziland. According to UNAIDS, “Lesotho’s HIV prevalence was 22.7% in 2015, and has 
been around this level since 2005” (UNAIDS, 2016). The same report showed additional 
statistics:  
…an estimated 310,000 people were living with HIV in Lesotho and 18,000 died from AIDS-
related illnesses in 2015. However, HIV incidence is declining, from 30,000 new infections in 
2005 to 18,000 new infections in 2015. Lesotho is a small country with a population of just over 
two million. High levels of poverty and inequality due to a struggling economy have left the 
country highly dependent on donors for financial support (UNAIDS, 2016). 
As a result of poverty and HIV-AIDS, life expectancy has dropped to “just 52 for men and 55 
for women” (Ibid.). “Lesotho’s 2014 Demographic and Health Survey (LDHS) reports 
prevalence among women to have increased from 26% in 2004 to 30% in 2014, while 
prevalence among men has remained stable at 19% over the same period” (Ibid.) Cultural issues 
related to strong patriarchy are thought to contribute to this situation.  
 According to an AVERT report, Swaziland leads with an adult prevalence rate of 
28.8%, noting that “…in 2015, 11,000 people were newly infected with HIV, and 3,800 people 
died of an AIDS-related illness” (AVERT, 2017). Although the country has “one of the highest 
rates of antiretroviral treatment coverage in sub-Saharan Africa… at 67%”, the high number of 
individuals living with HIV in Swaziland means “it is still the country’s biggest public health 
concern” (UNAIDS, 2016). It was also reported that, out of the 220,000 persons living with 
HIV in Swaziland, 120,000 were women. Yet Swaziland is only leading by percentage of its 
own population. In terms of real numbers, South Africa leads with “the biggest and most high 
profile HIV epidemic in the world, with an estimated 7 million people living with HIV in 2015” 
(UNAIDS, 2016). In the same year, “there were 380,000 new infections while 180,000 South 
Africans died from AIDS-related illnesses” (Ibid.).  
 A review of the history of HIV-AIDS in South Africa reveals slow progress towards a 




“HIV-AIDS in South Africa Timeline 1940s-2009” in which it reports the first deaths from 
AIDS to have occurred in South Africa in 1985, and that in 1987 “the apartheid government 
recognised that HIV and AIDS had the potential to become ‘a major problem’, even though 
there were few reported infections” (South African History Online, 2017). That was also the 
year in which the African Research and Educational Puppetry Programme (AREPP) was 
founded “as a community-based educational trust… to break down racial, cultural, language 
and educational taboos and barriers on HIV-AIDS…” in South Africa (South African History 
Online, 2017). In 1988 the AIDS Foundation of South Africa was “established as an agency 
seeking to identify and develop initiatives, which reduce the impact of AIDS in under-
resourced communities.” In January 1992 the Department of Health requested the South 
African Law Commission “to investigate how the law relates to HIV-infected persons.” The 
Commission later in 1993 reported that “the Constitutional Act 200 regulates the protection of 
the fundamental rights of the individual and prohibits unfair discrimination against any person 
infected or affected indirectly or directly by HIV-AIDS” (The Guardian, 2008). In 1999 when 
Manto Tshabalala-Msimang became the new Minister for Health (until 2008) AIDS in South 
Africa became a controversial issue because she emphasised on “treating South Africa’s AIDS 
epidemic with vegetables such as garlic and beetroot, rather than with western medicines…” 
(The Guardian, 2008). On the other hand, religious leaders took their campaigns on AIDS to 
the pulpit and other worship places. 
 Between 9th and 14th July 2000 South Africa hosted the 13th International AIDS 
Conference in Durban during which “Nkosi Johnson, an eleven year old HIV-positive boy, 
gave a speech in the opening of the conference and called for the government to give AZT to 
pregnant HIV-positive women” (The Guardian, 2008). At the same conference President Thabo 
Mbeki stressed “the role of poverty in explaining the problems faced by Africa.” In an interview 
with the Time Magazine, President Mbeki said, 
Clearly there is such a thing as acquired immune deficiency. The question you have to ask is 
what produces this deficiency. A whole variety of things can cause the immune system to 
collapse. But the notion that immune deficiency is only acquired from a single virus cannot be 
sustained. Once you say immune deficiency is acquired from that virus your response will be 
antiviral drugs. But if you accept that there can be a variety of reasons, including poverty and 
the many diseases that afflict Africans, then you can have a more comprehensive treatment 
response (The Guardian, 2008). 
This assertion by President Mbeki caused both national and international outcry and confusion 
on the official response of the South African government to the epidemic of HIV-AIDS. In 
October he actually admitted that his statement had caused confusion in South Africa. On 4th 




declaring highlights of poverty, underdevelopment and illiteracy as the main contributing 
factors to the spread of HIV-AIDS” (The Guardian, 2008). The government’s commitment 
remained fairly weak over the years until September 2008 when Thabo Mbeki resigned from 
the Presidency and his immediate successor Kgalema Motlanthe “immediately committed 
government to a concerted and decisive response to the epidemic.”  
 It is in the context of the above information that South Africa’s treatment policy on 
HIV-AIDS took a slow path and took long to become operational. However, in recent years 
South Africa has had “the largest antiretroviral treatments (ART) programme globally and 
these efforts have been largely financed from its own domestic resources. The country now 
invests more than $1.5 billion annually to run its HIV and AIDS programmes” (UNAIDS, 
2016). In 2013, an estimated 360,000 children aged 0 to 14 were living with HIV in South 
Africa (Ibid.). 
 The rest of sub-Saharan Africa fares no better. UNAIDS reports that “…an estimated 
60% of new infections in western and central Africa in 2015 occurred in Nigeria,” a country 
that had “3.5 million people living with HIV in the same year” (UNAIDS, 2016). In Malawi, 
“an estimated 980,000 people were living with HIV in 2015 and 27,000 Malawians died from 
HIV-related illnesses” (Ibid.). The same report says “that young people account for 50% of 
new HIV infections in Malawi” (Ibid.). In Tanzania in the same year “…1.4 million people 
were living with HIV, while 54,000 people were newly infected… and 36,000 people died from 
an AIDS-related illness” (AVERT, 2017). The heavier burden is on the women population, out 
of whom 780,000 aged 15 years and above live with HIV. In Uganda about 1.5 million people 
were living with HIV in 2015, while there were 28,000 deaths from AIDS-related illnesses 
(UNAIDS, 2016). There were “1.2 million people in Zambia living with HIV in 2015” when 
“55,000 adults and 5,000 children became newly infected” (Ibid). Out of the 1.2 million people, 
640,000 were women. Zimbabwe stood at “1.4 million people living with HIV in 2015, 
including 77,000 with new infections at 64,000 and AIDS-related deaths at 29,000.” The 
number of women living with HIV was about 790,000 in Zimbabwe (Ibid.). 
 Discussions about HIV-AIDS causes reflections of some of the world’s past epidemics, 
perhaps the worst of which were the Black Death of the 14th century and the Flu Epidemic of 
1918-1919, both of which wiped out huge sections of the world’s population. According to 
Britannica Online Encyclopaedia, Black Death originated in China and Inner Asia in 1347, 
from rat fleas living on black rats that lived on merchant ships, before swiftly moving into parts 
of Europe. According to Alchon, “the Black Death is estimated to have killed 30-60% of 




population from an estimated 450 million down to 350-375 million in the 14th century” 
(Alchon, 2003). The devastation of Black Death can be deduced from the following 
explanation: 
The Black Death arrived in Europe by sea in October 1347 when 12 Genoese trading ships 
docked at the Sicilian port of Messina after a long journey through the Black Sea. The people 
who gathered on the docks to greet the ships were met with a horrifying surprise: most of the 
sailors aboard the ships were dead, and those who were still alive were gravely ill. They were 
overcome with fever, unable to keep food down and delirious from pain. Strangest of all, they 
were covered in mysterious black boils that oozed blood and pus and gave their illness its name: 
the Black Death. The Sicilian authorities hastily ordered the fleet of “death ships” out of the 
harbour, but it was too late. Over the next five years, the mysterious Black Death would kill 
more than 20 million people in Europe – almost one-third of the continent’s population 
(History.com Staff, 2010). 
There seems to be variance of figures from one historical source to another. The Norwegian 
historian Ole Benedictow gives an estimate of 50 million people (which may have been 60% 
of Europe’s population at the time) to have died of the Black Death (Benedictow, 2005). There 
was evidence of desperation in the reactions of the people. It is reported that “…healthy people 
did all they could to avoid the sick. Doctors refused to see patients; priests refused to administer 
last rites. Shopkeepers closed stores. Many people fled the cities for the countryside, but even 
there they could not escape the disease. It affected cows, sheep, goats, pigs and chicken as well 
as people” (History.com Staff, 2010). It seems the situation was worsened by the fact that “no 
one knew exactly how the Black Death was transmitted from one patient to another…” 
(Benedictow, 2005). Black Death was indiscriminate in its attack, killed with speed, and left 
grievous devastation behind it.  
 In modern history, there was the influenza epidemic, which was also known as the flu 
epidemic or the Spanish Flu, from 1918 to 1919. It is reported to have “infected an estimated 
500 million people worldwide – about one-third of the planet’s population at the time – and 
killed an estimated 20 million to 50 million victims” (History.com, 2010). Billing says, “More 
people died of influenza in a single year that in four years of the Black Death Bubonic Plague 
from 1347 to 1351” (Billings, 2005). This disease attacked the human population 
indiscriminately. The symptoms are described as follows: 
Influenza, or flu, is a virus that attacks the respiratory system. The flu virus is highly contagious: 
When an infected person coughs, sneezes or talks, respiratory droplets are generated and 
transmitted into the air, and can then be inhaled by anyone nearby. Additionally, a person who 
touches something with the virus on it and then touches his or her mouth, eyes or nose can 
become infected (History.com Staff, 2010). 
In mild stages, victims experienced “chills, fever and fatigue”; in stronger waves, “their skin 
turned blue and their lungs filled with fluid that caused them to suffocate…” (Ibid.). According 




years old, and 65 years and older. The high mortality in healthy people, including those in the 
20-40 year age group, was a unique feature of this pandemic.” Apparently, modern science is 
yet to adequately explain the properties that made the virus so destructive within such a short 
time. 
 It may be concluded that, while the Black Death Plague had been bacterial in nature, 
the influenza pandemic was viral. And while the Black Death had progressed from one place 
to another for almost five years, the flu epidemic struck instantly in several places almost at 
the same time. Also, whereas age had not been a relevant factor in the Black Death attacks, it 
was a factor observed in the flu epidemic. Both epidemics can be contrasted with HIV-AIDS. 
One of the worst aspects of HIV-AIDS is that, unlike the other two epidemics, it targets a 
specific age group of the human population – the ages between 18 and 35 -- exactly the group 
that is economically most active and productive, whereas the other epidemics had been 
generally hitting indiscriminately. 
 From the UNAIDS statistics reviewed earlier, it becomes clear that the disease burden 
of HIV-AIDS is overwhelming for African countries. As Boutayeb observes, “AIDS does not 
only cause sickness, incapacity or death of workers, and severe emotional and economic 
upheavals for families; it also increases the cost of doing business” (Boutayeb, 2009). Boutayeb 
continues, “It (HIV-AIDS) has also continued to diminish the chances of alleviating poverty 
and hunger, achieving universal primary education, promoting gender equality, reducing child 
and maternal mortality, and ensuring environmental sustainability” (Boutayeb, 2009). In many 
countries of Africa the negative effects of HIV-AIDS are evident in the health care sector: 
Some of the most affected countries have lost more than 15% of their healthcare workforce due 
to AIDS and, in many other countries, midwives and health workers are living with HIV. It 
should also be stressed that the HIV-AIDS epidemic worsens the situation of other diseases like 
cardiovascular diseases, diabetes and tuberculosis. For instance, 80% of tuberculosis patients 
are HIV positive in countries with high prevalence of HIV (Boutayeb, 2009). 
The point raised by Boutayeb on the relationship between HIV and TB may be explained by 
the statement from the AIDS Centre that “TB is the leading cause of death among HIV infected 
people; the WHO estimates that TB accounts for up to a third of AIDS deaths worldwide. When 
someone is infected with TB, the likelihood of them becoming sick with the disease is increased 
many times if they are also HIV-positive” (UNAIDS, 2002-2010). This line of thought is 
supported by CDC (2016) whose report says, “People living with HIV are more likely than 
others to become sick with tuberculosis (TB). This is because HIV weakens the immune 




Boutayeb’s statement with regard to the big percentage of TB patients being at the same time 
HIV-positive in countries with high prevalence of HIV should raise concern. 
 The situation may be considered desperate if evaluated in the context of generally poor 
economic power of many African countries, thereby not prioritising the challenges posed by 
HIV-AIDS. One such grim picture is portrayed by Van Niekerk in his work ‘Moral and social 
complexities of AIDS in Africa’ as follows: 
The fact of the matter is that sub-Saharan Africa generates no more than one per cent of the total 
wealth produced in the world. The buying power of all the countries south of the Sahara, 
excepting South Africa, in total just about matches that of a country such as Norway. The 
developed world can no longer ignore the fact that Africa is the home of ten per cent of the 
world’s population, lives on one per cent of the global economy, and carries 70 per cent of the 
world’s HIV-AIDS burden. Furthermore, annual per capita expenditure on health care is less 
than US$10 in many African countries, as compared with between US$2000 and $4200 in 
industrialised nations (Van Niekerk, 2005). 
In other words, the burden is such that the developed nations can no longer ignore the HIV-
AIDS burden for Africa. There is a call for a global approach to seeking and finding solutions 
to the problem. Such a global approach will necessarily require collaboration among nations at 
government level, and among scientists and researchers at institutional and individual levels as 
well. 
 Controlling HIV-AIDS remains a major challenge in Kenya where new infections 
continue to rise. According to AVERT, in June 2014, the Ministry of Health published a report 
called Kenya HIV Prevention Revolution Roadmap, in which the government explained its aim 
of strengthening prevention, hoping to reduce new infections to zero by the year 2030 
(AVERT, 2017). According to an official report from the National AIDS Control Council, 
“…Kenya has an average HIV prevalence of 6%, with about 1.6 million people living with 
HIV infection” (Kenya National AIDS Control Council, 2014). This makes Kenya one of the 
six “high burden” countries in Africa, the others being Swaziland, South Africa, Lesotho, 
Botswana, and Mozambique. The report further reveals that counties2 in the western part of 
Kenya, such as “Homa Bay, Siaya, and Kisumu are the most affected with HIV with rates of 
25.7%, 23.7%, and 19.3% respectively,” followed closely by the neighbouring Migori and Kisii 
at 8% and 7.6% respectively (Ibid.). Ironically, the same report indicates that in these five 
counties ART is being received by about 65% of the adult individuals who should receive it, 
far less than the expected 97%. Recent reports from the Global Burden of Disease showed that 
“Kenya had the fastest-growing number of new HIV infections in sub-Saharan Africa in the 
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counties specifically mentioned here as leading in HIV infections are of interest to me because their ethnic 




last decade… between 2005 and 2015, the number of new HIV cases grew by an average of 
7.1 per cent per year… one of the highest in the world” (Muchangi, 2016). This makes it 
possible to conclude that, given the numbers and the ages involved, HIV remains a serious 
threat to the people of Kenya, the efforts against the pandemic notwithstanding.  
 The situation discussed above should cause the government and other stakeholders to 
invest additional effort and resources into preventing new infections, besides carrying out 
treatment and care for those already infected. That is one way of seeking to solve or resolve 
the problem. Another way is that the situation should also cause policy-makers to support new 
research to move into the direction of seeking to develop relevant genetic therapies for HIV-
AIDS. In human history there have been devastating diseases which have been effectively 
turned preventable through the development and application of medical vaccines which make 
the human body resistant to either the bacteria or the virus that causes the disease. It can be 
argued that a vaccine is a form of changing the capacity of the human body to respond to a 
source of potential harm, hence it is a form of modification. Vaccines do not change the 
structure of genes in the body; rather, vaccines alter and enhance the capacity to react in a 
certain way. This is how medical science has controlled polio, smallpox, and yellow fever. The 
Kenya AIDS Vaccine Initiative (KAVI) was established with the goal of developing a vaccine 
for HIV-AIDS, and has carried out reasonable research into the matter. However, in recent 
years, KAVI has diverted its attention to other issues other than the AIDS vaccine. But perhaps 
the original focus can be recovered. Or maybe there is need to think beyond the possibility of 
a vaccine, and start thinking of the possibility of genetic enhancement therapies, some of which 
have already been developed, and are undergoing trials, in the developed world. The possibility 
exists for human genes to be scientifically modified and enhanced to possess capacity to resist 
infection from HIV.  
 THE IMPACT OF INFECTIOUS DISEASES ON AFRICAN SOCIETIES 
 The transmission and control of communicable diseases continue to pose major 
economic and health challenges to nations in sub-Saharan Africa. Recent studies revealed that 
infectious diseases increased in rates during economic recessions due to “…infectious contact 
under poorer living circumstances, worsened access to therapy, or poorer retention in 
treatment” (Suhrcke, et al., 2011). Although the study was worldwide, its negative conclusions 
focus strongly on Africa where it identified “…certain high-risk groups, including migrants, 
homeless persons, and prison populations, as particularly vulnerable conduits of epidemics 




identification of “16 new infectious diseases… in the past two decades…” between 1990 and 
2010 by the United States National Institutes of Health (Fonkwo, 2008). Although smallpox 
and poliomyelitis had been more or less removed from nature, many infectious diseases 
continue to afflict human societies. This is because “…microbes have shown a tenacious ability 
to adapt, re-adapt, survive, and challenge the human ingenuity” (Ibid.). In sub-Saharan Africa 
particularly, the challenge seriously affects various sectors of national and societal life, 
including loss of qualified human resources due to HIV-AIDS, tuberculosis (TB), and malaria. 
As Fonkwo points out, “…these and other infectious agents not only take an enormous physical 
toll on humanity, but also cause significant economic losses both directly in the developing 
world and less directly in the developed world” (Fonkwo, 2008). 
 The problem of infectious diseases is not only a public health problem; it is also an 
economic one, which needs “an internationally coordinated strategy to fight… or at least bring 
under control” (Fonkwo, 2008). One would have thought that the challenge of such diseases 
would be easy to solve by simply eliminating the “…pathogens and their vectors from their 
natural hosts” (Ibid.). But Fonkwo explains that 
Pathogens constantly change their genetic make-up, which challenges the development of 
vaccines against infectious diseases. This genetic flexibility allows many infectious agents to 
mutate or evolve into more deadly strains against which humans have little or no resistance: the 
HIV and influenza viruses, for example, constantly mutate and recombine to find their way 
through the host defence mechanisms (Fonkwo, 2008). 
The complex behaviour of the pathogens necessitates international scientific collaboration in 
order to develop viable permanent solutions. Evidently, there is need for scientific explanations 
on the mutations of pathogens in relation to infectious diseases in order to develop appropriate 
control systems.  
When humans live in close contact with animals, pathogens are sometimes able to change hosts 
and infect humans. The new host – in this case a human – is often not as adapted to these zoonic 
diseases as the original host. The past outbreaks of avian influenza, severe acute respiratory 
syndrome (SARS), hanta-virus, Nipah virus, and the HIV epidemic were all due to pathogens 
that were normally found in animals, but which subsequently found a new, susceptible host in 
humans (Fonkwo, 2008). 
The lesson in this phenomenon is that, when infectious conditions are not properly addressed 
at their earliest possible stages to prevent escalation, the negative impact can have serious 
global consequences, some of which may take decades to resolve. This is confirmed by a recent 
Harvard research report3 which pointed out that “…while modern medicine and technology 
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have diminished the threat of many infectious disease pathogens in high-income countries, 
infectious diseases account for more than 17 million deaths worldwide every year. A significant 
number of those deaths occur in sub-Saharan Africa” (Harvard Research Report, 2015). The 
research concluded that “…while sub-Saharan Africa bears the burden of most major infectious 
disease pathogens, the prevention and control of new outbreaks is a global problem that 
requires global cooperation” (Harvard Research Report, 2015). This conclusion reinforces the 
need for collaborative research at the global level, with strong networks between scientists from 
Africa and those from Western research institutions. 
 The most prevalent infectious diseases are malaria, tuberculosis (TB), and HIV-AIDS, 
although there are numerous others in existence as well. The Centre for Disease Control (CDC) 
reports that “…approximately half of all deaths caused by infectious diseases each year can be 
attributed to just three diseases: tuberculosis, malaria, and AIDS. Together, these diseases 
cause over 300 million illnesses and more that 5 million deaths each year” (CDC, 2017). The 
report says that many infectious diseases are “endemic to developing countries” due to the fact 
that medical care largely remains inaccessible, unaffordable, or ineffective, among other 
factors. In the case of malaria, for example, although it “…is found in 90 countries of the 
world… 90% of all cases are found in sub-Saharan Africa” (Ibid.). The report (Ibid.) further 
states that “…in 2015 an estimated 214 million cases of malaria occurred worldwide and 
438,000 people died, mostly children in the African Region.” CDC describes the symptoms of 
malaria: 
The first stage consists of shaking and chills, the next stage involves high fever and severe 
headache, and in the final stage the infected person’s temperature drops and he or she sweats 
profusely. Infected people also often suffer from anaemia, weakness, and a swelling of the 
spleen (CDC, 2017). 
It may be calculated that, going by the estimate that 90% of the 214 million malaria infections 
in the world in 2015, more than 192 million occurred in sub-Saharan Africa. The disease burden 
for the continent, even from malaria alone, is disproportionately heavy, and should be cause 
for global concern. 
 The impact of malaria on women is worthy of review, since, as Gerberding (2004) 
explains, it causes “…serious illness in pregnant women and children below 5 years of age… 
mostly in Africa.” She further explains: 
Pregnant women suffer decreased immunity to malaria, which more than doubles their chances 
of contracting and dying of the disease. Pregnant women who contract malaria have an increased 
risk for severe maternal anaemia. The consequent impaired foetal growth contributes to low 
birth-weight in new-borns. Malaria during pregnancy causes as many as 10,000 maternal deaths 
each year, 8%-14% of all low birth-weight babies, and 3%-8% of all infant deaths in certain 





The continued negative impact of malaria on women in sub-Saharan Africa is, in the long run, 
a threat to the population of the continent. 
 The tuberculosis (TB) bacteria often affect lungs, and lead to pain in the chest and 
bloody coughs. “Other symptoms of the disease include fatigue, weight loss, appetite loss, 
chills, fever and night sweats” (CDC, 2017).  In South Africa a study of 618 TB patients 
established that TB patients bore a heavy burden in diagnosis and treatment, such that 
Patients incurred the greatest share of TB episode costs (41%) prior to starting treatment, with 
the largest portion of these costs being due to income loss. Poorer patients incurred higher direct 
costs during treatment than those who were less poor… Indirect costs accounted for 52% of total 
episode cost (Foster, 2015).  
These challenges are prevalent, despite the fact that South Africa provides free TB diagnosis 
and treatment (Ibid.), and despite South Africa running one of the strongest economies on the 
continent. The researchers in this case warned that this state could drive up what they called 
“the medical poverty trap” where medical costs far exceed income levels (Foster, 2015). A 
similar study across Africa concluded that “…the costs for hospitalization, medication, 
transportation, and care in the private sector were the largest” for TB patients (Barter, et al., 
2012). Since “…the patient costs incurred commonly amounted to 10% or more of per capita 
incomes…”, it is important for governments to develop “… policies to decrease direct and 
indirect TB patient costs… to prevent poverty due to TB treatment and care for those affected 
by the disease” (Barter, et al., 2012). 
 TB is a killer disease in Africa. In 2009, “…tuberculosis (TB) was the world’s 7th 
leading cause of death, resulting in 1.7 million deaths worldwide, more that 9.4 million new 
infections, and 14 million prevalent cases” (Barter, et al., 2012). It was further reported that 
“…26% of all TB cases are in sub-Saharan Africa” where poor communities are also the most 
vulnerable due to “…overcrowded living or working conditions, poor nutrition, smoking, 
alcoholism, diabetes, exposure to indoor air pollution, and HIV…” (Ibid.) combine in various 
measures to further complicate the situation. The vicious cycle then persists because TB, in 
turn, contributes to poverty by reducing labour productivity, as patients now lack physical 
strength and ability to work in order to contribute to the family, community and the nation’s 
economy. 
 Infectious diseases affect African peoples in a variety of ways. Fonkwo who reports 
that the “…misuse and overuse of antibiotics is eroding our ability to control common 
infections. Many bacteria have become resistant to even the most powerful antibiotics or 




useless” (Fonkwo, 2008). Fonkwo, quoting a WHO report of 1999, notes that 68% of deaths in 
Africa in 1999 had been due to infectious diseases, adding that 
…TB prevalence – a good indicator of overall quality of life – correlates strongly with political 
instability, even in countries that have already achieved a measure of democracy. The severe 
social and economic impact of infectious diseases is likely to intensify the struggle for the 
political power to control scarce resources. Health must therefore be regarded as a major 
economic factor and investments in health as a profitable business (Fonkwo, 2008). 
In other words, part of Africa’s political instability is caused by desire to control scarce 
resources, including resources useful for the control of infectious diseases in societies. TB 
affects working hours in “…the formal and informal economies, as well as within 
households…” The loss is estimated to be the equivalent of between 3 and 4 months of work 
time for each patient each year, and 20% to 30% of household income. Fonkwo says, “Families 
of people who die from the disease (TB) lose approximately 15 years of income.” Similarly, 
families in Africa “spend up to 25% of income on malaria treatment, with infected children 
suffering cognitive damage and anaemia” (Fonkwo, 2008). 
 The future impact of infectious diseases has been predicted to be dependent on three 
variables: 
…the relationship between increasing microbial resistance and scientific efforts to develop new 
antibiotics and vaccines; the future of developing and transitional economies, especially with 
regard to improving the basic quality of life for the poorest people; and the success of global 
and national efforts to create effective systems of surveillance and response (Fonkwo, 2008). 
These variables will determine how infectious diseases affect humans. On the one hand, it is 
quite possible that there will be “significant improvements in health care and medical 
research…” such that “infectious diseases will be replaced by non-infectious diseases such as 
diabetes, heart disease and cancer, as major health challenges” (Fonkwo, 2008). On the other 
hand, poverty and infectious diseases may combine effort, and viruses may spread throughout 
populations “…as a result of increased resistance to multi-drug treatments and the 
unavailability of expensive treatments in developing countries, which face the majority of the 
problem” (Fonkwo, 2008). The better option would be for better planning and the investment 
of finances into programmes that will help prevent and control infectious diseases through the 
use of new medicines and vaccines.  
 RATIONALE FOR THE STUDY 
 HIV-AIDS continues to pose major threats to human life and health in sub-Saharan 
Africa, with casualties persistently increasing despite efforts in medical science aimed at 
finding effective treatments. New infections continue to occur, and people continue to suffer, 




countries seek to find solutions to the challenges that arise from HIV-AIDS, the severity of the 
shortage of resources leads governments into justifying resource allocations to apparently more 
common, urgent and effectively treatable problems, such as malaria, tuberculosis, bilharzias, 
typhoid, cholera, and reproductive health issues. It is still argued that investment in HIV-AIDS 
research remains a luxury that Sub-Saharan African governments cannot afford out of their 
own inadequate budgets. Generally, expenditure on AIDS in Africa remains an issue of 
concern. Most African countries receive funding from Western donors in order to support HIV-
AIDS programmes, including research. It is reported that “… the three upper-middle-income 
countries (Botswana, Namibia, and South Africa) are the only ones to fund most of their AIDS 
programmes from domestic sources. Nigeria and Kenya contribute about 20% of their total 
national AIDS spending, whereas all other countries account for less than 15% of the total. 
Excluding the three upper-middle-income countries, external funding covers an average of 
87% of all AIDS spending in Africa. This emphasises the heavy dependence of the high-burden 
by low-income African countries on donor aid” (Resch, et al., 2015). In the case of Kenya, 
specifically, “…external resources continue to dominate HIV-AIDS financing” (UNAIDS, 
2016). A UNAIDS report stated that international “… organizations accounted for over 56% 
of funds. The public sector agents accounted for between 25% and 27% while local private 
organizations managed between 16% and 19% of the total funds” (UNAIDS, 2014). And these 
are general figures that include treatment, advocacy, administrative support, as well as 
research. Therefore, it is reasonable to conclude that, given the lack of internal financial support 
within Africa, for a huge undertaking like genetic research, they would rather wait until a 
scientific solution is found in Western countries; even then, there is likely to be a tendency to 
wait until cheaper provisions become available.  
 Evidently, the HIV-AIDS malady remains a great threat to health in sub-Saharan 
Africa. Presently governments in Africa remain focused on prevailing treatment and prevention 
options. When the developed countries have moved ahead to modern technological 
interventions, Africa remains inhibited by a perennial lack of resources to invest in such 
technologies. As van Niekerk observes, this reveals “…a kind of exclusion from the advantages 
of modern medicine”, a situation he fears might reinforce prejudice against the continent (Van 
Niekerk, 2014). But we need to ask, what kind of technologies should Africa seek? Well, the 
answer, or at least a significant part of it, lies in genetic therapies, especially those that also 
promote enhancement. In the developed countries, genetic science now holds the promise of 




infections. As research develops in this regard, it may seem wise for governments in Africa to 
invest some of their resources in the scientific efforts towards a solution. 
 Research in the developed countries is currently creating the hope that genetic therapy 
for HIV-AIDS is possible, and may soon be a common reality. For example, “…in 2012, HIV 
patients treated with genetically modified T cells” were reported to have remained “healthy up 
to 11 years after initial therapy” (Colovos, et al., 2012). This was a result of the work of 
scientists from the Perelman School of Medicine at the University of Pennsylvania who 
released their report in the Science Translational Medicine. “The results provided a framework 
for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, 
and a wide variety of other diseases. The patients showed long term persistence of the modified 
T cells in their bodies” (Colovos, et al., 2012). Presently, patients have access to anti-retroviral 
therapy for their lifetime, a treatment that remains expensive and often comes with adverse side 
effects. With this new genetic modification and therapy, there is potential for both curative and 
preventive approaches to the problem. Apart from enhancement therapies, there is also the new 
technology known as “clustered regularly interspaced short palindromic repeats (CRISPR),” 
which can change the genetic code of cells in an HIV-positive patient, thereby providing 
treatment. Scientists have reported that technologies for editing genes, “…including 
CRISPR/Cas9, now offer us the ability to directly modify or correct the underlying disease-
associated changes in our genome. Successfully editing or correcting a gene that encodes the 
dysfunctional or missing protein can in principle result in the expression of a fully normal 
protein and full correction of the disease” (CRISPR Therapeutics, 2015). Through this new 
technology, there is potential for a cure for AIDS. Therefore, research in genetic therapies must 
necessarily include this dimension as well, and will receive attention in this research at a later 
stage.  
 For the Kenya government and other governments in Africa to consider allocating 
scarce resources to the proposed research into enhancement therapy for HIV-AIDS, there is 
need for acceptable justification for such an effort. Given the presumed expensive nature of 
scientific research, even for the developed countries, there is need for collaboration, not just at 
individual and institutional level, but among nations as well. Professor Sir Kenneth Calman4 
acknowledges that “…eighty per cent of the world’s population lives in developing countries, 
                                                          
4 Professor Sir Kenneth Calman, while serving as Vice-Chancellor and Warden, University of Durham, UK, was 
the Chairman of the Working Party of the Nuffield Council on Bioethics (2002 - 2012), which was funded jointly 
by the Medical Research Council, the Nuffield Foundation, and the Wellcome Trust. The Council’s official report 




where both healthcare and research related to healthcare are severely constrained by limited 
financial and human resources and by the lack of appropriate infrastructure to deliver 
healthcare” (Calman, 2012). Furthermore, health has many determinants, which “…include 
social, cultural, economic, and environmental factors, genetic variation, and the quality of 
healthcare available. Research into these factors is an essential component of improving health 
and healthcare in developing and developed countries alike” (Ibid.). As Van Niekerk explains, 
“…Africa is the home of 15% of the world’s population, lives on 1% of the global economy, 
and carries 70% of the world’s HIV-AIDS burden” (Van Niekerk, 2014). He draws a contrast 
with the United States which spends more than “50% of the total health care expenditure in the 
world,” yet the US contains “only 5% of the world’s population” (Ibid.). Van Niekerk says, 
“Given Africa’s resources crisis, ideas about the possibility of all kinds of genetically induced 
personal enhancements are far removed from the urgent and immediate health care realities 
that policy makers have to face on a daily basis, given the prohibitive costs that such research 
or technologies might imply” (Ibid.). Western nations, with their advanced technology in 
medical science, especially genetic engineering, should consider it part of their human 
responsibility to contribute towards the alleviation of HIV-AIDS in Africa. It is an engagement 
in benevolence and distributive justice at the same time. 
In this research, the appropriateness of genetic therapies for the treatment of HIV-AIDS 
and alleviating the burden created by the disease is investigated, with a view to encouraging 
the Kenya government and other African governments, together with their partners from the 
developed world, to carry out research on these technologies and develop them for the benefit 
of the majority of Africans. Genetic therapies are proposed in the context of the present reality 
of having no known cure for HIV-AIDS in the whole world. The ARVs in use are not a cure 
but are a means of reversing the symptoms in order to prolong the life of an infected person. 
The ARVs do not remove the virus from the body and are, in this sense, only a temporal 
response. Results of recent scientific research show that combined antiretroviral therapy 
(cART) never eradicates HIV, but that the virus “persists for years and can re-establish 
replication if treatment is stopped” (Nolan, et al., 2018). It was found out that “the spleen is an 
HIV-1 during combined antiretroviral therapy” (Ibid), which means that once the virus hides 
in the spleen it cannot be affected by ARVs, and the virus then continues to re-infect the body 
through the circulation system. In other words, as soon as treatment is stopped, the plasma viral 
loads rebound. This idea is supported by Rose, et al, who explain that  
While combined antiretroviral therapy (cART) can result in undetectable plasma viral loads, it 
does not eradicate HIV infection. Furthermore, HIV-infected individuals while on cART remain 




and atherosclerosis, suggesting that during cART, tissue-based HIV may contribute to such 
pathologies (Rose, et al., 2016). 
 
We can safely conclude that cART, while effective in reducing the plasma HIV to very low 
levels, is not able to get rid of infection from the body. In their research, Rose, et al, used high-
resolution evolutionary analyses and found out that “tissue-based HIV continues to replicate, 
evolve, and migrate among tissues during cART.” They also concluded that 
…significant HIV comorbidities, including cancer, lipid disorders, and neurological diseases, 
develop in cART-treated (cART) patients at a higher rate than in the general population, despite 
fully suppressed VL (viral load) and restored immunity. Of the major HIV-related 
comorbidities, cancer is the leading cause of death for HIV-infected (HIV), cART-treated 
patients (Rose, et al., 2016). 
From the foregoing, it is apparent that ARVs are working only to the extent of suppressing 
viral load and restoring immunity against opportunistic infections, thereby alleviating 
suffering, but does not cure the disease. In fact, suffering sets back right in as soon as treatment 
lapses, a situation that puts the patient at greater risk than before. ARVs are not effectively 
containing the virus. What looks like a solution is actually not a solution at all to the problem 
of HIV-AIDS. If Africa in general, and Kenya in particular, is going to continue to rely on 
ARVs for dealing with the scourge, there is going to be continuity in the spread and negative 
impact on the population. This is precisely why there is need for genetic therapies as a 
permanent solution for HIV-AIDS.  
The research needs to be done in one of the countries with the leading rates of infection, 
of which Kenya is a significant part. Since Kenya, as an integral part of Sub-Saharan Africa, 
continues to record higher levels of new infections, besides bearing the burden of loss of young 
and middle-aged population, there is need for a solution that can effectively and safely prevent 
the human body from receiving and hosting the virus in the first place. Such a solution would 
not only prevent human suffering and degradation, but also significantly lower the socio-
economic impact of HIV-AIDS on the continent. The proposal in this study is that the solution 
may be best found in genetic therapies. Given that the virus remains prevalent without a real 
cure, and given that it affects the working and productive population in Africa, a remedy should 
be found which leads to great benefit to the infected and the affected people, while at the same 
time providing economic and health relief to African nations. The solution should bring relief 
to the suffering and save future generations from the disease burden. In order to maximise 
health and economic benefits to the people and the countries, while also minimising suffering 
and pain by preventing recurrence of the disease, I have chosen to address the problem by the 




fourth chapter of this dissertation is dedicated, although the sixth section of this first chapter 
makes a preliminary discussion as well.  
 PROBLEM STATEMENT 
 The central problem that this dissertation wishes to address, is whether genetically 
based enhancement therapies ought to be optimally pursued in Africa’s (with special reference 
to Kenya’s) struggle to overcome the human suffering and destruction caused by HIV-AIDS. 
Such a problem statement in turn raises the question of whether it is justifiable for an African 
country such as Kenya to allocate a significant amount of its limited intellectual and material 
resources to this kind of research, and if another model of co-operation with the West for 
realising the goal of fighting HIV-AIDS in this manner is not rather called for. As has been 
pointed out, there are very encouraging signs in Western countries that research on genetically 
based HIV-AIDS remedies can be highly beneficial to persons living with HIV-AIDS, and thus 
to the societies that must support them. Is this the way to go in terms of curative or preventive 
HIV research in the future, and if so, to what extent ought African countries become involved 
in this kind of research? If not, what is a better model for seeking a medical and social solution 
to the HIV pandemic? In other words, the question arises as to the wisdom or otherwise of 
paying more attention to research on enhancement, despite the huge costs involved, or treating 
what is treatable with the little funds available. Whichever choices are made, would they bring 
more benefits to the peoples of Africa, or would their benefits be minimal? 
 Let me elaborate a little on the issue as to who should do the research. Should the 
research be carried out in Africa by African scientists? It is well known that, with the possible 
exception of South Africa, research facilities in the rest of Africa are few and under-resourced, 
and that human research capacity is quite limited. The alternative may be to leave the actual 
research in the hands of the developed countries, where resources for scientific research are 
already strong and generally well-funded. But this will remove the research from the context 
in which the disease burden has the biggest impact. Consequently, it may create challenges in 
attempting to ensure that the benefits of the research actually come to Africa. There seems to 
be a need for collaborative research between the resource-strong Western institutions and 
countries on the one hand, and the resource-scarce African institutions and states. 
 In reflecting on this issue, a number of related problems present themselves. The first, 
inevitably, has to do with the general moral justification of enhancement therapies as such. In 
this regard, Alberto Giubilini and Sagar Sanyal, in their article “The Ethics of Human 




“…include whether specific types of enhancement are permissible or even obligatory, whether 
they are likely to produce a net good for individuals and for society, and whether there is 
something intrinsically wrong in playing God with human nature” (Giubilini & Sanyal, 2015). 
They characterize the main camps in this debate as permissive, restrictive and conservative. 
There are contributors who hold that the “most permissive positions have no objections to a 
wide range of enhancements,” some of which “…are not merely permissible but even morally 
obligatory” (Giubilini & Sanyal, 2015). On the opposing side are the objections, in principle, 
to any kind of biomedical enhancement, motivated by a range of arguments, including the 
alleged inviolability of “human nature” as a (again, allegedly) “moral desideratum”.  
 On this same issue, Savulescu and Bostrom, in their edited volume Human 
Enhancement, propose that a pro-enhancement position can be supported by highlighting the 
continuity between the “new controversial enhancement methods and the old accepted ways of 
enhancing human capacities” (Savulescu & Bostrom, 2009). In this argument, all of 
“…technology can be viewed as an enhancement of human capacities” (Ibid.). Education and 
training could fall into the same category. Their view is opposed by Leon R. Kass who warns 
“…that biotechnology may eventually be used as a substitute for virtue, hard work, study, or 
love” (Kass, 2003). “His concerns about biotechnology stem from what he calls ‘the 
technological disposition’ which transforms the meaning and character of human life by 
believing that all aspects of life can be rationally mastered through technique” (Kass, 2003).   
This argument is strongly reminiscent of the opinions of Michael Sandel, who argues 
that biomedical enhancements entrench the idea that we are supposed to be “masters of nature” 
and “perfect” in every respect. Sandel’s views have recently been comprehensively challenged 
by Van Niekerk in the South African Journal of Philosophy, and this has given rise to a robust 
debate in that journal (van Niekerk, 2016). Of significant concern is Sandel’s position on “the 
gifted character of human powers and achievements” (Sandel, 2007, p. 26) a view that he 
believes should constrain us from using everything, including our talents, in the world as “we 
may desire and devise” (Sandel, 2007, p. 27). In responding to Sandel’s notion of the giftedness 
of life, Van Niekerk argues that although they are not yet engaged in selecting the genetic traits 
of their offspring, parents engage in what essentially are forms of enhancement:  
…go out of our way to train, educate, instruct and guide them in certain directions. These later 
activities are, without doubt, efforts to enhance those children, i.e. to make people out of them 
that they are not yet and that we as the parents regard to be preferable to what they might become 
without our consistent prompting (van Niekerk, 2014, p. 161). 
Although I will, in a later chapter, discuss in further detail the idea of naturalistic arguments 




though quite sensible, is not necessary a valid premise for arguing against human effort in 
seeking to improve specific aspects of life and reality. To use the giftedness of life as an 
argument against genetic therapy or enhancement would be to negate all modern technological 
and medical advancements that make human life both bearable and pleasurable. Although 
Penrose defends Sandel’s position on the basis of certain philosophical technicalities, he admits 
the inevitability of enhancement gradually becoming “entrenched in first-world societies” 
(Penrose, 2016, p. 162).5 This inevitability is a key factor that partly motivates this research, 
though not with regard to enhancement but with regard to the relevance of genetic therapies. 
In other words, the future of human solutions to genetic diseases lies in genetic therapies and 
human enhancement, and we had better begin to get ready, morally, for that future. 
 Apart from issues about human dignity that are also normally associated with the debate 
about human enhancement, the other important issue that this thesis will have to address is the 
implications of possible genetic interventions in HIV-AIDS treatment for the question of social, 
distributive justice. For instance, if the technology turns out (as is expected) to be very 
expensive, and if it is only available on a limited basis, then only an especially privileged 
economic class of a country’s citizens would presumably be able to benefit and gain protection 
from disease. The application of the technology could result in the rich becoming physically 
stronger and mentally smarter because they would no longer be prone to HIV-AIDS. As Heller 
and Peterson explain, 
The gap would significantly widen between those who could afford enhancements and those 
who couldn’t, and the threat of creating a permanent un-enhanced underclass would be real. 
There is the further threat that those that control all the resources, the enhanced class, would feel 
increasingly disconnected from the underclass, and as a result would not want to engage in 
politics of economic redistribution, trapping the poor in their position (Heller & Peterson, 2018). 
 
They would possibly regard themselves as superior and only promote their own interests. The 
net result very easily could be an exacerbation of the already stark divide between rich and 
poor in society, as well as the (further) violation of human dignity in a society where poverty 
is consistently eroding relevant claims to such dignity. 
 
 
                                                          
5 Van Niekerk’s article A Response to Penrose’s “Sandel on Enhancement: A Response to Van Niekerk” gives an 
elaborate reply, essentially summarized in the statement, ‘It strikes me that Sandel creates the impression that 
whenever the possibility of acts that could amount to “taking our evolution in our own hands” or “re-engineering 
our nature” present themselves, the (almost knee-jerk) reaction is necessarily negative’ (van Niekerk, 2016, p. 
168). In other words, it is not always necessary to have an adversarial response and “see red flags flickering” 
every time genetic technology moves towards “genetically influencing human progeny.” This idea forms part of 




 RESEARCH METHODOLOGY 
1.7.1. Research Goal: This research aims at developing a philosophical-ethical framework 
in which the challenge of the obstinate disease of HIV-AIDS can be resolved within the 
context of a utilitarian ethics theory. It proposes models and possibilities that may help 
in the changing policy framework for the health benefit of the vulnerable and the 
dependent members of the Kenyan and African society. 
1.7.2. Assumptions:  
1.7.2.1.It is assumed that genetic therapies are still in their developmental stages, and 
are not yet an open practice in medical science. However, it is also assumed that 
the scientific and medical research will continue and seek to make it available 
for general use in healthcare in future. 
1.7.2.2.It is assumed that genetic therapy will endeavour to use some, or all, of the 
human enhancement techniques that will be developed, for the benefit of 
healthcare clients. 
1.7.2.3.It is assumed that good health is a basic human right which must be sought after 
and protected in all bioethics engagements. 
1.7.3. Research Questions:  
The research questions that this dissertation seeks to address are: Should African 
countries in general, and Kenya in particular, pursue the possibilities of genetically based 
biomedical therapies for prevention and cure for the rampant HIV-AIDS pandemic in their 
midst? Should these countries seek to advance such research in their own midst, or should 
possibly more fruitful models of co-operation with researchers in the developed world be 
sought and explored? If the latter option is preferred, how can benefit sharing for African 
communities be optimised? What is the value of a utilitarian approach to moral decision-
making for this enterprise, and why is this approach to be preferred? Does a utilitarian ethic 
provide moral justification for the use of genetic therapies as solutions to the obstinate malady 
of HIV-AIDS? How can the issues of distributive justice provoked by both the HIV-AIDS 
pandemic and the possibility of genetic therapies be fairly addressed in the African context, 
with special reference to Kenya?  
1.7.4. Research Design and Methods 
  In view of the nature of this research in philosophy and applied ethics, especially in 
bioethics, the methods used involve a careful study of relevant literature, which includes 
philosophical works, the voluminous literature on ethical issues related to HIV-AIDS research 




AIDS pandemic, as well as scientific journal articles on the progress made in the research in 
genetic therapies. In addition, the study involves philosophical reflections on genetic therapies 
in the context of a utilitarian appreciation of the disease burden in Africa. Apart from such a 
comprehensive literature study, the method involves regular consultations with my Supervisor. 
 A third pivotal aspect of this method of research, is independent reflection, as is 
required from a philosophy and/or ethics student. This reflection entails not only a preparation 
for careful conceptual analyses, but indeed the construction of thought experiments that could 
underlie the development of relevant and even novel ideas about the problematic. What is 
notable about this approach to ethics reflection in this study, is the use that I make of 
utilitarianism as my prominent approach to moral decision-making in this area. In the context 
of this dissertation, genetic therapies are examined through the lens of utilitarianism as an ethics 
theory whose application is not only a philosophical-ethical framework and reflection, but also 
a method of interpretation and a criterion of assessment. I now proceed to say more about the 
relevance of utilitarianism for approaching this problem. 
 THE CHOICE OF UTILITARIANISM 
 The study is dominated by the question as to how beneficial the envisioned research 
into the genetic enhancement therapies for HIV-AIDS would be for the people in Africa 
generally, and in Kenya specifically. In other words, we seek to find out if the benefits outweigh 
any presumed challenges related to costs or to other scientific, political or moral concerns. 
Africa has long suffered from inadequate health provision and services. It carries, as has been 
pointed out, an inordinate burden of the HIV-AIDS scourge. Although one takes cognisance of 
a variety of approaches to moral decision-making procedures, and although their legitimacy 
could in principle often be affirmed, it is the conviction of this candidate that the question of 
whether genetically based biomedical therapies for HIV-AIDS should and ought to be pursued 
in the African context, is fundamentally determined by the question as to whether or not such 
a practice will be accompanied by justifiable benefit-sharing for the peoples of the continent 
generally, and for Kenyans in particular.  
 When the issue of benefit sharing is so prominent in an ethics study, it seems inevitable 
to utilise utilitarianism as the most appropriate ethical approach and method of ethical 
reflection for this research. African states have often been accused of wasteful mismanagement 
of resources, including corruption, even as they continue to depend on Western nations for the 
funding of essential services, including health care. With possible improvements in resource 




enhancement for preventing and treating HIV-AIDS. But, even with this in view, there is an 
urgent need to be fairly certain that the research will be of benefit to the majority of peoples. 
This dilemma calls for the use of utilitarianism as a philosophical-ethical theory that most 
effectively and convincingly provides moral justification for such undertakings as being 
beneficial, and with minimum negative consequences.  
 Utilitarianism has been described as “an altruistic approach” because in a society where 
the majority of people receive greater happiness, one has an obligation to honour that society’s 
decisions, even if it is not to one’s own advantage (Wilkens, 2011). We can see that 
utilitarianism acknowledges that happiness cannot be achieved in every situation for everyone. 
Where there may be conflicts in people’s interests, some people may have to compromise their 
own happiness for the sake of the greater good for other people.  
 This research will examine the matter of genetic therapies through the lens of 
utilitarianism as developed by Jeremy Bentham (1748-1832) and John Stuart Mill (1806-1973). 
In Bentham’s utilitarianism, what matters is how much happiness can be derived from an 
action, and for how many people in a given context (Bentham, 1781 (2010)). If we end up 
listing the benefits and harms of genetic therapies on opposite sides of a page, we will have 
engaged in what philosophers call “Bentham’s hedonistic calculus”. Bentham said, “A thing is 
said to be for the interest of an individual, when it tends to add to the sum total of his pleasures; 
or what comes to the same thing, to diminish the sum total of his pains” (Bentham, 1781 
(2010)). In our case of genetic enhancement therapies, we will evaluate whether they add to 
comfort and happiness among African peoples, while at the same time diminishing their pain 
and suffering. Mill, however, taught that the quality of happiness is also important; not just the 
quantity. He viewed reason and intellect as higher desires, while biological needs were lower 
desires. 
 The choice of utilitarianism for this research is a deliberate one made in the context of 
the variety of ethical theories that are available for ethical issues related to bioethics in general 
and health care in particular. The other alternatives are deontology and virtue ethics, which are 
primarily Kantian and Aristotelian in style, respectively. Without attempting to indicate any 
preference, Brown gives a summarised comparison of the three ethical theories, and points out 
that virtue ethics (Aristotelianism) provides a model of practical reasoning in which the main 
questions to ask oneself are: what habits should I develop; and what is the best kind of person 
to be? In this model, the will and reason have to combine with desires and character traits to 
form personal identity. What is good is whatever results from the actions of good people 




Deontology (Kantianism) differs and asks, instead: how does one determine what is 
rational? In this model, will and reason are sufficient for determining what is good, when it is 
conclusive that there are neither inconsistencies nor self-contradiction in policies. The primary 
object of evaluation is the act, which is what determines one’s moral duty. From these two, 
utilitarianism differs and defines the good in terms of the results that the act is likely to bring 
out. In other words, the main question is: how do I achieve what is ultimately good? Action is 
a means for achieving an end, and not an end in itself. In this context, the right actions are 
actions that maximise the good. Deontology places the emphasis on adhering to ethical 
principles or duties and fulfilling obligations. But exactly how these duties are defined may be 
a point of contention and debate. Moral absolutes make best sense because there is an objective 
in view which makes the action moral, regardless of circumstances. There are no rules whose 
purpose is purely to achieve nothing. In the context of ordinary human life, laws exist to achieve 
some purpose: for instance, prohibition against murder ensures security and continuity of 
human life; laws that recognise human rights propagate respect and peaceful coexistence; and 
obeying God is good because it results in objectivity of divine imperatives. 
 It is easy to associate morality with human character and the need to only engage in 
acts that are good. Hence virtue ethics is attractive to us. We find it desirable to live with good 
people, that is, people who are honest, generous, kind, courageous, loyal, fair, and dependable. 
It is in this context that I agree with Rachels & Rachels in their definition of a moral virtue as 
“a trait of character, manifested in habitual action that is good for anyone to have” (Rachels & 
Rachels, 2012, p. 159).  They are qualities that are worth having because they are good in 
themselves; not because of their potential results or because certain rules demand that they be 
part of our lives. As Aristotle states, “moral qualities are so constituted as to be destroyed by 
excess and by deficiency” (Aristotle, 1996, p. 35).6 In other words, “…virtues are the midpoints 
between extremes” (Rachels & Rachels, 2012, p. 160). When one looks carefully at virtue 
ethics, there are certain difficulties in identifying what is the "virtuous" action to take in all 
circumstances, and how to define a virtue. As Thiessen explains, a system of virtue theory “… 
is only intelligible if it includes an account of the purpose of human life, or in popular language, 
the meaning of life” (Thiessen, 2011). It seems possible that, in some way, the end has to be 
brought into perspective for a virtue to be affirmed by an action. Aristotle may have had this 
in mind when he stated, “In fact pleasures and pains are the things with which moral virtue is 
                                                          
6 Aristotle explains at length the ethics theory of virtue ethics and the need to keep balance in order to achieve 




concerned” (Aristotle, 1996, p. 36). Aristotle further explained, “Again, if the virtues have to 
do with actions and feelings, and every feeling and every action is attended with pleasure or 
pain, this too shows that virtue has to do with pleasure and pain” (Aristotle, 1996, p. 36). As 
Rachels & Rachels summarise, “…virtues are important because the virtuous person will fare 
better in life” (Rachels & Rachels, 2012, p. 165). Although the virtuous person may not 
necessarily be a richer person than others in the same context, every person needs virtues to 
thrive or flourish. However, one of the most serious weaknesses of virtue ethics is its inability 
to specify exactly when the virtues apply. For example, “…to be kind is to look out for 
someone’s best interest”, yet virtue ethics does not specify “what someone’s best interests are” 
(Rachels & Rachels, 2012, p. 171). In addition, where there may be a conflict between the 
virtues, there is need to look elsewhere for solution. It is reasonable to say with certainty that, 
although virtue ethics are truly important, it is not a suitable theory for assessing the relevance 
of genetic therapies for HIV-AIDS, especially since it will not tell us what the good action is, 
unless we reach beyond and begin to think about the potential effect those actions will have on 
the people.  
Given the arguments above, the rightness or wrongness of research into genetic 
therapies cannot be determined by a rule of any kind prior to the research. Research, by itself, 
cannot be judged to be a virtuous engagement, without first predicting its intended purpose, 
which in turn must be predictably good. It seems more reasonable to judge the morality of such 
research by the results it is likely to bear in relation to human health needs. Since utilitarianism 
teaches that people should maximise human welfare or well-being, including health needs, it 
seems ideal to employ this theory in this research in which medical research is seeking to find 
a solution to a human problem that negatively affects a significant population of Africa. Of 
course, this choice is not ignoring the fact that utilitarianism has challenges when applied 
wholesale to all ethical issues that may arise. For instance, we cannot always ignore the needs 
of the minority merely because the needs of the majority are in focus. But in a situation where 
the likely results will turn misery into good health, happiness, and human dignity, there is need 
for a form of results-based ethics, which is utilitarianism. In later chapters of the dissertation, 
the matter of making this deliberate choice of utilitarianism will receive adequate attention. 
 Since utilitarianism views happiness as the only thing that is intrinsically good, and 
pain as intrinsically evil, this research will evaluate the disease burden described in the context 
of Africa in relation to this understanding. In addition, since an action should only be judged 
on the basis of its consequences, the research will evaluate how genetic therapies can lead to 




pursued. Finally, the research will evaluate whether genetic therapies will lead to happiness for 
the greatest number of people in Africa who have remained vulnerable to disease burden. It is, 
in addition, possible that African governments will benefit significantly from a stronger human 
resource capacity when the disease burden is alleviated, thereby potentially contributing to 
economic growth. Stronger economies presumably strengthen citizens who, in turn, become 
more proactive about their own health issues, and rely less on government. 
 OVERVIEW OF CHAPTERS 
In order to address the problem under study, the dissertation will be apportioned into 
eight chapters as outlined below: 
Chapter 1: Background information about the impact of infectious disease generally, and HIV-
AIDS in particular, on African societies, as well as stating the problem that the dissertation 
addresses, as explained above. It also outlines the methodology used in the research and how 
utilitarianism is applied. 
Chapter 2: The Health Crisis in Kenya. This chapter examines the challenge of HIV-AIDS in 
Africa in general, and Kenya in particular, including some ongoing research. 
Chapter 3: Genetic therapies and their potential to curb the pandemic: a literature survey. 
Chapter 4: Utilitarianism. This chapter gives a comprehensive motivation and justification for 
the choice of utilitarianism as a philosophical-ethical approach in this research, while giving 
due recognition of the existence of alternative ethical systems. This is followed by a review of 
the ethical theory of utilitarianism as stipulated primarily by Jeremy Bentham and John Stuart 
Mill, as well as contemporary philosophers. The focus is the application of utilitarianism to 
bioethics, especially the new genetic enhancement therapies available for resolving human 
disease burdens. 
Chapter 5: Arguments against Pursuing Genetic Therapies in Kenya. Based on philosophical 
reflection on utilitarianism, this chapter focuses on the possible ethical reasons as to why 
genetic enhancement therapies should not be pursued, and whether alternative remedies may 
be preferable. It establishes if the application of such therapies may be more harmful than 
beneficial to societies. 
Chapter 6: Arguments in Favour of Pursuing Genetic Therapies in Kenya. With a 
comprehensive understanding of utilitarianism, this chapter endeavours to establish the 
desirability and ethical appropriateness of using genetic therapies. It seeks to establish the 




Chapter 7: Evaluation. The chapter is an evaluation of the relevance and the ethical implications 
of the arguments against and in favour of genetic enhancement therapies on the health situation 
in Kenya. 
Chapter 8: Conclusion 
 CONCLUSION 
In this chapter I have given background information on the disease, HIV-AIDS and the 
effect it has had on the continent of Africa, taking important note of the fact that Africa 
continues to bear the greatest burden of the illness and its related consequences. The review of 
the problem helps prepare the stage for the need for a more effective solution than is currently 
available. The chapter has also provided information on the infectious disease burden in Africa, 
thereby showing that HIV-AIDS is not the only serious challenge facing the continent, but is 
one that aggravates an already bad health situation. In the remainder of the chapter I have 






CHAPTER 2: THE HEALTH CRISIS IN KENYA 
 INTRODUCTION  
 Having reviewed the prevalence and impact of infectious diseases in general and HIV-
AIDS in particular on African societies or countries in the first chapter, this chapter examines 
the challenge of HIV-AIDS in Kenya in particular as a key component of the health crisis in 
the country. The term crisis is used here in its broad sense, taking cognisance of the more 
specific recent health crisis in Kenya’s health sector caused by the doctors’ strike that literally 
paralysed medical services in all public hospitals and health centres for slightly over 100 days 
between 5th December 2016 and 14th March 2017.7 Although research is yet to be either carried 
out or concluded, it is reasonable to remark that HIV-AIDS patients, most of whom depend on 
the public healthcare system for the provision of antiretroviral treatment and follow-up, 
underwent much suffering during and after the doctors’ strike. This chapter examines the 
challenge of HIV-AIDS in Kenya in particular, including some ongoing research related to the 
scourge.  
 RATIONALE FOR THE FOCUS ON KENYA 
In terms of policy in Kenya, the National AIDS Control Council (NACC) has focused 
on programming the prevention and control of HIV and AIDS in the country since the 
establishment of NACC in 1999. From 2009 to 2013 the agency sought to provide “…a 
coordinated, comprehensive, high quality combination prevention, treatment and care services” 
(NACC, 2019, p. para 5). The current framework continues to build on the previous themes 
“…through universal access to comprehensive HIV Prevention, treatment and care” hoping for 
“a Kenya free of HIV infections, stigma and AIDS related deaths” (NACC, 2019, p. para 6). 
Under NACC, specific strategies and policies have been developed, including “the Youth 
Communication Strategy, Condom Policy and Strategy, Male Circumcision Policy, HIV and 
AIDS policy at the workplace, HIV and AIDS Prevention and Control ACT, NACC and 
Stakeholder’s Code of Conduct and guidance notes…” (NACC, 2019, p. para 7). From the 
foregoing, it is clear that NACC remains focused on public education on prevention of HIV-
AIDS, as well as treatment and care, without engaging in any research at all. In regard to human 
                                                          
7 On 5th December 2016 all doctors and dentists under government service went on strike under their the Kenya 
Medical Practitioners and Dentists Union (KMPDU) complaining about the government’s perceived refusal to 
implement a 2013 Comprehensive Bargain Agreement (CBA) that had been signed between the Ministry of Health 
and KMPDU for the improvement of salaries, allowances, and working conditions. The strike ended on Tuesday 
14th March 2017 after KMPDU, the Council of Governors, and the Ministry of Health signed a new CBA which 
is enforceable by the High Court in case the government defaults again. I followed the related events both from 




rights and the resolution of violations, the HIV and AIDS Tribunal of Kenya was established 
in 2006 under the HIV Prevention and Control Act. It seeks to “advance the human rights of 
people living with and affected by HIV in Kenya, notably through addressing barriers to access 
to justice, swift ruling, and purposeful application of the law” (Eba, 2015, p. 169). However, 
its mandate is purely legal, and does not extend into research. The Kenya HIV Research 
Agenda is under NACC, mainly as a coordination function handling such matters as “ethics 
review committees, outlines capacity development options for research, reviews and data 
analysis and embraces the use of technology to facilitate availability of research findings to 
programmers, policy makers, students, implementers and communities” (NACC, 2019, p. para 
1a). Its objectives remain limited to items like “define HIV research priorities for the next five 
years; provide a national framework to guide HIV research; facilitate coordination of HIV and 
AIDS research among stakeholders; and serve as a tool for resource mobilization and allocation 
for HIV research” (NACC, 2019, p. para 3a). In all the policies, frameworks, and research that 
goes on in Kenya, there is no thinking yet on the possibility of any research in genetic therapies 
as possible solutions to the HIV-AIDS pandemic. There is also, apart from research at the 
University of Nairobi and KEMRI, no national policy that seeks collaboration with institutions 
in other countries in genetic research. And since collaboration is not part of the agenda, growth 
in genetic science is slow and lacks attention. The only provisions made in concerning research 
are guidelines that provide for the protection of research participants through such laws as “No 
person shall undertake HIV or AIDS related human biomedical research on another person, or 
on any tissue or blood removed from such person unless such research conforms to the 
requirements under the Science and Technology Act (Cap. 250) or any other written law for 
the time in force” (Laws of Kenya, 2012, p. 21). However, although the protection of 
participants is important, the country would do much better in moving the agenda forward by 
beginning to look beyond routine research that only looks into distribution of drugs, the number 
of recipients under treatment, how many people are infected, the economic impact of HIV-
AIDS, and the efficacy of ARVs. There is now need for policies and guidelines for the next 
level of research, especially genetic therapies and collaboration arrangements on the same. 
 BASIC FACTS ABOUT KENYA AND HER HEALTHCARE SYSTEM 
 Kenya is a politically independent republic in the East African region, and is composed 
of 47 semi-autonomous county governments. The population of Kenya is 47,564,296 people, 
according to the 2019 official population census (Kenya National Bureau of Statistics, 2019, 




With an estimated annual growth of one million people, by 2020 the population will be likely 
over 50 million. Based on the Constitution of Kenya 2010, the government is composed of one 
national government with a legislature, an executive and a judiciary, as well as 47 counties, 
each of which has a semi-autonomous government.  
 In order to serve the health care needs of the aforementioned population, the 
government organises its health institutions from the national level to the location levels. At 
the county level, there are hospitals that used to be classified as provincial hospitals under the 
old constitution (1963-2010). Some counties did not inherit any such facility. But there are 
county-level hospitals, and sub-county hospitals ranking right below. Progressively, there are 
health centres and dispensaries in wards8, although not every ward has such facilities, thereby 
causing much hardship for the residents. In addition to the public health system, the private 
sector provides private hospitals, nursing homes, and clinics. These come at very high costs, 
mostly only affordable to the middle class and the rich. 
 Dispensaries are the smallest unit in the healthcare system in Kenya, and treatment is 
usually done by nurses. Dispensaries provide simple outpatient services for such sicknesses as 
common cold, uncomplicated malaria, and simple skin conditions. Health centres provide 
comprehensive primary care, and are managed by a clinical officer who oversees a team that 
would normally include “…a clinical officer, nurses, a health administration officer, a medical 
laboratory technologist, a health information officer, a nutritionist, a driver, a housekeeper, and 
supporting staff” (Muga, et al., 2004). A sub-county hospital functions as a coordinating and 
referral centre for the smaller units, and are managed by a medical superintendent. Normally 
they would provide comprehensive medical services and surgeries. Each of the 47 counties in 
Kenya has a county hospital. These should normally be equipped to provide minimum 
specialised care, including intensive care. Kenya as a whole has three national hospitals namely 
Kenyatta National Hospital, the National Spinal Injury and Referral Hospital, and Moi 
Teaching and Referral Hospital.9 Kenyatta National Hospital provides referral services for 
Kenya and a number of countries in East and Central Africa. “The equivalent private referral 
hospitals are the Nairobi Hospital, the Aga Khan Hospital Nairobi” (Muga, et al., 2004), and 
the Karen Hospital which is a recent addition. The Kenya Healthcare Sector report states that 
“…there are a total of 9,696 health facilities in the country. About 4,616 of these facilities are 
owned by the public sector, 3,696 falls under ownership of the commercial private sector and 
                                                          
8 A ward is an administrative unit under the devolved county government under the Constitution of Kenya 2010. 
9 This statement is made from general knowledge as a citizen of Kenya who has general awareness of the country’s 




1,384 are owned by FBOs10, NGOs11 or Community Based Organisations (CBOs)” (Kenya 
Healthcare Federation, 2016). The 2017 GIZ-DE Report says that  
The 2010 constitution grants Kenyans access to affordable high quality health care. Currently, 
however, much remains to be done to realise this right in practice. The quality of basic health 
services is often poor and, despite strong economic growth in recent years, many Kenyans face 
financial barriers to accessing care. Only 20 per cent of Kenya’s 48 million inhabitants have 
health insurance, and most of them are employed in the formal sector (GIZ, 2017). 
According to the 2018 Economic Survey by the Kenya National Bureau of Statistics, the four 
leading causes of registered deaths in Kenya in 2017 are pneumonia, malaria, cancer, and HIV-
AIDS. The report indicates that 21,584 people died of pneumonia in 2017, another 17,553 
succumbed to malaria, while deaths caused by cancer stood at 16,953. Tuberculosis was the 
fourth leading cause of death at 9,081 followed by HIV-AIDS at 8,758 (Kenya National Bureau 
of Statistics, 2018). It is noteworthy that a combination of TB and HIV-AIDS would make the 
combination second only to pneumonia. 
 With regard to the allocation of resources such as equipment and healthcare personnel, 
“Kenya health sector has inadequate crucial health staff like doctors, nurses, and diagnostic 
scientists” with an establishment of 8,092 doctors for both public and private sector health 
facilities, out of whom only about 5,000 work in the government sector (Ministry of Health, 
2014).  The document further elaborates: 
Inadequate staffing levels, lack of appropriate skills, poor staff attitude, low morale, and weak 
supervision undermine the quality of public health services provided, especially at the rural 
health facilities. The shortage of health workers compromises service delivery and eventual 
health and development of a nation… In addition, there are regional disparities in the distribution 
of the existing health workers and the hard-to-reach get disadvantaged with less staff (Ministry 
of Health, 2014). 
Against the recommendation of the World Health Organisation (WHO) of “…at least 23 
doctors, nurses and midwives per 10,000 people, Kenya has one doctor, 12 nurses and 
midwives per 10,000 people” (Ministry of Health, 2014). According to Kenya Healthcare 
Sector report, the Kenya government’s healthcare cadres are dominated by men. For instance, 
there are 110 male dentists against 103 females, 307 male pharmacists against 203 females, 
and 332 medical specialists of various kinds against 87 females. The only female-dominated 
cadre is nursing and midwifery with 15,428 nurses and midwives against 4,943 males (Kenya 
Healthcare Federation, 2016). These are figures of personnel serving in the government 
healthcare system. It is also worth noting that “…75% of all medical doctors and 66% of all 
nurses and clinical officers work in the private sector because the regulatory board allows 
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health workers to work in both public and private sectors at the same time” (Kenya Healthcare 
Federation, 2016). Those who do so give preference to the private clinics because they earn 
much more than they get in the public institutions. This means there is a big shortage of 
qualified health workers in the public sector. 
 The health sector human resources face a number of challenges that compromise 
service delivery. At a conference of health experts in 2015, Dr. Ouma Oluga of the Kenya 
Medical Practitioners and Dentists Union (KMPDU) pointed out the challenges which included 
limited training opportunities and career progression, poor working environment, and skewed 
distribution of doctors. With the devolution of health services in 2013, the problems seem to 
have compounded: 
With devolution, the HRH problems compounded many times, and are characterised by 
tribalism and nepotism, deployment of staff with low capacity; staff harassment, threats and 
political interferences especially by the County Assemblies and community members rejecting 
members of staff, retarded career progression and; lack of horizontal and vertical transfers. 
There have been reported hostilities between County Health Managers and Health Workers, too 
many workers’ strikes, and mass exodus of the Human Resource... (Health Rights Advocacy 
Forum, 2015). 
The same challenges were cited by Purity Matu of the Kenya National Union of Nurses, who 
added to her list the lack of pharmaceutical supplies, insecurity at work places, and lack of 
political good will. 
 The basic facts, as discussed above, reveal an over-stretched healthcare system 
managed by a physically exhausted workforce whose main preoccupation is to try to make a 
living, a situation that leads to frequent strikes. The situation should cause concern, as 
healthcare personnel continue to seek migratory opportunities, thereby leaving the country’s 
healthcare in the hands of fewer and less-motivated service providers. Development agencies 
may need to view this situation as one that provides great opportunities for them to contribute 
to capacity building for strengthening the public healthcare systems.   
 THE CHALLENGE OF HIV-AIDS IN KENYA 
 In relation to HIV testing and counselling, “…more than half (53%) of the 1.6 million 
people living with HIV in Kenya are unaware of their HIV status. There are an estimated 
260,000 couples in HIV sero-discordant couples, where one partner is HIV positive and the 
other one is negative” (Kenya National AIDS Control Council, 2014). The report says these 
couples significantly contribute to new infections. This phenomenon makes HIV testing and 
counselling an important aspect of the control programme. Apart from “…targeted community-
based HIV testing and door-to-door testing campaigns, in 2015, Kenya announced plans to 




there has been a great increase in the numbers of people going for testing. It is reported that 
“…in 2008, about 860,000 people were being tested annually for HIV. By 2013, this had 
increased to 6.4 million” (Kenya National AIDS Control Council, 2014). The Kenya National 
AIDS Control Council places emphasis on prevention and reduction strategies, as evidenced 
by its four objectives set out in the KASF 2014/15-2018/19 policy document over its lifespan 
of five years: reducing “new HIV infections by 75%, AIDS-related mortality by 25%, HIV-
related stigma and discrimination by 50%, and increasing domestic financing of the HIV 
response to 50%” (Kenya National AIDS Control Council, 2014). A UNAIDS report points 
out that in 2015,  
…government representatives from Kenya, Zimbabwe and South Africa met to plan the 
development of a regional roadmap to increase the use of combination HIV prevention services 
in each country. Combination prevention mixes behavioural, medical and structural 
interventions and is widely regarded as the most effective approach to preventing new infections 
(UNAIDS, 2016). 
In 2016, Kenya issued a “…full regulatory approval of pre-exposure prophylaxis (PrEP), which 
uses antiretroviral drugs to protect HIV-negative people from HIV before potential exposure 
to the virus” (UNAIDS, 2016). Kenya was “the second country in Africa to do so,” after South 
Africa. Currently in the country, there is an on-going “research into the uptake and impact of 
PrEP, specifically among young women and girls in high-incidence areas” (Ibid.).  
 Addressing the challenge of TB and HIV co-infection, the Kenya National AIDS 
Control Council reports that in Kenya, “…up to 38% of people with tuberculosis (TB) are co-
infected with HIV” (Kenya National AIDS Control Council, 2014). It is also reported (Ibid.) 
that “83% of people with a co-infection are being treated for both illnesses” (Ibid.). Although 
this figure may show commitment to tackling both diseases as a public health concern, the 
untreated 17% reveals a probable weakness in following up and counselling co-infected 
patients; small numbers are not necessarily insignificant.  
 The problem of stigma and discrimination against infected persons remains high, 
despite the general perception that HIV-AIDS awareness is high. It is reported that “…many 
people living with HIV face high levels of stigma and discrimination” an experience that 
“…deters many people living with HIV - particularly vulnerable groups - from seeking vital 
HIV services” (Kenya National AIDS Control Council, 2014). Stigma affects patient care when 
a relative declines to take care of an HIV-infected relative; it affects small-scale business when 
potential customers decline to buy fresh fish or vegetables from an HIV-infected vendor; and 
it affects careers when parents refuse to allow an HIV-infected teacher to teach their children. 




which required infected persons to disclose their HIV status. “In 2015, the High Court of Kenya 
declared that law unconstitutional, thus making Kenya the first country in the world to take 
such a stance, seen by many as a breakthrough for the rights of people living with HIV” 
(AVERT, 2017). Despite such a milestone, the Kenya National AIDS Control Council reports 
that HIV-infected people still face stigma, discrimination, and violence, sometimes through 
denial of essential services, arbitrary arrests and beatings (Kenya National AIDS Control 
Council, 2014). 
 It may be stated with a measure of certainty that funding for the HIV response in Kenya 
is at risk, given reports that “…approximately 68% of Kenya’s national HIV response is 
externally funded. The remaining 30% is funded by the Kenyan government (17%) and private 
individuals (13%)” (Kenya National AIDS Control Council, 2014). The same report further 
notes that “…dwindling funds from international donors pose a challenge for the sustainability 
of Kenya’s HIV response.” The allocation of these funds is of interest here as “…HIV treatment 
and care accounted for the majority of HIV expenditure (52%) between 2009 and 2013. 
Prevention, which includes the provision of HIV testing services, accounted for 21%” (Ibid.). 
Assuming that the status has not changed positively, it is clear, then, that there are no funds 
allocated formally for any on-going research in HIV-AIDS in the country. Any research carried 
out by institutions has to be separately funded by agencies that provide funds for academic 
research purposes, in addition to the work that international and national organisations carry 
out in terms of empirical data collection and analysis. 
 The future, in regard to HIV-AIDS in Kenya officially lies in the Kenya HIV Prevention 
Revolution Road Map that was published by the Ministry of Health in 2014. The official policy 
guideline therein “outlines a new approach to drastically reduce new HIV infections that is 
evidence-informed, rights-based and gender sensitive.” Its goal is to bring HIV infections to 
‘near zero’ by 2030” (Ministry of Health, 2014). The roadmap “…commits to combination 
interventions, targeted towards the different needs of key populations and geographical 
locations. If implemented successfully, the government projects that it will avert 1,149,000 
new HIV infections and 761,000 AIDS related deaths by 2030” (Ibid.). Although the objectives 
of the roadmap are apparently quite noble, the previously discussed imbalance in funding is 
likely to frustrate the plans, since the plan seeks to rely heavily on funds from external sources. 
There is need for Kenya to deliberately budget for prevention, treatment, and research, possibly 
in equal measure. There is need to progressively decrease donor-dependence, while at the same 




 THE IMPACT OF HIV-AIDS ON KENYA 
 A review of previous studies carried out reveals various ways in which HIV-AIDS has 
impacted the people of Kenya in various sectors. Bollinger, Stover and Nalo observe that the 
household impacts of HIV-AIDS “begin as soon as a member of the household starts to suffer 
from HIV-related illnesses,” as indicated by “loss of income of the patient who is frequently 
the main breadwinner” (Bollinger, et al., 1999, p. 4). In addition, “…household expenditures 
for medical expenses may increase substantially… other members of the household, usually 
daughters and wives, may miss school or work less in order to care for the sick person” (Ibid.). 
When death occurs, the reality of lost income is reflected in “…less labour on the farm or from 
lower remittances; funeral and mourning costs; and the removal of children from school in 
order to save on educational expenses and increase household labour, resulting in a severe loss 
of future earning potential” (Ibid.). There are cases where children who are withdrawn from 
school are sent away to live with relatives, thereby further compromising their chances for 
education. Bollinger, Stover and Nalo have observed that 
In some instances, due to poverty, many communities have found it extremely difficult to cope 
with the rising number of orphans, forcing some orphans to drop out of school and start engaging 
in child labour. With high dropout rates of orphans, the quality of future labour force will be 
compromised …most parents do not arrange for other homes for their children before they die; 
instead, more and more households are being headed by children, particularly in the rural areas. 
Schooling becomes a luxury, and agricultural production is negatively affected, as the children 
are less capable than were the adults (Bollinger, et al., 1999, p. 4). 
As the impact of HIV-AIDS is experienced in the households, a heavier burden seems to fall 
on the children who have to either get scattered among relatives for care or take up adult roles 
for which they have no prior preparation or training. In the process, they have to forego their 
real future potential. 
 There have also been discussions around the various ways in which HIV-AIDS affects 
education among children and communities. A study reports that  
As parents, guardians and members of communities increasingly become infected by HIV-AIDS 
and eventually succumb to diseases, children are increasingly lacking basic needs such as food, 
clothing, shelter, health and even education. Children are now becoming subject to many 
psycho-socio impacts of HIV-AIDS such as stigma, fear, worry, depression and hopelessness. 
All these impact negatively on their learning and development (Akunga, et al., 2000). 
It is further revealed that “…pupils themselves are getting infected and some of them infect 
others, attendance and performance in schools is affected, pupils drop out of school, and some 
even die due to suspected HIV-AIDS-related illnesses” (Akunga, et al., 2000). The situation is 
worsened by the effect of HIV-AIDS on the teaching workforce as well. It may also be 
reasonable to conclude that, due to the death of parents and guardians, children would easily 




any meaningful access to education. Bruhns also makes a similar observation that “…surviving 
children divide their time between working and learning” (Bruhns, 2006), with learning losing 
out in cases of conflict of schedule between the two. Bruhns speculates that “…if there had 
been no epidemic, parents would have had more and better-educated children, whose 
hypothetical income and lives involve losses which need to be taken into account when 
measuring the effects of HIV-AIDS” (Bruhns, 2006). This can be generalised into other aspects 
of life in society: funds spent on prevention efforts, treatment and care would be spent on other 
important economic ventures; labour dynamics would be positively different for the general 
well-being of the economy; social life would be more cohesive; and societies would be happier, 
perhaps. 
 The study previously referred to from Bollinger, Stover and Nalo shows that “…AIDS 
will have adverse effects on agriculture, including loss of labour supply and remittance 
income” (Bollinger, et al., 1999, p. 4). The effect is likely to be felt at household levels as well 
as on a wider scope, as Bollinger, Stover and Nalo argue: 
The loss of a few workers at the crucial periods of planting and harvesting can significantly 
reduce the size of the harvest. ...where food security has been a continuous issue because of 
drought, any declines in household production can have serious consequences. Additionally, a 
loss of agricultural labour is likely to cause farmers to switch to less-labour-intensive crops. In 
many cases this may mean switching from export crops to food crops. Thus, AIDS could affect 
the production of cash crops as well as food crops (Bollinger, et al., 1999, p. 4). 
With the general knowledge that a larger percentage of the population works in agriculture and 
related sectors, agriculture is likely to be the most significant recipient of negative impact of 
HIV-AIDS. This is likely to set off a difficult situation in which declining agricultural output 
leads to additional expenditure on food and other essential agricultural products, thereby 
denying other sectors much-needed funds for growth and development. 
 Other studies have revealed the negative and damaging impact of HIV-AIDS in Kenya 
on “fertility patterns” (Magadi & Agwanda, 2010), “among caregivers of persons living with 
HIV-AIDS” (Musangali, et al., 2016), and “among maternity care providers” (Turan, et al., 
2008). 
 PAST AND CURRENT REMEDIES FOR HIV-AIDS IN KENYA 
 Responses to the challenge of HIV-AIDS are varied in both form and magnitude. The 
use of condoms as a preventive measure against HIV-AIDS infection has been promoted by 
the government only since 2001. Before then, condoms were only promoted by non-
governmental organisations (NGOs). According to the International Business Times (2013), in 




demand.” There were also reports of wrong usage in parts of the country. “One report from 
rural northern Kenya found men reusing condoms or using plastic bags and cloth rags due to 
shortages and difficulties accessing free supplies at government health facilities” (IRIN, 2011). 
That was in situations where people experienced scarcity of condoms. But, even where they 
are available, their use is not guaranteed. The Kenya Demographic and Health Survey of 2014 
reported that “…only 40% of women and 43% of men who had two or more partners in the 
previous 12 months reported using a condom the last time they had sex” (Kenya National 
Bureau of Statistics, 2015). This raises questions with regard to both efficiency and efficacy of 
condoms as a preventive measure against HIV-AIDS, although it is generally commonly 
known that, with proper use, they are mostly effective.  
 Kenya’s strategies towards the possibility of eliminating mother-to-child transmission 
of HIV include “…efforts to increase knowledge of PMTCT12, greater male involvement, 
universal attendance of pregnant women at antenatal clinics, universal uptake of HIV testing 
among pregnant women and the provision of antiretroviral drugs for those who test positive” 
(Kenya National AIDS Control Council, 2014). The same report further states that 
The number of women in need of PMTCT over the last 10 years is estimated at an annual average 
of 80,000. However, this annual need for PMTCT decreased slightly from about 98,000 in 2004 
to 79,000 in 2013. This data underscores the need to address epidemic in order reduce the 
number of infants exposed to HIV infection (Kenya National AIDS Control Council, 2014). 
According to UNAIDS, “…in 2015, 59,000 women were offered PMTCT services, out of an 
estimated 79,000 who were eligible, reflecting 74% coverage” (UNAIDS, 2016). KNACC 
noted that this was “lower than the 2010 coverage rate of 86%” but argued that the shortfall 
was “mainly due to the increased demand for PMTCT services” (Kenya National AIDS Control 
Council, 2014). On a positive side, UNAIDS reported that “…the number of children (0-14 
years) newly infected with HIV fell from 12,000 in 2010 to 6600 in 2015, due in large part to 
PMTCT services” (UNAIDS, 2016). 
 When voluntary medical male circumcision (VMMC) was identified by the government 
and implemented as a method for HIV prevention in 2008, priority was given to regions of the 
country that had the highest HIV prevalence among uncircumcised men (CDC, 2012). Going 
by the UNAIDS report, “…by 2015, the programme had circumcised 860,000 males (aged 15-
49) and met its universal coverage target of 80%. Kenya was one of only three countries in 
sub-Saharan Africa to increase VMMC in 2015 (the other two having been Ethiopia and 
Tanzania). There has been a worrying decline in this intervention throughout the rest of the 
                                                          




region” (UNAIDS, 2016). One would hope that the increment of numbers in those seeking this 
service were not a reflection of any probable misconception that VMMC in isolation might 
prevent HIV infection among males, and that the service were accompanied with clear 
counselling on the need for the integration of other known measures of prevention. Counselling 
support is called for before and after the circumcision, just as is the normal practice in HIV 
testing and counselling.  
 In order to promote HIV education and awareness, education policy was revised in 2013 
to enhance “care and support for school pupils as well as education personnel such as teachers,” 
with sensitivity to women and girls because they are “disproportionately affected by the 
epidemic” (Education Sector Policy, 2013). Since 2003, the national school curriculum in 
Kenya has integrated HIV and AIDS. However, the Kenya Demographic and Health Survey 
found that “only 54% of young women and 64% of young men (aged 15-24) had 
comprehensive knowledge about HIV prevention” (Kenya National Bureau of Statistics, 2015). 
A research study carried out by Mwamwenda found “…HIV knowledge to be significantly 
higher among university students” (Mwamwenda, 2014). Controversy continues among 
Kenyans with regard to HIV and sexual health education. For instance, “the Kenya 
Demographic and Health Survey 2014 found around 60% of both men and women to be in 
favour of educating young people about condoms, with the remaining 40% against it. Many 
cited fear of encouraging young people to have sex as a reason for being against the promotion 
of condoms” (Kenya National Bureau of Statistics, 2015). There may be need to review 
curriculum content for the HIV and sexual education to address the society’s reservations 
against the promotion of condom use among youth. 
 Perhaps the last means of intervention in the HIV-AIDS epidemic in Kenya, as in other 
sub-Saharan countries, is antiretroviral treatment (ART). In 2015 when Kenya began to 
implement the recommendations of the World Health Organisation for immediate ARV 
treatment for people diagnosed with HIV, “…around 826,000 adults and 71,500 children were 
accessing antiretroviral treatment (ART). This equates to 58% of adults who are in need of 
treatment receiving it, and 73% of children” (UNAIDS, 2016). There is need for empirical 
research to establish what leads the left-out percentage to miss out on the available ART 
treatment, as well as how to integrate them into the treatment programme. 
 CURRENT TRENDS IN HIV-AIDS RESEARCH IN KENYA 
 Much research that goes on in Kenya on HIV-AIDS is basic empirical economics 




well as the efficacy of the various programmes put in place for prevention and treatment. A 
review of available literature, as carried out in the chapters above, reveal a cycle of repeated 
evaluation research showing statistics on the infected population, medical care expenditure, 
costs on the economy, and whether there is a decline or an increment. It seems only a small 
percentage of the research is scientifically biomedical in focus, and there is yet to be seen any 
policy document that places priority on the scientific research. Both the Kenya Medical 
Research Institute (KEMRI) and the Kenya AIDS Vaccine Initiative Institute of Clinical 
Research (KAVI-ICR) are generally known to be carrying out scientific research on HIV-
AIDS, but with funding coming from overseas partners; not from the Kenya government.  
 The KAVI-ICR is a research hub at the College of Health Sciences at the University of 
Nairobi, and has been conducting basic research in HIV and epidemiology, as well as eight 
vaccine trials. The website of KAVI-ICR shows that their research focus has diversified beyond 
HIV-AIDS and now extends to non-communicable diseases including “…cancers such as 
breast, colon, prostate cancers as well as the diseases of the cardiovascular, respiratory, and 
endocrine systems” (Kenya AIDS Vaccine Initiative, 2014), while retaining the communicable 
diseases section which focuses on “…HIV-AIDS, along with research on tuberculosis, 
zoonoses, and childhood respiratory and gastrointestinal diseases” (Kenya AIDS Vaccine 
Initiative, 2014). One would hope that the institution has not digressed into peripheral diseases, 
which are also critical in their own right, to the possible neglect of the original core mandate 
of HIV-AIDS. A research carried out at KAVI-ICR explained that a VRC HIV-1 rAd5 vaccine 
is one that is delivered by needle and syringe intramuscularly to research volunteers who are 
healthy people without any HIV infection prior to the vaccination.13 In that study, “…the VRC 
HIV-1 rAd5 vaccine was generally well-tolerated when given alone or as boost following the 
VRC HIV-1 DNA vaccine to healthy, HIV-seronegative African adults at low risk for HIV 
infection” (Jaoko, et al., 2010).  “At the end of the study, most vaccine recipients tested positive 
on at least one commercial HIV antibody kit without being HIV-infected” (Jaoko, et al., 2010). 
The study concluded that 
The effect of pre-existing immunity to these vectors on the immunogenicity of rAd vectored 
vaccines remains to be seen. In addition, enormous efforts are being made to develop HIV 
vaccines capable of inducing neutralizing HIV antibodies and to design replicating viral vectors. 
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While basic discovery and applied research are crucial for the development of a safe and 
efficacious HIV vaccine, it is important to continue to perform focused human clinical trials of 
different vaccine strategies to develop a highly effective and safe preventive HIV vaccine. New 
functional T cell assays that allow determination of correlates of protection and/or predict 
vaccine efficacy are also urgently needed (Jaoko, et al., 2010). 
The programmes at KAVI-ICR are funded by foreign partners from the developed world, 
including the Canadian Institute of Health Research, Centres for Disease Control and 
Prevention (CDC), USAID, and universities abroad.  
 Other research is carried out at the Kenya Medical Research Institute (KEMRI) where 
“…laboratory research focus has been on understanding B cell biology in HIV infection, 
specifically describing phenotypes, function and potential mechanism by which viral antigens 
affect this compartment” (KEMRI, n.d.). Funding here, too, is from overseas institutions. In 
1999 the Military HIV Research Programme (MHRP) of the US government launched an HIV 
vaccine programme in partnership with KEMRI to offer support in prevention, care, and 
treatment through the provision of ART. According to MHRP, the main highlights of the 
programme include conducting “the first HIV vaccine study outside of Nairobi and the largest 
to date in Kenya,” establishing “Kenya’s first and only College of American Pathologist 
(CAP)-accredited laboratory,” participating in “a study that found starting antiretroviral 
therapy (ART) soon after beginning tuberculosis treatment could significantly reduce the onset 
of new AIDS-defining illness and death in those with advanced HIV (the results were published 
in NEJM in 2011),” and participating in “the OCTANE Study, which was published in the 
NEJM in 2010 and influenced revision of WHO guidelines for treating some HIV-infected 
women” (US Military, 2017). In October 2016 the MHRP started a new research in Kenya in 
collaboration with the Kenya Defence Forces (KDF) focusing on the prevalence of HIV-1, 
HIV/TB co-infection, and malaria among the Kenyan soldiers. Earlier on in August 2015, 
MHRP has conducted a study that indicated an increase in the HIV subtypes in Kenya, which 
“could complicate the picture for HIV vaccine researchers” (US Military, 2017).  
 It has recently been reported that the CDC is “working on a HIV vaccine that could see 
an end to new HIV infections in Kenya” (Bulterys, 2019). According to the CDC officials, 
“…the vaccine - HPTN-081 - is an antibody-mediated prevention that involves giving 
antibodies to individuals to protect them from HIV infections” (Bulterys, 2019). Given that the 
report came through a celebration speech rather than through a scientific journal, this could be 
something that is still a long way away, and may take years to become a reality and become 
useable in the prevention of HIV infections. And if, as the report stated, the focus will be on 




discrimination in its intended application to women while leaving out the men for unstated 
reasons. Also, while prevention through a vaccine will be helpful, there will still be need for 
treatment for the people who are already sick. 
 As can be concluded from the foregoing review, research in HIV-AIDS in Kenya is 
currently focused on reviewing what is going on, how to improve prevention, how best to 
provide care, and how to implement treatment plans. The research is yet to scale up to start 
making any attempts at any modification or enhancement of genes as a way of providing 
therapy to the people. 
 CONCLUSION 
 I have provided a review of the challenge of HIV-AIDS in Kenya and highlighted the 
health crisis in the country. This helps explain the context in which special reference is made 
with regard to the need for genetic therapies. In examining the challenge of HIV-AIDS in 






CHAPTER 3: UNDERSTANDING GENETIC THERAPIES 
3.1. INTRODUCTION 
In this chapter I provide a review of contemporary genetic therapies and their potential 
to curb the HIV-AIDS pandemic. The review begins with an explanation on what makes it 
necessary to consider genetic therapies and what these therapies really are. It also explains the 
life cycle of the HIV, especially how the virus gets into the human body and how it survives 
there. The intention here is to develop an appreciation of the necessity of genetic therapies. The 
chapter discusses the various types of genetic therapies that have been developed so far, ending 
up with a more detailed discourse on CRISPR/Cas9 which, so far, is the most suitable proposed 
genetic therapy. The chapter develops an understanding of genetic therapies, a necessary goal, 
before their relevance is evaluated. 
3.2. THE NECESSITY AND MEANING OF GENETIC THERAPY 
The continued lack of a cure for the infectious HIV, despite much research undertaking 
over the years in various countries, makes it necessary for scientific research to persist in 
seeking to find a definitive cure. So far, the use of Highly Active Antiviral Treatment (HAART) 
for suppression of viral multiplication is the best available treatment option in which one is 
advised to take a dose at least once a day for the rest of his or her life. Of the HIV-infected 
number people globally, some are well into their second decade of treatment with these 
antiretroviral drugs. It is conclusive, then, that the survival rates and the quality of life for HIV-
AIDS patients have been significantly improved by the intervention currently available. 
However, despite the benefits of having supressed viral load on an individual taking these 
drugs, missing the pills for a number of days unleashes a rapid viral replication. Additionally, 
some patients experience adverse effects which may interfere with their usual daily activities 
or lifestyles, leading to poor adherence for some, thereby posing risks of treatment failure of 
the drugs in use. In other words, with continued treatment interruptions, resistance to these 
drugs may occur. It is also common that the cost of the HAART drugs is way beyond the 
capacity of the ordinary patient to afford. In countries such as Kenya and South Africa, where 
the government provides free HAART to the patients, the cost of transport and other hidden 
costs still make it expensive for the poor, especially the rural poor, to access treatment. A 
research done in South Africa showed how transport costs, loss of income on the day of visiting 




factors to lack of access to treatment (Rosen, et al., 2007). In Kenya, recent research revealed 
that, although the average costs had significantly lowered per patient, it was still a major issue: 
The median economic unit cost1 per patient-year was $248.91 (2011 U.S. dollars [USD]) for 
established adult ART patients; or $120.72 when the cost of ARVs is excluded. The median cost 
per patient-year was $116.71 for pre-ART patients. Costs were higher for established pediatric 
patients ($292.60) compared to established adult patients. Newly initiating ART patients were 
also associated with higher costs than established ART patients at $274.95 for adults and 
$318.73 for pediatric patients. ARVs, the largest single cost component, cost a median of 
$123.03 per year for ART patients (CDC & Kenya Ministry of Health, 2013).  
Another issue that came out was that WHO had recommended that the use of Stavudine14 be 
stopped due to its “long-term, irreversible side effects,” and it be replaced with either 
Zidovudine or Tenofovir which are “less toxic and equally effective.” However, Kenya has 
continued to use Stavudine because it is relatively low-cost (CDC & Kenya Ministry of Health, 
2013). The dilemma for the country is to either continue with the low cost Stavudine with full 
awareness of the long-term side effects of the drug on the patients, or to turn over to the newer 
drugs recommended by WHO, and pay higher costs per patient. It is theoretically estimated 
that, if all Stavudine were to be replaced with Zidovudine, “the median per ART patient among 
29 sites will increase from $240.33 to $292.71” (CDC & Kenya Ministry of Health, 2013). An 
ethics question related to this is whether the public health system fully informs the patients of 
both the short-term and the long-term side effects that are known. The patients, even if they 
were fully made aware, however, do not seem to have any alternative that they can afford 
without government assistance. Also, like in South Africa, patients in Kenya spent on transport 
and lost income whenever they had to visit clinics. 
According to Richman, et al, apart from adverse effects, “there is some growing 
concern about the increasing rates of heart disease, diabetes mellitus, liver disease and various 
forms of cancer in ageing HIV-infected patients” getting antiretroviral treatment (Richman, et 
al., 2009). It is still unclear whether the rise of these illnesses is related to antiretroviral drugs 
or to being HIV infected or due to the combined effects. It seems clear that eradicating the 
lethal infection of HIV-AIDS remains a mirage, unless gene therapy is developed as a viable 
option. Gene therapy promises to offer an alternative treatment option that, if successful, may 
                                                          
14 “Stavudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. 
Stavudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by 
decreasing the amount of HIV in the blood. Although Stavudine does not cure HIV, it may decrease your chance 
of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections 
or cancer... Stavudine may cause serious or life-threatening lactic acidosis (build-up of acid in the blood) that will 
probably need to be treated in the hospital. The risk that you will develop lactic acidosis is higher if you are a 
woman, if you are overweight, and if you have been treated with medications for human immunodeficiency virus 
(HIV) for a long time. The risk may also be higher if you are pregnant and you are taking Stavudine along with 




have less adverse effects. In the last 25 years “AIDS has turned from an untreatable, rapidly 
lethal syndrome into a chronically manageable, tolerable disease compatible with a long life-
span… and …anti-HIV-AIDS gene therapy is one of the most promising strategies, although 
challenging, to eradicate HIV infection” (Richman, et al., 2009). Other scientists have observed 
that 
Although successful treatments with highly active antiretroviral therapies have made a major 
impact on survival, there still remains no vaccine for prevention and the available therapies do 
not cure the disease. As a result, AIDS has been transformed into a chronic, lifelong disease 
which requires continuous antiretroviral drug treatment together with on-going treatment of the 
associated systemic medical complications. It appears that as survival improves, the prevalence 
of chronic central nervous system involvement may be increasing (Paul, et al., 2009). 
This context in which HIV-AIDS is not adequately treatable raises a number of 
questions, on genetic therapies, which should lead into an exploration: What are genetic 
therapies? In what forms have they been developed, so far? How do they work? Is there any 
hope in their efficacy? Are they relevant to African needs, especially with regard to the 
treatment of HIV-AIDS? 
Genetic therapy may be one of the most welcomed preventive and/or treatment 
advancements in medicine. The use of the phrase gene therapy initially surfaced when there 
was a need to differentiate it from the Orwellian meaning of “human genetic engineering” 
which evolved from “the term genetic engineering first used at the Sixth International Congress 
of Genetics hosted in 1932” (Wolff & Lederberg, 1994). According to Wolff and Lederberg, 
“genetic therapy” has evolved through the decades with the transfer of genes into bacteria 
having been founded around the 1960s. To transfer a gene into a human body, a technique 
which included using “either a viral vector and or genetically modified cultured cells” was 
utilized (Wolff & Lederberg, 1994). Although there was an inadequate trustworthy method of 
gene transfer, scientists and researchers continued to persist resulting in establishment “of 
retroviral vectors in the 1980s” which brought about a possible “efficient gene transfer into 
mammalian cells” (Ibid), with the intent of gene therapy which has now become widely 
accepted, although not used as a preferred method of treatment for a variety of diseases in many 
countries.  
Before delving deeper into gene therapy, it is essential to understand the concept of 
gene therapy in order to correctly discuss its relevance in the treatment of HIV-AIDS. The 
Genetics Home Reference (GHR) of the US National Library of Medicine explains “gene 
therapy” as “…an experimental technique that uses genes to treat or prevent disease” (National 
Library of Medicine (US), 2017). Ongsimei states the same definition, adding that “the goal of 




disease. It involves introducing a normal copy of the gene into cells containing the damaged 
version” (Ongsimei, 2016). Gene therapy has also been defined as “the introduction of nucleic 
acids into cells for the purpose of altering the course of a medical condition or disease” (Kay, 
et al., 1997). Mandal defines it as “a form of therapy that involves inserting one or more 
corrective genes that have been designed in the laboratory into the genetic material of a 
patient’s cells to cure a genetic disease” (Mandal, 2014). The “Your Genome” website is the 
only one that specifically includes the deoxyribonucleic acid (DNA) in the definition: “Gene 
therapy is when DNA is introduced into a patient to treat a genetic disease. The new DNA 
usually contains a functioning gene to correct the effects of a disease-causing mutation.” This 
means genetic therapy actually causes the modification of the genes or DNA of a patient. The 
same idea has been summarised that 
Gene therapy is a medical intervention consisting in the introduction of genetic material into 
cells to cure a disease. Although somatic gene therapy was developed with the primary intention 
to correct genetic diseases, it was soon recognized that ex vivo or in vivo genetic modification 
could be applied as well to cancer, cardiovascular, and infectious diseases (Bovolenta, et al., 
2012). 
A futuristic perspective says “In future, this technique may allow doctors to treat 
disorder by inserting a gene into a patient’s cells instead of using drugs or surgery” (National 
Library of Medicine (US), 2017). This means that, firstly, the technique is still in research 
stages, and conclusions are not yet drawn as to the efficacy of this type of therapy. Secondly, 
the use of the technique is not yet available for doctors to use on patients, but there is hope that 
it will be available in the future, whether distant or near. Research is on-going on various 
approaches to gene therapy that may become possible in future, including “replacing a mutated 
gene that causes disease with a healthy copy of the gene; inactivating or knocking out a mutated 
gene that is functioning improperly; and introducing a new gene into the body to help fight a 
disease”(Ibid). 
3.3. PATHOGENS AND THE LIFE CYCLE OF HIV 
In order to carry forward a discussion on gene therapy as a possible solution for HIV-
AIDS, it seems necessary to seek basic understanding of how the virus enters and establishes 
itself in the human body. The HIV is transmitted into the human body through contact with 
various bodily secretions from a person with HIV. Such body fluids include blood, semen, pre-
seminal fluid, vaginal fluids, rectal fluids, and breast milk. Upon entry into the human body, 




Stage, and Acquired Immune Deficiency Syndrome (AIDS)”15 (US Department of Health, 
2017). Upon entry into human body, the HIV life cycle begins by the virus attaching itself to 
“CD4 cell receptor and one of the two co-receptors, CCR5 or CXCR4 receptors” located on the 
surface of the “CD4+ T-lymphocyte16” (Ibid.). In this attachment the virus gets into a union 
with the host cell where it releases its genetic material, that is, the RNA [Ribonucleic Acid], 
which is single stranded. The single-stranded genetic material is, in turn, transformed into DNA 
(Deoxyribonucleic Acid) by an enzyme called “reverse transcriptase”. The DNA is double 
stranded and it stores the genetic material of the human immunodeficiency virus. This DNA 
accesses the host cell nucleus via an enzyme referred to as the integrase. Through this 
integration of the HIV DNA into that of a host, the viral DNA is in other words hidden inside 
the host nucleus as a “provirus which may remain dormant for a number of years, produce few 
or no new copies of the virus” (Ibid). It is an intricate process in which the HIV tricks the 
human immune system. When the host cell receives a message prompting it to become active, 
the host’s “RNA polymerase enzyme” is used by the HIV genetic material (viral DNA) to 
multiply, thereby unleashing enormous copies of the virus within the human body cells. As the 
new viral copies are formed, they push out of the infected cell taking along with them part of 
the outer cell envelope, which is used as the virus’ cover that later combines with the HIV 
glycoprotein to invade and infect other cells.  
To enable one to have some clarity on how the virus may look like, the following image 
is taken from the website of AIDS Info (2017) to depict the HIV structure and its contents 
which are essential for its attachment and survival in a host cell: 
                                                          
15 AIDS stands for Acquired Immune Deficiency Syndrome: Acquired means you can get infected with it; Immune 
Deficiency means a weakness in the body's system that fights diseases. Syndrome means a group of health 
problems that make up a disease. www.aidsinfonet.org/fact_sheets/view/101  
16 “T-lymphocyte cells are divided into antigen-naïve and antigen-experienced memory cells.” The antigen-
experienced memory is further sub-divided into “central memory cells and effector memory cells” (Grossman, 
Meier-Schellersheim, Paul & Picker, 2006). The effector T memory cells are the type of cells targeted by the HIV 





Figure 1: The Structure and Content of HIV17 
Consequently, at each of the seven stages in the HIV life cycle, the HIV attacks a CD418 
cell and uses the machinery of the cell to multiply. The behaviour of the HIV in the body is 
vividly illustrated in the following image, which is also from AIDS Info (Ibid.): 
                                                          
17 Figure 1 is adopted from http://aidsinfo.nih.gov. 





Figure 2: The Life Cycle of HIV19 
The image shows how the HIV virus mutates in the body and modifies the genetic structure 
and function of the human genetic make-up, thereby effectively insulating itself from any 
attempts at treatment, thereby necessitating genetic therapy. 
                                                          




According to an article in the Gene Therapy Net, “…all cells in the human body contain 
genes, making them potential targets for gene therapy. However, these cells can be divided into 
two major categories: somatic cells (most cells of the body) or cells of the germ-line (eggs or 
sperm)” (Gene Therapy Net, 2018). In theory, either somatic cells or germ cells can be 
transformed. Gene therapy that focuses on germ-line cells produces “permanent changes that 
are passed down to subsequent generations.” The article further explains that 
If done early in embryologic development, such as during pre-implantation diagnosis and in 
vitro fertilization, the gene transfer could also occur in all cells of the developing embryo. The 
appeal of germ line gene therapy is its potential for offering a permanent therapeutic effect for 
all who inherit the target gene. Successful germ line therapies introduce the possibility of 
eliminating some diseases from a particular family, and ultimately from the population, forever 
(Gene Therapy Net, 2018).  
The perceived impact, especially the possibility of eliminating a debilitating disease, such as 
HIV-AIDS, from the human population makes germ-line gene therapy an attractive mode of 
potential treatment. As Ongsimei explains, “Germ-line gene therapy involves the reproductive 
cells. In germ-line gene therapy, the germ cells (sperms and eggs) are modified by the 
introduction of functional genes into their genomes” (Ongsimei, 2016). The article further 
explains the two main ways in which germ-line gene therapy will be used:  
…the use of in vitro fertilization technique to treat a pre-embryo that carries serious genetic 
defects before implantation into the mother; and the application of some expertise to remove 
the defective genes from the germ cells of the afflicted adults to avoid the defects to pass on to 
the subsequent generations (Ongsimei, 2016). 
In other words, germ-line gene therapy has the potential to benefit both the unborn and the 
grown-up adult members of the human population, in terms of eliminating deadly diseases. 
However, there are likely to be ethical concerns that make germ-line gene therapy 
controversial. For instance, although a family may be helped to avoid passing on a genetic 
disorder to future generations, no one presently knows what long-term negative impact the 
treatment may cause in the unborn. In addition, it is worthy of consideration that consent is 
impossible to obtain from the individuals to be affected by germ-line gene therapy simply 
because they are not yet born and cannot choose whether they would have the treatment or not. 
Somatic cells, however, are non-reproductive, and “it affects only the targeted cells in 
the patient, and is not passed on to future generations… In other words, the therapeutic effect 
ends with the individual who receives the therapy” (Gene Therapy Net, 2018). Certain 
challenges have been noted with this type of gene therapy: 
Often the effects of somatic cell therapy are short-lived. Because the cells of most tissues 
ultimately die and are replaced by new cells, repeated treatments over the course of the 
individual's life span are required to maintain the therapeutic effect. Transporting the gene to 




In a few countries in the developed world, such as the US and parts of Europe, this type of 
therapy is already accepted to the treatment of such disorders as “cystic fibrosis, muscular 
dystrophy, cancer, and certain infectious diseases. Clinicians can even perform this therapy in 
utero, potentially correcting or treating a life-threatening disorder that may significantly impair 
a baby's health or development if not treated before birth” (Ibid). In broad understanding, 
somatic gene therapy can be divided into two categories: 
Ex vivo, which means exterior (where cells are modified outside the body and then transplanted 
back in again). In some gene therapy clinical trials, cells from the patient’s blood or bone 
marrow are removed and grown in the laboratory. The cells are exposed to the virus that is 
carrying the desired gene. The virus enters the cells and inserts the desired gene into the cells’ 
DNA. The cells grow in the laboratory and are then returned to the patient by injection into a 
vein. This type of gene therapy is called ex vivo because the cells are treated outside the body. 
In vivo, which means interior (where genes are changed in cells still in the body). This form of 
gene therapy is called in vivo, because the gene is transferred to cells inside the patient’s body 
(Gene Therapy Net, 2018).  
Additional explanations may be useful for a deeper understanding of ex vivo somatic gene 
therapy. Ongsimei shows how ex vivo gene therapy corrects disorders by using viral vectors to 
alter cells and transplanting them back to the body of the patient. 
Ex vivo gene therapy modifies the cells outside the body and transplanted back after selection 
and amplification. Ex vivo gene therapy normally targets on bone marrow stem cells, liver cells, 
blood vessel smooth muscle cells, and tumour-infiltrating lymphocytes for cancer treatment 
(Ongsimei, 2016). 
Ex vivo gene therapy is quite specific in its target and is able to avoid rejection, since in the 
first place the cells are collected from the patient. However, “host cells must be capable of 
dividing, thus certain post-mitotic cell populations such as neurons cannot be targets of 
transduction for ex vivo gene therapy” (Ongsimei, 2016).  
In vivo gene therapy, on the other hand, involves “the direct introduction of the genetic 
materials into the human body.”  
Physical methods applied for in vivo gene delivery are based on making transient penetration in 
cell membrane by mechanical, electrical, ultrasonic, hydrodynamic, or laser-based energy so 
that DNA entrance into the targeted cells is facilitated. The target tissues of this technique 
include skin, lung, colon, muscle, pancreases, liver, bone marrow, spleen and brain (Ibid). 
In vivo gene therapy is simple and repeatable, and is achieved by a “single step of direct vector 
injection into the desired target organ to correct the disorders” (Ibid). Some disadvantages have 
been pointed out, such as the possibility that “different cell types can be infected when in vivo 
vectors are injected… including neurons, glia, and vascular cells. Besides, this technique might 
cause toxicity. Some in vivo vectors are toxic to host cells and elicit immune responses” (Ibid). 





 It is important to understand the primary concept of genetic therapy, which is “…to 
introduce a gene with the capacity to cure or prevent the progression of a disease. Gene therapy 
introduces a normal, functional copy of a gene into a cell in which that gene is defective,” say 
Bowen, et al, who further explain that 
Cells, tissue, or even whole individuals (when germ-line cell therapy becomes available) 
modified by gene therapy are considered to be transgenic or genetically modified. Gene therapy 
could eventually target the correction of genetic defects, eliminate cancerous cells, prevent 
cardiovascular diseases, block neurological disorders, and even eliminate infectious pathogens 
(Bowen, et al., 2003).  
The point Bowen, et al, are making is that genetic therapy has the potential of resolving much 
of humanity’s struggle against disease and disability. They also point out that gene therapy 
“should be distinguished from the use of genomics to discover new drugs and diagnosis 
techniques, although the two are related in some respects” (Ibid.). 
 It is considerably important to understand how gene therapy works in order to 
appreciate its potential use in the treatment of HIV-AIDS. In gene therapy, genetic material is 
introduced into cells to either “compensate for abnormal genes or to make a beneficial protein” 
(National Library of Medicine (US), 2017). It is explained that “…if a mutated gene causes a 
necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy 
of the gene to restore the function of the protein” (Ibid.). The article further explains that  
A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a 
vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors 
because they can deliver the new gene by infecting the cell. The viruses are modified so they 
can't cause disease when used in people. Some types of virus, such as retroviruses, integrate 
their genetic material (including the new gene) into a chromosome in the human cell. Other 
viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is 
not integrated into a chromosome. The vector can be injected or given intravenously (by IV) 
directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a 
sample of the patient's cells can be removed and exposed to the vector in a laboratory setting. 
The cells containing the vector are then returned to the patient. If the treatment is successful, the 
new gene delivered by the vector will make a functioning protein (Ibid.). 
The foregoing explanation, therefore, calls on research scientists to develop reliable and 
efficient ways by which genes can be targeted to specific cells and also bring the new genes 
under the control of the body before genetic therapy is made available for practical treatment 
of diseases. Serious risks, including toxicity and inflammation, have to be eliminated by 
researchers, research institutions, and agencies responsible for regulation. 
3.4. VARIOUS TYPES OF GENETIC THERAPIES 
 There are various types of genetic therapies for which a degree of understanding is 
necessary as an integral aspect of this research. Changqing Su discusses the concept of 




to treat diseases with functional genes or therapeutic genes by transferring these genes into 
cells” (Su, 2011). But what are adenoviruses? Benaroch defines adenoviruses as “a group of 
common viruses that infect the lining of your eyes, airways and lungs, intestines, urinary tract, 
and nervous system. They're common causes of fever, coughs, sore throats, diarrhoea, and pink 
eye” (Benaroch, 2016). He observes that adenoviral infections “happen in children more often 
than in adults, but anyone can get them. Most kids will have at least one type of adenovirus 
infection by the time they are 10” (Ibid). Su points out that most of the gene therapy treatments 
for cancer on clinical trials are using adenovirus as the vector, and explains the superiority of 
oncolytic adenoviruses which can be “…genetically modified to target, infect and replicate in 
cancer cells causing them to lyse with an improved, superior efficacy compared to non-
replicating adenoviral vector” (Su, 2011). The viruses do not replicate in normal cells, but do 
so in cancer cells in tumours. He further explains that, whereas the “…traditional strategies for 
cancer treatment, including surgery, chemotherapy and radiation, are difficult to eradicate the 
root of various cancers, the gene therapy absolutely searches for the roots cause of 
carcinogenesis, and corrects the genetic defects in transformed cells” (Ibid.). In other words, it 
will be possible to avoid the currently prevailing means of cancer treatment in preference for 
the yet-to-be-perfected adenovirus genetic therapy. It implies that, with further research, maybe 
eventually HIV-AIDS too can be treated through this method.  
 There have been reports of much progress in the development of treatment of HIV-1 
through gene transfer. Scientists have worked from previous failures to improve their 
understanding of such associated factors as “the HIV-1 replicative cycle, host factors involved 
in HIV-1 infection, vector biology and application, transgene technology, animal models, and 
clinical study design…” (Strayer, et al., 2005). The improved understanding will, in turn, help 
in the development of strategies for genetic treatment of HIV-AIDS, thereby giving hope to 
patients. This should encourage scientific research in this area to continue. However,  
…the success of highly active antiretroviral therapy (HAART) has brought into question the 
need for continued research in AIDS gene therapy. Why study expensive, risky, and potentially 
impractical treatments if safe pharmacologic approaches produce durable remissions? (Strayer, 
et al., 2005).  
The response lies in the fact that HAART remain non-curative, they are expensive, and they 
are still significantly toxic. It has been observed that 
Drug-resistant HIV-1 is increasingly frequent, even in lymph nodes of patients receiving 
HAART with undetectable HIV-1 in the blood. Studies of structured treatment interruptions, 
designed to provide respite from HAART’s burdensome toxicities, complexity, and cost, show 




It seems reasonable that science should pursue research into other approaches, including 
genetic therapies, which will complement rather than replace. Strayer, et al, explain the four 
goals of anti-HIV-1 gene therapy as 
…to deliver transgenes: (a) to hematopoietic progenitor cells (HSC) to protect their 
differentiated progeny from HIV-1; (b) directly to HIV-1-susceptible cells, to render them 
resistant to HIV-1 infection or inhibit HIV-1 replication in them; (c) to immunize against HIV-
1 antigens; and (d) to inhibit HIV-1 in discrete organ target sites e.g., central nervous system 
(Ibid.).  
Although gene therapy focused on HIV-1 has not achieved any of the above objectives, it is 
reasonable to believe that it may be of significant value or contribution to the treatment of HIV-
AIDS in future.  
 Another type of genetic therapy is the kind that is used for restoring muscle strength 
and functioning that have been lost due to either disease or age factors. When athletes use this 
technology to enhance muscle performance, it is called gene doping. The World Anti-Doping 
Agency (WADA) defines gene doping as “the non-therapeutic use of cells, genes, genetic 
elements, or of the modulation of gene expression, having the capacity to improve athletic 
performance” (Gene Therapy Net, 2018). This matter becomes a subject of debate in ethics, as 
it borders types of human enhancement in which “the recreational use of gene therapies is 
intended to treat muscle waste disorders” (Ibid). An example is erythropoietin which athletes 
are already abusing to form red blood cells. Concern over gene doping in sport circles may be 
deduced from the following description: 
In 2003, WADA decided to include a prohibition of gene doping within their World Anti-
Doping Code, which is formalized in its 2004 World Anti-Doping Code. In 2004, the 
Netherlands Centre for Doping Affairs (NeCeDo) and the WADA have organized a “Gene 
Doping” workshop. In addition, NeCeDo has published a report on gene doping as an inventory 
of the possible applications and risks of genetic manipulation in sports. Although there have 
been no documented cases of gene doping, the science of gene therapy and interest in the 
techniques by the sports community has risen to a level that makes gene doping inevitable (Ibid). 
Scientists have already been asked by WADA to find ways of preventing gene therapy from 
becoming a doping mechanism is sports (Ibid.). In other words, in the world of sports, there is 
already express fear that gene therapy may introduce negative dimensions in athletics, not just 
in human competition, but in horse racing as well. It has been reported that in Germany, a blood 
test kit has been developed that can detect gene doping “even after 56 days” using ordinary 
blood samples (Ibid). 
 The science of gene editing technology has seen the development of transcription 
activator-like effector nuclease (TALEN) which is becoming a prominent tool. Its use is 




By combining such an engineered TALEN with a DNA cleavage domain (which cuts DNA 
strands), one can engineer restriction enzymes that will specifically cut any desired DNA 
sequence. When these restriction enzymes are introduced into cells, they can be used for gene 
editing or for genome editing in situ, a technique known as genome editing with engineered 
nucleases (Gene Therapy Net, 2018). 
This technology has already been applied efficiently to solve a number of problems such as 
“…to efficiently engineer stably modified human embryonic stem cell and induced pluripotent 
stem cell (IPSC) clones and human erythroid cell lines; to correct the genetic errors that 
underlie disease; to correct the genetic defects that cause disorders such as sickle cell disease, 
xeroderma pigmentosum, and epidermolysis bullosa” (Ibid.). It can also, potentially, be used 
as a tool to harness the immune system to fight cancers. The lack of an efficient mechanism of 
delivery limits its use, although the technology can be easily combined with other genome 
engineering tools for better performance, as illustrated by the following report: 
In 2015, Physicians at the Great Ormond Street Hospital announced the first clinical use of 
TALEN-based genome editing. An 11-month old baby suffering from CD19+ acute 
lymphoblastic leukaemia20 was treated with modified donor T cells that had been engineered to 
attack leukaemia cells, to be resistant to Alemtuzumab, and to evade detection by the host 
immune system after introduction. A few weeks after therapy, the patient's condition improved; 
though physicians are cautious, the patient has been in remission for several months following 
treatment (Ibid).   
The impressive factor in this technology is its capacity for combination with others as well as 
its proven efficacy in the treatment of leukaemia, a blood disease whose treatment has been a 
challenge for ages, thereby, by implication, giving hope that other serious challenges, such as 
HIV-AIDS may receive solutions related to this. 
 There are also the zinc finger nucleases (ZFNs), which are “artificial restriction 
enzymes generated by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain” 
(Ibid.). The relevance of this technology is that it has been used “…in a clinical trial of CD4+ 
human T-cells with the CCR5 gene disrupted by zinc finger nucleases to be safe as a potential 
treatment for HIV-AIDS” (Ibid). In other words, there is a high likelihood of this technology 
emerging as an effective treatment for HIV-AIDS, once research eliminates any potential risks. 
3.5. TREATMENT-ENHANCEMENT DISTINCTION 
There is need for clarity in the understanding, distinction, and usage of the terms 
treatment and enhancement in this dissertation, especially in view of the moral significance of 
the distinction between the two. Treatment refers to an intervention that aims at the cure or 
                                                          
20“Childhood acute lymphoblastic leukaemia (ALL) is a type of cancer in which the bone marrow makes too many 
immature lymphocytes (a type of white blood cell). Leukaemia may affect red blood cells, white blood cells, and 




prevention of a disease, or even to only reduce its effects on a human being. The term disease, 
then, is “an adverse departure from species-typical normal functioning” (Holtug, 2011, p. 137). 
Enhancements have a completely different, though related, aim from treatment: enhancements 
aim “to affect various non-disease related factors that have a genetic component, including 
intelligence, talent, strength and height” (Holtug, 2011, p. 137). In other words, whereas 
treatments of disease and disability either restore or preserve normal functioning, 
enhancements seek to compensate nature’s victims of insufficiency in desired aspects of life. 
This matter has been given attention by Norman Daniels who explains that 
The treatment-enhancement distinction draws a line between services or interventions meant to 
prevent or cure (or otherwise ameliorate) conditions that we view as diseases or disabilities and 
interventions that improve a condition that we view as a normal function or feature of members of 
our species. The line drawn here is widely appealed to in medical practice and medical insurance 
contexts, as well as in our everyday thinking about the medical services we do and should assist 
people in obtaining (Daniels, 2000, p. 309). 
In Daniels’ discussion of the treatment-enhancement distinction, he draws a close relation to 
the concept of “medical necessity” in which “medically necessary services are those that 
effectively treat physical or mental disease and disability or ameliorate conditions deriving 
from them” (Daniels, 2000, p. 309). He argues that, although some medical services may be of 
benefit to certain people, they do not count as medically necessary. He gives two examples 
from insurance practice to illustrate his point: 
For example, insurance coverage is provided by public and private schemes for growth hormone 
treatment for children projected to be very short, provided that there is an underlying disease 
condition, e.g., some diagnosable growth hormone deficiency. Insurers do not cover the 
treatment for children whose parents simply want them to be taller, regardless of how short they 
will be, if there is no underlying disease condition. Similarly, insurers will generally reimburse 
reconstructive breast surgery following mastectomy or trauma. But they do not reimburse 
“cosmetic” surgery, however strongly a woman may feel that her life will be improved if her 
breasts are made larger or smaller (Daniels, 2000, p. 310).  
Hormone deficiency is understood to be a condition that denies normal functioning to a child, 
whereas ordinary shortness does not interfere with normal functioning. Seeking to resolve the 
former falls under treatment, while seeking to resolve the latter falls under enhancement. A 
similar argument suffices for the breast surgery example. This is what Daniels calls the “normal 
functioning model.” This dissertation proposes that HIV-AIDS should be classified as a 
condition that threatens, interrupts, or stops normal functioning in human beings, hence one 
that needs treatment through somatic genetic therapies. However, HIV-AIDS is a complex 
disease that gets transmitted to one’s children as well, and such children need capacity for 
immunity as may be best achieved through germline genetic enhancement of well-being. In 




therapies for HIV-AIDS patients, while germline genetic therapies should be permissible as 
well to those who would prefer and afford them.  
3.6. THE POTENTIAL OF CRISPR/CAS9 TO CURB HIV-AIDS 
 Since 2014 much scientific research has focused on CRISPR/Cas921, which is “an 
adaptation of an elegant, naturally occurring gene splicing mechanism” (Kirtley, 2016). 
CRISPR/Cas9 is “a unique technology that enables geneticists and medical researchers to edit 
parts of the genome by removing, adding or altering sections of the DNA sequence” (Your 
Genome, 2016). It is a new technology that is faster, cheaper and more accurate than previous 
techniques of editing DNA and has a wide range of potential applications. It is further known 
that 
…depending on whether the goal is to obliterate gene function or introduce specific changes in 
the DNA sequence, different modifications of the CRISPR/Cas9 system are used. The system 
has worked in almost every organism tested, including organisms previously resistant to more 
traditional forms of DNA manipulation (Kirtley, 2016). 
The usage of this technology and its potential for solving a number of human problems is 
significant. For example, already the producers of yoghurt are testing its use in the protection 
of yoghurt-making bacteria “from infections that can ruin large batches of yogurt” (Ibid.). 
Agribusiness establishments need it “to create genetically modified livestock and crops” 
(Ibid.). There has been some reasonable progress in the potential that lies in the technology to 
produce herbicide-resistant crops, through genome editing, without introducing a foreign DNA 
into the modified plant. In 2014, “…scientists used CRISPR to precisely target two genes in 
cynomolgus monkeys (a variety of macaque), the first time researchers were able to selectively 
disrupt genes in primates” (Niu, et al., 2014). Through additional research, scientists have 
shown that “…a mutation associated with tyrosinemia, a human metabolic disease, could be 
corrected in an adult mouse using CRISPR/Cas9 to fix the mutation” (Yin, et al., 2014). In 
other words, there is now hope that viral diseases that remain devastating due to the mutation 
of the virus in the human body, such as HIV-AIDS, may soon be tackled through similar 
approaches. 
 There is on-going research on the possibility of using CRISPR/Cas9 to create gene-
drives with which “…scientists could eradicate vector-borne diseases such as yellow fever, 
malaria or Zika by engineering disease-free mosquitoes specially designed to take over the 
entire mosquito population in a few generations” (Kirtley, 2016). Such a development “could 
                                                          
21CRISPR stands for “Clustered Regularly Interspaced Short Palindromic Repeats,” while Cas9 stands for 
“CRISPR-associated” and the number 9 is the protein enzyme’s serial number in the scientific research series. 




have an enormous public health benefit” (Ibid). However, there is need to proceed with great 
caution, “…since the release of these organisms could have unintended ecological 
consequences as there is no way to control the genetic drift of the engineered mosquitoes once 
released into the wild.” But suppose scientific research would develop means for such control 
for genetically engineered mosquitoes; the world would be a much better residence for humans, 
with such devastating diseases completely eradicated. There may also be a possibility that the 
envisaged genetically modified mosquitoes may cause a positive ecological impact. 
 The most significant area of interest is the potential for CRISPR/Cas9 emerging as an 
effective means of treating HIV-AIDS. Kirtley explains how “…the CRISPR/Cas9 system has 
generated so much enthusiasm is its potential for use in human gene therapy protocols” 
especially since it can be used “to correct mutations in human adult stem cells or induced 
pluripotent stem (iPS) cells.”22 He further explains that 
These edited cells could then be transplanted back into the patient to treat diseases. In basic 
laboratory experiments, scientists have already used CRISPR/Cas9 to excise HIV from the DNA 
of human cells and to correct a mutation that causes a blood disorder called Fanconi’s anaemia 
in iPS cells that are then differentiated into hematopoietic (blood) stem cells. Although this has 
not yet been tested in human patients, these now-healthy stem cells could in theory be 
transplanted back into a human patient to reconstitute a healthy blood cell population. 
Researchers are exploring a similar technique to re-engineer patients’ blood cells to become 
HIV-resistant (Kirtley, 2016). 
This is where research into genetic therapy for HIV-AIDS begins to give much hope to 
humanity on the possibility of a permanent solution to the pandemic. The moment it becomes 
possible to re-engineer the blood cells so that people become HIV-resistant, humanity will 
become free from one of the most dehumanising diseases ever known to human societies. It 
will be a solution to the desperation often expressed across the world through voices 
represented by the statement that 
AIDS is a global scourge that has killed millions, has brought heartache and suffering to millions 
more, and is likely to continue its grim lethal crescendo for the foreseeable future. The success 
of HAART in controlling HIV-1 offers hope, but the difficulties of this therapy and the ability 
of HIV-1 to mutate into drug-resistant variants necessitate continuous development of new 
therapies. The sobering results of clinical gene therapy trials for AIDS are cause, not for despair, 
but for reflection. Gene delivery may yet have a role to play in the fight against AIDS: continuing 
work in tissue culture and animal models encourages cautious optimism (Strayer, et al., 2005). 
 
As the preceding review reveals, scientific research on genetic therapies for HIV-AIDS have 
been largely fragmented and uncoordinated among the various institutions involved. In order 
                                                          
22 Induced Pluripotent Stem Cells (iPS) are derived from skin or blood cells that have been reprogrammed back 
into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human 
cell needed for therapeutic purposes. For example, iPS cells can be prodded into becoming beta islet cells to treat 
diabetes, blood cells to create new blood free of cancer cells for a leukaemia patient, or neurons to treat 




to develop an effective solution, there is need for coordination and linkage among investigators 
and institutions.  
 Discussions on CRISPR indicate that it may offer a solution sooner than the other 
attempts, although it may be too early to judge at this point. In April 2015, a research group 
reported results of their research on “…an attempt to alter the DNA of non-viable human 
embryos using CRISPR to correct a mutation that causes beta thalassemia, a lethal heritable 
disorder. The experiments resulted in changing only some of the genes, and had off-target 
effects on other genes” (Liang, et al., 2015). From this statement, CRISPR is yet to reach the 
optimum level where it can be applied as a reproductive technology or for gene editing in 
embryos. The Chinese scientists summarised their findings as follows: 
Repair template of HDR can be either the endogenous homologous gene or exogenous DNA 
sequence. This competition between exogenous and endogenous sequence complicates the 
analysis of possible gene editing outcomes make it difficult to predict the consequence of gene 
editing. Furthermore, mosaicism and mutations at non-target sites are apparent in the edited 
embryos. Taken together, our data underscore the need to more comprehensively understand the 
mechanisms of CRISPR/Cas9-mediated genome editing in human cells, and support the notion 
that clinical applications of the CRISPR/Cas9 system may be premature at this stage (Liang, et 
al., 2015). 
Granted that clinical applications of this technology are still considered premature by experts 
as outlined above, there seems to be likelihood of a more thorough development after further 
research and tests. Such research may produce solutions to various threats, including HIV-
AIDS.  
 While notable strides have been made with regard to the gene editing research, 
significant security concerns have been raised which may either slow down on-going research 
or refocus it positively. In the United States, the National Intelligence has recently included 
gene editing among weapons of mass destruction because of its ease of use and access. James 
R. Clapper, the Director of National Intelligence, in his report to the Senate Armed Services 
Committee on 9th February 2016, wrote:  
Research in genome editing conducted by countries with different regulatory or ethical standards 
than those of Western countries probably increases the risk of the creation of potentially harmful 
biological agents or products. Given the broad distribution, low cost, and accelerated pace of 
development of this dual-use technology, its deliberate or unintentional misuse might lead to 
far-reaching economic and national security implications. Advances in genome editing in 2015 
have compelled groups of high-profile US and European biologists to question unregulated 
editing of the human germ-line (cells that are relevant for reproduction), which might create 
inheritable genetic changes. Nevertheless, researchers will probably continue to encounter 
challenges to achieve the desired outcome of their genome modifications, in part because of the 
technical limitations that are inherent in available genome editing systems (Clapper, 2016).  
Even when Clapper’s report does not mention CRISPR directly, the description clearly has this 




they do not discuss financial implications, the report is likely to influence the possibility or 
otherwise of any further funding and support from the US government and its allies in global 
politics. There is, therefore, need for the scientific researchers to bring clarity to the US 
government and other governments as to the potential benefits of genetic technologies, 
especially with regard to therapies for devastating illnesses, in order that research funds may 
not be withheld. This is in view of the possibility of the US government, and other governments 
in the developed world, proverbially throwing out the baby with the bathwater. 
 In recent research in CRISPR/Cas9, focus has been on seeking to improve its efficacy, 
especially with regard to HIV. “Given its popularity and availability, CRISPR dominates 
genome-editing predictions. CRISPR-based systems will continue to improve 
incrementally…” (Tachibana, 2019). It appears that the practice of using CRISPR to correct 
disease-causing mutations is growing, and this is where it gives hope to sufferers of a constantly 
mutating virus such as the HIV. Already trials are going on for inherited blindness in humans. 
Recently, for the first time, doctors in the US used the gene-editing technique CRISPR to try 
to treat a patient with a genetic disorder that causes sickle cell disease. Victoria Gray, the first 
patient to be publicly identified as one involved in a study testing the use of CRISPR for a 
genetic disease, said she had always “hoped that something would be done” and that she was 
happy over that possibility. “But it probably will take months, if not years, of careful 
monitoring of Gray and other patients before doctors know whether the treatment is safe and 
how well it might be helping patients” (Stein, 2019). Reports like this are evidence that the 
technology will only get better with time, and will eventually apply to such illnesses as HIV-
AIDS too. 
3.7. CONCLUSION 
 In this chapter the discourse has focused on the need for clarity of meaning on the 
concept of “genetic therapy” in order to appreciate what the subject under study is. I have also 
sought to provide an understanding of the various types of genetic therapies that already exist 
and how they are used, in order to clarify on the potential benefits and challenges posed by the 
new genetic technologies. The chapter ends with a discussion on the potential of genetic 
therapies to curb HIV-AIDS, which is the focus of this dissertation. The main idea in the 
chapter is that, despite the challenges that are posed by genetic therapies in their current state 
of research, trials and development, they remain possibly the best remedies for devastating 
diseases if the challenges are eliminated through further research. Therefore, research into 




encouraged through adequate funding and enhancing collaboration among scientists, 






CHAPTER 4: UTILITARIANISM 
4.1. INTRODUCTION 
In this chapter I give a comprehensive motivation and justification for the choice of 
utilitarianism as a philosophical-ethical approach in this research, as I also recognise the 
existence of alternative ethical systems. I follow this with a review of the ethical theory of 
utilitarianism as stipulated primarily by Jeremy Bentham and John Stuart Mill, as well as 
contemporary philosophers. The focus is the application of utilitarianism to bioethics, 
especially the new genetic enhancement therapies available for resolving human disease 
burdens, especially HIV-AIDS. The ethics theory of utilitarianism is the framework within 
which reflections are done on genetic therapies, while it is, at the same time, also a criterion 
for evaluation. 
4.2. MEANING AND MOTIVATION FOR THE CHOICE OF UTILITARIANISM 
 In the first chapter of this dissertation, the ethics theory of utilitarianism was introduced 
as the most appropriate theory for assessing genetic therapies for the problem of HIV-AIDS in 
Africa. The question of how the perceived benefits of research into genetic therapies would 
benefit the people of Africa dominates the study. Despite the availability of various approaches 
to ethical decision-making, the question of benefit-sharing for the majority of the people is 
fundamental. It is the point of benefit sharing, with minimum negative consequences, that 
makes utilitarianism the most suitable ethical approach and method of ethical discourse. The 
theory of utilitarianism as developed by Jeremy Bentham (1748-1832) and John Stuart Mill 
(1806-1973) will be the lens through which the relevance of genetic therapies will be examined.  
 In order to proceed with clarity, it is necessary to understand what the term 
‘utilitarianism’ means. As Van Niekerk explains,   
Utilitarianism refers to an ethics theory that, strictly speaking, forms a sub-category of a group 
of theories known as consequentialism. Consequentialism as an approach to moral theorizing 
simply means that the consequences of actions are to be taken, and taken exclusively, as the 
only concern in terms of which the moral status (i.e. the moral rightness or wrongness) of an 
action is to be decided (Van Niekerk, 2017).  
He cites the classic example of the manner in which the Second World War was brought to an 
end through “…the explosion of two atomic bombs in the cities of Hiroshima and Nagasaki in 
Japan in August 1945…” (Ibid.). The argument here is that, although death and suffering was 
inflicted on the immediate victims, worse consequences were effectively prevented by the 
immediate surrender of Japan upon the bombing of the two cities. The matter of the strengths 




of this chapter. For the time being, further reflections on the meaning of utilitarianism will be 
sought.  
According to Blackburn, utilitarianism is an ethics theory that teaches the maximising 
of utility or happiness through life and action. He also says it is “the view of life presupposed 
in most modern political and economic planning, when it is supposed that happiness is 
measured in economic terms,” and quotes from J. S. Mill the statement that “actions are right 
in proportion as they tend to promote happiness, wrong as they tend to produce the reverse of 
happiness” (Blackburn, 2008). Merriam-Webster defines utilitarianism as “a doctrine that the 
useful is the good and that the determining consideration of right conduct should be the 
usefulness of its consequences; specifically a theory that the aim of action should be the largest 
possible balance of pleasure over pain or the greatest happiness of the greatest number” 
(Merriam-Webster, 2019). The same idea is defined as “the doctrine that the morally correct 
course of action consists in seeking and attaining the greatest good for the greatest number, that 
is, in maximizing the total benefit resulting, without regard to the distribution of benefits and 
burdens” (Collins English Dictionary, 2012) and further explained as “…a system of ethics 
according to which the rightness or wrongness of an action should be judged by its 
consequences. The goal of utilitarian ethics is to promote the greatest happiness for the greatest 
number” (Ibid.). The same line of thought is carried by Business Dictionary which defines 
utilitarianism as 
…an ethical philosophy in which the happiness of the greatest number of people in the society 
is considered the greatest good. According to this philosophy, an action is morally right if its 
consequences lead to happiness (absence of pain), and wrong if it ends in unhappiness (pain). 
Since the link between actions and their happy or unhappy outcomes depends on the 
circumstances, no moral principle is absolute or necessary in itself under utilitarianism 
(Business Dictionary, 2017).  
The definitions provided place emphasis on happiness, as a result of an action, being a criterion 
for deciding that a course of action is either good or bad, and right or wrong. It is also important 
that the envisaged happiness be beneficial to the greatest number possible in a given context.  
In the assumption that actions that promote good health also, at the same time, promote 
happiness, a deliberate choice is made to apply utilitarianism in assessing the relevance of 
genetic therapies for HIV-AIDS in Africa. 
 There are other ethics theories, such as virtue ethics and deontology, which can be 
applied in the assessment of genetic therapies. From previous discussions in the first chapter 
of this dissertation, virtue ethics places emphasis on the character of the moral agent in order 
to form personal identity which, in turn, leads to judgement of the agent’s action in the principle 




good habits which guarantee good results. But one may argue that virtue ethics creates a 
situation in which one has to consider results in order to judge an action virtuous. In this sense, 
then the practical value of virtue ethics is in its link with utilitarianism. Similarly, there is 
deontology as an ethics theory which is based on the agent’s moral duty, and where the right 
actions are those that maximise the good, based on commitment to duty as the means of judging 
any action. But rules and duties are always intended to achieve certain outcomes, which are 
viewed to be good, hence the link with utilitarianism. 
 My argument is that before the research is carried out and concluded, genetic therapies 
cannot be judged to be either good or bad speculatively. Similarly, rules cannot be set for or 
against the genetic therapies without already knowing with absolute certainty the consequences 
of these therapies. It is reasonable to use conclusive scientific evidence of their goodness or 
badness to, in turn, make rules on their use. In other words, the purpose and efficacy of the 
therapy must be potentially good for human health. Given the disease burden of HIV-AIDS as 
described in the first chapter, and in the assumption that the resultant pain is intrinsically evil, 
a utilitarian assessment is proposed to be the most reasonable approach. In any case, it is also 
reasonable to assume that any effective and efficient relief from the burden of HIV-AIDS is 
intrinsically good for Africa in general and Kenya in particular. 
4.3. ALTERNATIVE APPROACHES TO MORAL REASONING 
 There are a number of alternative ethics theories and systems by which the relevance 
of genetic therapies for the treatment of HIV-AIDS in Africa may be assessed, and it is worth 
the effort to seek to understand at least some of them, even if not all. Time and space do not 
allow for the consideration of all the ethics systems available, hence my preference to review 
only the Aristotelian and the Kantian theories. I shall begin with Aristotle’s virtue ethics. 
 Aristotle (c.384–c.322) views the ultimate purpose of human life, which is happiness, 
as the goal of ethics. For him, all other goods are temporal; only happiness is ultimate. So the 
main question for any human being is how to attain happiness. For Aristotle, both pleasure and 
honour fail the test of ultimately attaining happiness because, while pleasure reduces human 
beings to the level of animals, honour “places too much emphasis on the praise of others.” He 
concludes that the true means to happiness is virtue, which involves both habit and choice. 
Based on our choices in the past, we develop a virtuous character by which we make current 
choices. Indeed for Aristotle, “the virtuous choice was the mean between two extremes: excess 
and defect. For example, between profligacy and insensibility there lies self-discipline; 




 We may then ask, what is virtue? Cambridge dictionary defines virtue as “…a good 
moral quality in a person, or the general quality of being morally good” (Cambridge Dictionary, 
2017). Blackburn defines virtue as “a trait of character that is to be admired; one rendering its 
possessor better, either morally, or intellectually, or in the conduct of specific affairs” 
(Blackburn, 2008). For Aristotle, a virtue is “a trait of character that enables a person to 
flourish.”23 Hume goes a little further and says, “…a virtue is a trait of character with the power 
of producing love or esteem of others, or pride in oneself, by being useful or agreeable to its 
possessors and those affected by them” (Ibid). For Kant, however, “…virtue is purely a trait 
that can act as a handmaiden to the doing of duty, having no independent ethical value…” 
(Ibid.). Virtue ethics takes the notion of virtue as the foundational factor in morality. Rather 
than look at action as the producer of good, or at duty to provide rules for human action, virtue 
ethics views the qualities of moral goodness as the producers of human happiness.  
 It is useful, at this point, to turn to Beauchamp and Childress for an application 
argument with regard to health professionals. They argue against replacing virtuous 
judgements of health care professionals with rules, codes, or procedures.  Their opinion is that 
Rather than relying on institutional rules and government regulations to protect human research 
subjects, for example, the most reliable protection is the presence of an “informed, 
conscientious, compassionate, responsible researcher.” The claim is that character is more 
important than conformity to rules and that a premium should be placed in inculcating and 
cultivating the virtues through educational interactions and guidance by role models. Persons 
who are respectful, benevolent, and just reliably perform right actions: The respectful person 
respects others; benevolent persons act beneficently; and just persons conform their behaviour 
to the rules of justice. Even if a virtuous person makes a mistake in judgement, leading to a 
morally questionable act, he or she is less blameworthy than a habitual offender who performed 
the same act (Beauchamp & Childress, 2013). 
From the above reasoning by Beauchamp and Childress, the great value of virtue ethics is in 
the transformation of the character of the health care practitioner. It seems, then, that virtue 
ethics can be applied as a motivational theory with which to educate researchers on the right 
virtues or values to inculcate in themselves as they proceed with human subjects in biomedical 
research, including genetic therapies. In addition, virtue ethics enhances human relationships 
as a fundamental reason for getting involved in solving human problems, rather than doing so 
only on the basis of commitment to duty. However, there is much limitation in attempting to 
                                                          
23 In Nicomachean Ethics II 6, Aristotle points out virtue as the mean in the various situations. For example: 
“…with respect to acting in the face of danger, courage is a mean between the excess of rashness and the 
deficiency of cowardice; with respect to the enjoyment of pleasures, temperance is a mean between the excess of 
intemperance and the deficiency of insensibility; with respect to spending money, generosity is a mean between 
the excess of wastefulness and the deficiency of stinginess; with respect to relations with strangers, being friendly 
is a mean between the excess of being ingratiating and the deficiency of being surly; and with respect to self-





use virtue ethics alone to justify why research into genetic therapies is necessary, and why 
African governments should prioritise it in budgeting and resource allocation. One such 
limitation is the apparent need to relate the required expenditure in research with potential 
outcomes, which cannot be done on the basis of virtue ethics; at least not exclusively and 
comprehensively. 
 It is worthy of note that other thinkers also point out to a link between virtue ethics 
and the practice of medicine. Walker explains that 
An affinity between medicine and virtue ethics can be traced to ancient Greek philosophers: 
Plato, who praised Hippocrates’ method for understanding the body as a model for efforts to 
understand the soul and Aristotle, who compared the goal of medicine as health with the goal of 
virtue as human happiness or flourishing. Aristotle criticized the idea that the physician’s aim 
was health as an abstract idea, but rather emphasized that the goal was human health, and more 
specifically the health of the physician’s individual patients (Walker, 2010). 
There is a clear emphasis on the care of the patient as an individual through the exercise of 
practical wisdom based on the character of the physician. 
 In discussing Kantian ethics, Sjöstedt-H presents a popular saying among philosophers, 
“You can philosophise with Kant, or philosophise against him, but you cannot philosophise 
without him” (Sjöstedt-H, 2007). Immanuel Kant (1724-1804) can be classified as one of the 
most influential of all philosophers, perhaps equal in influence to Socrates, Plato and Aristotle. 
Kant argues that morality is deontological, which means moral acts are done because they are 
good in themselves, and not because they cause good consequences. For instance, when both 
necessity and opportunity direct one to steal food to feed a hungry family, we hold and uphold 
the duty to avoid theft, “…not because we may end up in prison, nor because we may feel 
regret or remorse, but because it is a wrong thing to do per se (in itself).” Whereas in 
utilitarianism we would assess the action based on the pleasure it would cause and the pain it 
would reduce or alleviate, in moral deontology we are bound to abide by duty. Kant teaches 
that “humans have reason above instinct, and this means that our motivations go beyond mere 
pleasure.” In this regard, the function of reason is not pleasure or happiness, but “to produce a 
will that is good in itself (not good for something else, such as happiness)” (Sjöstedt-H, 2007). 
Kant argues for the following of the Categorical Imperative as not doing so would mean that 
one acted for one’s own pleasure. This would mean that one is misusing reason – being 
irrational. The Categorical Imperative of Kant teaches two maxims: the first one is ‘I ought 
never to act except in such a way that I can also will that my maxim should become a universal 
law’ (Kant, 1956), while the second one is ‘Act in such a way that you always treat humanity, 
whether in your own person or in the person of any other, never simply as a means, but always 




ourselves would like to be treated, while the second one requires us to treat people as ends in 
themselves, and not as means to achieving other objectives for ourselves. In the context of this 
research, Kantian ethics is applicable to the ethics of research in genetic therapies in so far as 
affirming human dignity goes. However, as a theory for assessing their relevance, the theory 
would have minimal applicability into the discourse, because it does not address any potential 
or perceived impact. 
4.4. A REVIEW OF THE THEORY OF UTILITARIANISM 
 A general understanding of utilitarianism is that morality is primarily concerned with 
maximising happiness and minimising pain and misery. This means that an action is judged to 
be right when it affirms this principle, and wrong when it negates the same principle. Of course, 
when it does neither, then it is judged to be neutral. There are various notions of utilitarianism 
worthy of looking into in order to appreciate the theory in so far as it relates to genetic therapies. 
One of the notions is hedonistic utilitarianism which generally views pleasure as the only good 
to be cherished and enhanced, and pain as the only evil to be fought or prevented. Good, in this 
context, is defined as “that for which people feel approval” (Ewing, 1948). On the basis of an 
empirical argument, Ewing points out the weakness of defining “good” only on the account of 
people’s approval. He says, “…it may well be the case that people only feel approval for the 
kinds of action and qualities of character which will in general bring pleasure to someone; but 
it is certainly not true that the approval is proportionate to the amount either of actual or of 
anticipated pleasure”24 (Ibid). In other words, the level of actual pleasure may be quite far off 
from the mere fact of pleasure hence people’s approval may not be a valid measure of validating 
what is good.   
 So, one may ask, what is the nature of utilitarianism? What are its basic concepts? 
Henry R. West, in discussing this concept, explains that utilitarianism is an effort to provide an 
answer to the practical question “What ought a person to do?” to which the answer is that “a 
person ought to act so as to produce the best consequences possible” (West, 2015). West 
continues to say, 
                                                          
24 Ewing (1948:101) argues “Suppose, in the first place, I were offered as alternatives thirty years more of life as 
pleasant as the most pleasant week I have ever experienced on condition that I went mad or could only enjoy the 
pleasures of a pig and twenty-nine years of life equally pleasant with the pleasures of a good and reasonably 
cultivated human being. Would it not be rational and right to choose the second alternative rather than the first 
even though the pleasure was exhypothesis less and even if my choice neither increased nor diminished the 
pleasures of others?” He further gives an example: “…suppose two men who are deriving at the moment equal 
pleasure, one from enjoying the company of friends he loves and the other from torturing enemies he hates (West, 




In the notion of consequences the utilitarian includes all of the good and bad produced by the 
act, whether arising after the act has been performed or during its performance. If the difference 
in the consequences of alternative acts is not great, some utilitarians do not regard the choice 
between them as a moral issue. According to Mill, acts should be classified as morally right or 
wrong only if the consequences are of such significance that a person would wish to see the 
agent compelled, not merely persuaded and exhorted, to act in the preferred manner (West, 
2015). 
Both Bentham and Mill were hedonists who sought to establish an understanding of happiness 
as a balance of pleasure over pain, and that these two feelings alone are of intrinsic value. 
Utilitarianism argues for the possibility of comparing “…the intrinsic values produced by two 
alternative actions and to estimate which would have better consequences” (Ibid). Bentham 
believed in a hedonic calculus by which a moralist “…could sum up the units of pleasure and 
the units of pain for everyone likely to be affected, immediately and in the future, and could 
take the balance as a measure of the overall good or evil tendency of an action” (Ibid). In other 
words, whenever one has to compare values that derive from alternative acts, it becomes 
necessary to apply Bentham’s hedonistic calculus in order to arrive at what is good.  
 As a consequentialist ethics theory, utilitarianism takes seriously the potential or actual 
outcome of every action, whether such a consequence is observable during the action or at the 
end of it. There has to be a clearly discernible difference between the consequences of acting 
in a certain way and acting differently, for it is that difference that determines whether the act 
is moral or amoral. In this regard, according to Mill, “…acts should be classified as morally 
right or wrong only if the consequences are of such significance that a person would wish to 
see the agent compelled, not merely persuaded and exhorted, to act in the preferred manner” 
(West, 2015). This means that, if an act is to be judged to be good, it has to be so good that 
legislation would probably compel such action from those responsible for it. Conversely, if an 
act is to be judged to be bad, legislation would prohibit it. 
 It is still necessary to seek a deeper understanding of the concept of happiness and 
unhappiness in utilitarianism since it is the epicentre of this theory. Hodder endeavours to 
explain: 
By happiness, therefore, is intended pleasure and absence of pain; meaning to imply by this that 
not only those acts cause happiness which give someone pleasure, or which actually free him 
from pain, but those also which lessen his unhappiness. By unhappiness is intended pain, 
including every irksome and uncomfortable state of mind whatsoever, and implying that not 
only those acts cause unhappiness which actually give(s) one pain, but those also which curtail 
his happiness (Hodder, 1892). 
In other words, it matters that an act leading to happiness has the dual consequences of causing 
pleasure and freeing one from pain or harm. It also matters that an act leading to unhappiness 




friend to be embraced is happiness that leads to pleasure and freedom from pain; the enemy to 
be fought is unhappiness that causes pain and discomfort.  But what do utilitarians mean when 
they talk of the word ‘pain’? They have to use quantitative words like ‘bigger’ or ‘more’ to 
create a comparison with the desired opposite. So the pain could be ‘bigger’ than a certain 
pleasure; or that an act brings about ‘more’ pain than pleasure.  
 In discussing the historical development of utilitarianism25 Bertrand Russell records of 
Bentham’s use of the words ‘pleasure’ and ‘happiness’ synonymously, and held them as good, 
while holding ‘pain’ as bad. He says, “Therefore one state of affairs is better than another if it 
involves a greater balance of pleasure over pain, or a smaller balance of pain over pleasure. Of 
all possible states of affairs, that one is best which involves the greatest balance of pleasure 
over pain” (Russell, 1948, p. 802). From a calculus of pleasures and pains, Bentham developed 
a strong belief in equality, which caused him “to advocate equal division of a man’s property 
among his children” (Ibid). This idea is supported by Nathanson who explains that 
Utilitarians believe that the purpose of morality is to make life better by increasing the amount 
of good things (such as pleasure and happiness) in the world and decreasing the amount of bad 
things (such as pain and unhappiness). They reject moral codes or systems that consist of 
commands or taboos that are based on customs, traditions, or orders given by leaders or 
supernatural beings. Instead, utilitarians think that what makes a morality be true or justifiable 
is its positive contribution to human (and perhaps non-human) beings (Nathanson, 2017).  
Nathanson proceeds to explain the necessity of knowing three things that are important for a 
reasonable understanding of the theory of utilitarianism: “what things are good and bad; whose 
good (i.e. which individuals or groups) we should aim to maximize; and whether actions, 
policies, etc. are made right or wrong by their actual consequences (the results that our actions 
actually produce) or by their foreseeable consequences (the results that we predict will occur 
based on the evidence that we have)” (Nathanson, 2017). This is necessary because, although 
utilitarianism appears simple due to its only one evaluative principle, it has various nuances to 
it, such as act utilitarianism and rule utilitarianism, which may make it complicated.  
 What is good may not be limited only to happiness, but may extend to include other 
aspects of life such as health, freedom, friendships, food, knowledge, wealth, and a few more, 
all of which may fit into what Nathanson refers to as ‘well-being’.26 A lack of these items, then, 
diminishes well-being. On the concern over whose good should be maximised, utilitarians 
think of individuals, specific groups, and those who are affected by the subject of moral 
                                                          
25 According to Russell, utilitarianism was initially advocated by Hutcheson in 1725, long before Bentham whose 
main contribution in the development of the theory was in “his various application to various practical problems” 
(Russell, 1948, pp. 802-3). 
26 The nature of well-being is discussed in great detail in chapters 1-4 of Russ Shafer-Landau, The Fundamentals 




reasoning. At the individual level, one only needs to consider what would enhance one’s well-
being, like in ethical egoism.27 For instance, an individual in a restaurant may opt to eat either 
a pizza or a hamburger, and has no obligation to consider the preference of any other person; 
he or she simply chooses what is likeable and most suitable for his or her well-being. But if the 
same consideration has to made by a group, then there may arise a situation in which probably 
eight out of ten persons select to eat pizza, and only two prefer hamburgers. If only one type 
of food is to be prepared and served for the entire group, then the serving of pizza to the entire 
group will bring the greatest fulfilment to the greatest number in the group. In overriding the 
preferences of the two who would want hamburgers, the justification would be that at least they 
have something good to eat, and they have not been left to go hungry, which would have 
diminished their well-being. At the furthest end, in considering all affected persons, it would 
be important to focus on the fact that there are people who are hungry and need food to eat. 
Providing food for them would be the beneficial action to take, over against denying them food. 
Similarly, if certain people are sick of a disease for which treatment is available, it is a morally 
good act to provide the necessary treatment to them, rather than deny them the same. In relation 
to the subject of this research, the relevance of genetic therapies should be assessed in the 
context of the needs of affected people, rather than at group or individual levels. I will return 
to this aspect in greater detail at a later stage. 
 Deciding whether moral judgements should be “based on the actual consequences of 
actions or their foreseeable consequences” is a cause for differences among utilitarians. 
Nathanson refers to J. J. C. Smart who explains this difference by imagining the action of a 
person who, in 1938, saves someone from drowning:  
While we generally regard saving a drowning person as the right thing to do and praise people 
for such actions, in Smart’s imagined example, the person saved from drowning turns out to be 
Adolph Hitler. Had Hitler drowned, millions of other people might have been saved from 
suffering and death between 1938 and 1945. If utilitarianism evaluates the rescuer’s action based 
on its actual consequences, then the rescuer did the wrong thing. If, however, utilitarians judge 
the rescuer’s action by its foreseeable consequences (i.e. the ones the rescuer could reasonably 
predict), then the rescuer—who could not predict the negative effects of saving the person from 
drowning—did the right thing (Nathanson, 2017). 
In the story narrated above, the rescuer could not possibly foresee the future bad consequences 
of saving the drowning man, and it would not be fair to judge the rescuer of acting wrongly. 
What was foreseeable was that the rescue may allow someone to live who would otherwise 
drown. 
                                                          
27 “Ethical egoism claims that it is necessary and sufficient for an action to be morally right that it maximizes 




 Although utilitarians unanimously focus on producing the best overall result, they 
disagree on how to make that possible. They are divided into act utilitarians and rule 
utilitarians. For act utilitarians, the focus is on the greatest net utility resulting for an action. 
The right action is that which will cause more well-being than other actions would. For rule 
utilitarians, a specific action should be in conformity with a specific rule, and that specific rule 
is justified because it leads to greater well-being. As Nathanson further affirms,  
The key difference between act and rule utilitarianism is that act utilitarians apply the utilitarian 
principle directly to the evaluation of individual actions while rule utilitarians apply the 
utilitarian principle directly to the evaluation of rules and then evaluate individual actions by 
seeing if they obey or disobey those rules whose acceptance will produce the most utility 
(Nathanson, 2017). 
This distinction is important for the creation of a balance in moral decision-making that is based 
on a utilitarian theory. On the one hand, act utilitarianism delivers moral agents from dry rule-
based moralities and making moral judgements more objective. On the other hand, while rule 
utilitarianism tends to maximise utility, it ends up dissolving into act utilitarianism because, in 
the end, it is the action taken that actually matters.  
There is need to develop further the aspects of utilitarianism that attract criticism and 
the counter-arguments advanced in its favour. The broad theory of consequentialism is the view 
that “the value of an action derives from the value of its consequences” (Blackburn, 2008). It 
runs in contrast to virtue ethics which places emphasis on the character of the moral actor, and 
deontology which focuses on the intrinsic value of an action. The most prominent version of 
consequentialism is utilitarianism, which “…was first formulated by the English philosopher 
Jeremy Bentham (1748-1832) towards the end of the eighteenth century and refined by his 
successor John Stuart Mill (1806-1873) in the nineteenth century.” Christopher Falzon explains 
the foundation of utilitarianism as follows: 
Human beings, for utilitarianism, are primarily creatures that feel; creatures that seek to 
maximize pleasure and avoid pain. The role of reason is now to calculate what we can do to best 
bring about pleasure and avoid pain. And morality is now a matter of the consequences of our 
acts, of doing whatever will maximize the amount of pleasure, of happiness, in the world 
(Falzon, 2002). 
In consequentialism, of which utilitarianism is only part, the rightness or wrongness of 
a moral act is judged by the kind of consequences it produces. Only consequences matter and 
are to be considered when weighing moral acts. In utilitarianism, right acts are discerned only 
on the basis of the good results they bring about. No consideration is made of either the 
character of the person who does the act or the motive behind the act. Certain questions may 
be raised with regard to the morality of an act, questions on whether the individual recipients 




are violated or respected, and whether they are treated as means for achieving other ends. Such 
questions are ignored in utilitarianism and considered irrelevant. What matters is that the results 
of the act should maximize happiness. Furthermore, in strict impartiality utilitarian acts include 
every affected person, such that not even the moral agent’s happiness would receive special 
attention. In other words, in utilitarianism, three features stand out as fundamental: only 
happiness matters, only consequences matter, and moral acts must be applied impartially on 
all. 
 The features of utilitarianism discussed in the above paragraph are the prominent ones 
which are strongly criticised by opposing philosophers. Rachels and Rachels give strong 
criticism of these characteristics of utilitarianism as reasons for rejecting the theory. First on 
the line is the notion that happiness is the only factor that matters intrinsically, such that 
pleasure is the only good, and pain the only bad. Rachels and Rachels argue against hedonism 
in its false assumption that “things are good and bad only in terms of how they make people 
feel” (Rachels & Rachels, 2012). They point out that other things, such as artistic creativity 
and friendship, are also of intrinsic value to us. They cite the example of the loss of hands for 
a young pianist, and point out that the loss of hands is not bad simply because it makes the 
pianist unhappy, but rather because of her loss of talent. Similarly, a friend who ridicules one 
behind one’s back is wrong even if one is not aware of the ridicule, and cannot be excused 
merely because the subject of ridicule was not aware. Through these arguments, Rachels and 
Rachels portray as mistaken the utilitarian notion that only happiness or unhappiness of the 
consequences of an action matter. It is worth pointing out that contemporary utilitarianism is 
no longer strictly confined to hedonistic assumptions, but has streamed in new strands like 
“preference utilitarianism, where good is whatever individuals prefer, and ideal utilitarianism, 
where good involves a number of ideals, including friendship, pleasure, and aesthetic 
enjoyment” (Rachels & Rachels, 2012). This is especially so because quantifying various 
pleasures and pains is not easy. For instance, the joy of parenthood cannot be equated with the 
joy of eating something sweet. Peter Singer is an example of a philosopher who once held the 
preference utilitarian position, and would argue that  
…the consequences to be promoted are those which satisfy the wishes or preferences of the 
maximum numbers of beings who have preferences. In other words, the more people get what 
they want, the better, from a moral point of view, the world is. The more people's desires are 
frustrated, the worse the world is. It is only morally right to frustrate the preferences of others 
if by so doing we enable more beings to satisfy their preferences. Actions should not be judged 
on their simple pain-and-pleasure outcomes, but on how they affect the interests, the 




It is worth noting that Singer has shifted his position and now aligns closer to the 
sophisticated hedonistic view of Henry Sidgwick. Singer now believes that “only 
consciously experienced events matter, although we should construe hedonic experience 
more broadly than just raw pleasure and pain” (Tomasik, 2016). 
The second notion in utilitarianism that receives criticism from Rachels and Rachels is 
that of consequences as the only thing that matters, which would make utilitarianism seem to 
ignore matters of justice, individual rights, and moral considerations that look into the past. It 
is neither fair nor just that an innocent person should not be punished just to stop a race-based 
riot in a city; the police should not violate a woman’s privacy just to make themselves happy; 
and past events or commitments have a bearing on present moral actions, such that we cannot 
simply ignore the past. It is practically easier to rely on the past than to predict outcomes and 
impacts of human actions. The third notion of utilitarianism that Rachels and Rachels challenge 
is that of strict impartiality which they find too demanding. Equal concern for everyone may 
require that we change our lifestyles significantly in order to help those who are in need. 
Besides, the theory’s emphasis on happiness for the many seems to ignore the plight of the few. 
In other words, utilitarianism seems to guarantee nothing for the minority. 
Mark Sheskin and Nicolas Baumard have recently criticised utilitarianism, arguing that, 
“…although people may judge that utility maximization is morally acceptable (in some cases), 
they do not think it is morally required. Second, people do not think equal utility trade-offs 
(e.g., sacrificing one life for a different life) are even acceptable” (Sheskin & Baumard, 2016). 
In other words, in the first statement, what is acceptable is not necessarily required; and in the 
second one, sacrificing one person’s life in order to save another or others is wrong. 
The points raised against utilitarianism are worthy of paying attention to, especially the 
systematic manner in which the issues are raised by Rachels and Rachels. However, there are 
counter-arguments that not only respond to the points of criticism, but also strengthen a defence 
of the theory. Firstly, it is not always the case that the most favourable consequences will result 
when an innocent person is punished, or when an individual’s rights are violated, or when one 
fails to keep a promise. Indeed, a utilitarian argument would propose that treating people justly 
and keeping promises would normally promote good consequences. But Rachels and Rachels 
argue that “…once in a while, one can bring about a good result by doing something repugnant 
to moral common sense” (Rachels & Rachels, 2012). In instances where this is the case, 
utilitarianism will be “in conflict with common sense” (Rachels & Rachels, 2012). On the other 
hand, it must be pointed out that the occasional instances are not the norm. Secondly, in order 




rules that can be used to maximise overall happiness. This is what rule utilitarianism is all 
about. The moral act, in this case, will be one that conforms to the rules, such that the outcome 
will bring maximum happiness and minimum pain. For instance, the rules that prohibit 
violation of people’s right, the ones that promote justice and fairness, the ones against lying, 
and the kind in favour of loyalty to friends and family, will also be the rules that result into the 
greatest happiness. However, although this is tenable, Rachels and Rachels argue that there 
may be an instance in which “the ideal rules have exceptions,” a situation that may arise when 
“a forbidden act would greatly increase the overall good.” Either the utilitarian sticks to the 
rules, or grant an exception to the rules. Strictly sticking with the rules will move rule 
utilitarianism into the likeness of another moral theory, other than utilitarianism. It will lead to 
what J. J. C. Smart (Ibid.) calls “irrational rule worship.” Conversely, granting any exception 
takes rule utilitarianism back to act utilitarianism whose apparent weakness it was intended to 
resolve. But it must remain clear that the focus of rule utilitarianism is not the rules in 
themselves, but in the outcomes of actions that conform to those rules. In other words, the 
utilitarian rules are not an end by themselves but are a means to an end: they are rules that 
should lead to greater good for the people involved. Rules from which no benefit would accrue 
are typically not utilitarian rules; they are part of deontological ethics theory.  
The arguments presented by Sheskin and Baumard are valid to the extent of the first 
point they raise that not all that is acceptable is required. But it may be challenged because 
once an act is found acceptable its usefulness makes it viable for replication in similar contexts. 
The aspect that needs closer scrutiny is their second point in which they propose that sacrificing 
one person’s life in order to safe another or others is morally wrong. This seems to suit better 
in a deontological presentation than a utilitarian one. Human experience is full of stories of 
sacrifice with the intention to save others. This is the stuff of which heroism is composed. A 
vivid illustration is found in the Christian doctrine of salvation in which Jesus Christ teaches 
the virtue of love through self-sacrifice in a statement in John 15:13, “Greater love has no one 
than this; that He lay down His life for His friends.” A similar statement is repeated in Romans 
5:8, “God demonstrates His own love for us in this: while we were still sinners, Christ died for 
us.” Without getting into the theological arguments related to these statements, the idea that 
one dies in order to save many is held high as a perfect example for humanity. It blends well 
with intuitive responses of parents when an offspring is in grave danger: a parent risks 
drowning in order to safe a drowning child. Similarly, a soldier risks death in war so as to 
ensure the safety of citizens. Surely, if we say this is wrong, then humanity would behave 




A fair evaluation that focuses on all consequences of a moral act, while not dismissing 
the points of criticism against utilitarianism, will find the theory possessing advantages that 
make it suitable, especially in dealing with challenges that have severe negative impact on 
human life and health. It is reasonable to conclude in agreement with Rachels and Rachels that 
“All values have a utilitarian basis” (Rachels & Rachels, 2012). Although happiness is 
prominent in utilitarianism, it is not the only value that has intrinsic worth in the theory. Other 
values such as love, life, freedom, respect, peace, justice, art, and knowledge, also have 
intrinsic worth that makes them good and beneficial to individuals and societies. The human 
intuition that harming people is wrong finds a strong anchor in utilitarianism. The theory is 
easy to apply, as it only requires one to weigh up positive effects of an act against negative 
ones before making a choice. Additionally, its neutrality on beliefs makes the theory fair and 
objective to the religious and irreligious alike. And since it seeks to affirm general good instead 
of individual pursuit, utilitarianism turns out to be democratic in the way it functions for 
society. 
4.5. APPLICATION OF UTILITARIANISM TO NEW GENETIC THERAPIES 
 The fundamental focus of utilitarianism is to promote actions that can result into the 
greatest well-being for the greatest number of people. In the context of the scourge of HIV-
AIDS in Africa in general and in Kenya in particular, utilitarianism focuses on advocating for 
such research actions as have the potential of turning around the situation and bringing about 
desired curative treatment for the disease, thereby relieving individuals, families, communities 
and nations of devastating burdens. Although no cure is presently ready for clinical testing on 
human beings, a review of the genetic therapies that are currently undergoing research and 
development reveals great potential for treatment. I will now endeavour to apply the theory of 
utilitarianism to the new genetic therapies for HIV-AIDS.  
 Firstly, there is the magnitude of the problem of HIV-AIDS affecting a huge portion of 
Africa’s population. The infected people are under treatment which only suppresses the 
symptoms of the disease without actually curing it. Many people still die of HIV-AIDS related 
complications. A utilitarian approach to this problem looks at whether genetic therapies, if 
confirmed through research, would bring the greatest well-being to the greatest number. The 
theory would also seek to confirm if genetic therapies would minimise or even eliminate pain, 
as far as AIDS-induced suffering is concerned. In this regard, I conclude that a utilitarian 
approach will enhance the well-being of the infected and the affected people of Africa and the 




cure for their own illness, but also a means for preventing future infections in the respective 
families. 
 Secondly, there is the matter of looking into the possibility of foreseeing the potential 
results, and whether the results will be negative or positive. For example, until scientifically 
observed or verified, it is not yet known whether any genetic modification of the human genes 
to make humans resistant to HIV-AIDS infections will in future lead to other forms of genetic 
abnormalities in humans. For the sake of speculation, suppose in future it is established that all 
persons whose genes have been modified to make them resistant to HIV infections end up 
producing one-eyed offspring. Would it be said at that time in future that the implementers of 
genetic therapies did the wrong action? I would argue that, since such a result cannot be 
foreseen right now, the implementers should not be judged of wrong action because in the 
present the focus is on the saving of the millions of human beings whose lives and well-being 
are severely compromised by the infections. In any case, since research is still on-going, it is 
possible to eliminate potential extremities in this regard. 
I refer here to Albert R. Jonsen for an argument proposing that medical treatment does 
not focus only on the patient presenting at the clinic but also on the population, and that the 
population should form the new base for the practice of medicine. And if population is the new 
base, then it follows that diseases that affect large populations need more serious attention.  
The drift of medicine from a patient base to a population base poses a major challenge to the 
ethics of medicine, ethics that have grown up around the imperative of competence in patient 
care. The intrinsic ethical limits to competence, based on undesirability of care from the 
patient’s viewpoint or futility of care from the physician’s, are no longer sufficient. Even if a 
particular patient should judge medical attention to be undesirable, we know that others in the 
relevant population may be affected by that refusal or need information or therapy that depends 
on the patient’s decision (Jonsen, 1990, p. 35).  
If the focus were to remain on only one patient, the medical profession would miss out on the 
benefits that go to other people. Jonsen argues that even if a particular intervention fails to help 
a specific patient, it may be of help to another, and cites two examples: “the brain-dead mother 
perfused for two months to bring her fetus to vitality, or the anencephalic perfused until his 
heart and liver can be transplanted into another baby.” The professional relationship between 
the doctor and the patient can benefit significantly from the population which should be an 
integral part of that relationship. This is a new approach that is unfamiliar to both the 
Hippocratic and Cabotean28 medicine (Jonsen, 1990, p. 35). 
                                                          
28 The term “Cabotean medicine” was coined by Jonsen from the name of Dr. Richard Cabot (born 21st May 1868; 
died 7th May 1939) who served as a member of the Harvard Medical School faculty. Dr. Cabot was the first to 




 In application of a utilitarian ethics theory on the relevance of genetic therapies for 
treating HIV-AIDS, three points seem to emerge: the patient will be cured; the patient’s family 
will be relieved of burdens arising out of having to care for a sick member; the descendants of 
the patient will be prevented from inheriting the disease; and future societies will be saved from 
a devastating disease burden. Of course an opponent of utilitarianism may argue that consent 
will not be obtained from future generations on the modification of their genetic make-up. But 
such an argument would not stand, given that the change would not lead to their pain, disability, 
or stigmatisation in any way. Surely, any measure to prevent a future child from inheriting a 
deadly virus must be in the child’s best interests. 
4.6. CONCLUSION  
Here I have provided a comprehensive motivation and justification for the choice of 
utilitarianism as a philosophical-ethical approach in this research, while I have also recognised 
alternative ethical systems such as deontology and virtue ethics. I have reviewed the theory of 
utilitarianism as postulated by Bentham and Mill. I have attempted to apply the theory of 
utilitarianism to bioethics, especially the new genetic enhancement therapies available for 
resolving human disease burdens, especially HIV-AIDS. The ethics theory of utilitarianism is 
established in this chapter as the framework within which reflections are done on genetic 
therapies. In the subsequent chapters, I argue in further details on the merits, or otherwise, of 
the use of genetic therapies through the lens of utilitarianism. 
  
                                                          
physician consisted of one understanding specific diseases, their causes, signs, symptoms, courses, prognosis, and 




CHAPTER 5: ARGUMENTS AGAINST GENETIC THERAPIES 
5.1. INTRODUCTION 
The fifth chapter of the dissertation discusses various possible reasons that either have 
been raised or may be raised against any research and usage of genetic therapies. The goal is 
to seek to establish if genetic therapies may be more harmful than beneficial if applied in Africa 
for the treatment of HIV-AIDS, and whether existing remedies may be satisfactory and 
therefore preferable. The arguments developed are slippery slope, naturalist, distributive 
justice, lack of consent, and negative theological-ethical arguments. Later on, in Chapter 7 of 
this dissertation, evaluations and responses are made to these arguments, as well as arguments 
in support of genetic therapies as discussed in Chapter 6.  
5.2. SLIPPERY SLOPE ARGUMENTS 
There are arguments known as “Slippery Slope Arguments”29 that are advanced against 
genetic therapies on the grounds that such therapies are likely to lead the scientific society into 
a slippery slope of carrying out other forms of genetic engineering which may be unacceptable 
to the human society for various reasons. The first argument is that once one level or form of 
genetic therapy is accepted by the human society scientists will yield to the temptation to move 
to another level or form. Accepting a second phase of moral action is considered a logical 
commitment that follows the acceptance of a first phase. For example, there may be fear that 
using genetic therapy to treat HIV-AIDS may put medical science on a slippery slope in which 
soon a desire will grow for 'curing' baldness, obesity, poor eyesight, and other kinds of human 
bodily challenges through genetic therapy. It may lead couples into seeking what has been 
referred to as “designer babies”, a term that generally refers to babies whose physiological, 
intellectual, psychological characteristics are designed, through genetic manipulation, to meet 
the exact desires and expectations of parents. Such action may turn out to be actual 
enhancements of the human population, which may very much be like eugenics and Hitler's 
idea of a master race. The argument is that accepting genetic therapy for HIV-AIDS logically 
leads to a commitment to accept genetic solutions to other aspects of human defects. The 
                                                          
29 The term “Slippery Slope” is commonly used in ethics arguments to refer to situations in which permission to 
carry on with an act has the potential of leading into morally more precarious acts in the same area or other 
dangerous acts in other areas but based on similar ethics reasoning. In this chapter, however, I have borrowed the 
phrase “Slippery Slope Arguments” from McGleenan who discusses the idea in fair detail (McGleenan, 1995). 
Frederick Schauer defines slippery slope argumentation as one in which “a particular act, seemingly innocent 






assumption is that there are challenges that humans have which are natural and should be left 
to continue without interference. I will argue in the next chapter that there is nothing morally 
wrong with the use of genetic therapies to solve human disadvantages such as the kind 
mentioned above. Wharam explains that the fear is with reference to “…the development of 
gene therapy for a valid medical reason, but used for purposes not initially intended” (Wharam, 
1999, p. 2). He reports of a discussion that arose at the first Gene Therapy Policy Conference 
that was sponsored by the Recombinant DNA Advisory committee (RAC) of the National 
Institutes of Health (NIH) in the United States, where scientists predicted that within two years,  
a researcher will propose a gene-therapy experiment that, although initially aimed at curing 
disease, could eventually be used to enhance a trait in healthy people (Vogel). One such example 
has to do with hair loss as a result of chemotherapy. A biotechnology company has developed a 
means of transferring genes into hair follicles, and is looking for the genes that promote hair 
growth. The objective is to reverse hair loss due to chemotherapy, which seems to be a worthy 
cause. If the company is successful and develops a protocol to stop hair loss, cancer patients 
would no longer have to be bald. However, those opposed to gene therapy worry that many 
naturally balding people will be receiving gene therapy to treat their hair loss (Wharam, 1999, 
p. 2).  
The example cited here may seem frivolous, or simplistic, but it exemplifies of the kind of fear 
that is in the minds of people who see gene therapy as an attempt to make superior human 
beings. 
The second slippery slope argument is based on fear of the perceived “historical link 
between eugenics and genetics,” a perception that arises out of “…the Nazi experiment and the 
scientific and technological advancements of the last decade (of the 1990s)” (McGleenan, 
1995, p. 350).  This argument says, in the case of euthanasia for example, that “if we allow the 
legislation of mercy killing of individuals in terminal and intractable pain, we will be taking 
the first step towards the type of genocide perpetrated by the Nazis” (McGleenan, 1995, p. 
352). In other words, if we allow ‘A’ we will end up in a situation where ‘B’ is also allowed. 
If we allow genetic therapy for HIV-AIDS we may end up in a situation where genetic solutions 
are applied to other kinds of problems, including racial and ethnic problems, and this is what 
some people fear may lead to something similar to eugenics. I will later argue against the 
danger of throwing away the baby with the bathwater, so to speak. In other words, it may be 
incorrect to conclude that just because eugenics is morally wrong does not necessarily make 
genetic therapy also morally wrong. We cannot reject genetic therapy for such a devastating 
illness like HIV-AIDS merely because fear the return of eugenics. There should be stronger 
moral reasons for doing so. Besides, realistically, it is not possible to accurately predict, with 




science. It may be possible, but it is unlikely, and no one can accurately predict its future 
occurrence.  
The third slippery slope argument is based on the general fear of any new frontiers in 
medicine as potentially more harmful than beneficial to humans. With regard to both somatic 
and germ-line gene therapy, some would accept one form while rejecting the other. In the 
United Kingdom, for instance, the Clothier Committee decided that a clear line be drawn 
between somatic gene therapy and germ-line gene therapy. The report mandated scientific 
research on somatic gene therapy to continue and stated that “…the development and 
introduction of safe and effective means of gene modification for this purpose is a proper goal 
for medical science. We, therefore, recommend that the necessary research continues” 
(Committee on the Ethics of Gene Therapy, 1992). The Clothier Committee decided to allow 
and regulate research on somatic gene therapy. However, they declined doing the same for 
germ-line gene therapy due to insufficient knowledge on possible risks at the time: 
The purpose of gene modification of sperm or ova or cells which produce them would be to 
prevent the transmission of defective genes to subsequent generations. Gene modification at an 
early stage of embryonic development, before differentiation of the germ line, might be a way 
of correcting gene defects in both the germ line and somatic cells. However, we share the view 
therefore that there is at present insufficient knowledge to evaluate the risks to future 
generations… We recommend, therefore, that gene modification of the germ line should not yet 
be attempted (Committee on the Ethics of Gene Therapy, 1992). 
The argument here is that, if a mistake is made on germ-line therapy, it will be passed on to 
future generations; and depending on the magnitude of the mistake, thousands of people may 
be affected. In case any germ-line gene therapy goes wrong, in this case, terrifying mutations 
could result, with the possibility of a completely new species of genetically modified humans. 
This argument seems valid at this stage in the research of gene therapy, which is why, 
ironically, it may also be reasonable to argue the research should continue in order to not only 
ascertain the efficacy of the therapy but also take care of all known safety concerns. Of course, 
the argument also assumes that the regulatory framework on genetic therapy will, for the most 
part, be either extremely weak or absent altogether, an assumption which is unjustifiable given 
that regulatory frameworks have previously existed and worked. The question then is, do the 
potential benefits of germ-line gene therapy outweigh the potential risks that may arise? In the 
foregoing argument, the answer is in the negative because the effects of gene therapy are too 
unpredictable at present. Even if genetic therapy successfully cures the disease for which it is 
designed, other mutations may potentially be introduced into the genetic makeup of the 
individual. The resulting fear is that, since germ-line gene therapy targets the reproductive 




generation. Theoretically germ-line gene therapy could be used to select for particular physical 
characteristics regardless of whether they are important for the health of the individual. On a 
large scale, germ-line gene therapy could result in the selection of characteristics to “improve” 
the genetics of a population, thereby alienating sections of the human population that are yet 
to benefit from similar therapy. In the end, the widespread use of germ-line gene therapy may 
make society less accepting of people who are different or who have a particular disability or 
genetic condition. 
 Slippery slope arguments against genetic therapies are worthy of attention in order to 
address the concerns raised. But, as I will argue later in the next chapter, they are weak and 
flawed in logic. As I will argue in the evaluation chapter from a utilitarian ethics theory 
perspective, they are not sufficient to lead to a prohibition of both somatic and germ-line 
genetic therapies. I must now look at another type of argument raised against genetic therapies, 
namely naturalist arguments. 
5.3. NATURALIST ARGUMENTS 
The set of arguments that I herein refer to as naturalist arguments are those that seek to 
preserve and defend the natural state of human beings, an endeavour in which genetic 
engineering in general and genetic therapy in particular are perceived as enemies that need to 
be kept at bay. These arguments are closely related to (but not necessarily based on) the 
philosophy of naturalism which refers to “the theory that everything in the world and life is 
based on natural causes and laws, and not on spiritual or supernatural ones” (Hornby, 2010, p. 
983). That which is natural is what exists in nature without having been made or caused by 
humans. A naturalist proposes that something is good because it is natural. In this context 
specifically, the human body is good as it is, without being re-made, or modified, or materially 
altered in any way. On the contrary, an act may be judged morally wrong because it is not 
natural. An argument that states preference of the natural over the unnatural is a naturalist 
argument.  
The first naturalist argument in this category is the one that says genetic therapies are 
not natural. But what is natural? What sort of idea does the term ‘natural’ convey? To be natural 
is to be usual and normal; it is to be ordinary and accepted; it is to be in a state that society is 
familiar with. One may then ask, is natural good or bad? Is it right to be natural or is it wrong? 
In what physical, spiritual, emotional, psychological, intellectual, social, or economic state 
would a human being be considered natural? As far as the physical part goes, it is natural to be 




football match, or is the shower a good act that society socialises me to consider as a 
requirement? Being a worshipper of some supernatural or natural being may be natural; but 
being a Christian may not be natural. One consciously decides to become a Christian, or a 
Muslim, or an atheist. Further on, is the process of decision making natural, or is it dependent 
on socialisation by one’s immediate family or society? To be uneducated or unschooled is the 
natural state of most regular humans. Getting an education, becoming a technician, or 
becoming a university professor are forms of improvement of the human state. It seems 
education, for the most part, produces improved human beings, at least intellectually. Similarly, 
the human body is susceptible to disease and death, which are enemies of human well-being. 
One of the ways human beings improve eye sight is through the use of spectacles and optic 
lenses, and one may wonder whether the wearing of such devices is unnatural. It seems 
plausible that most corrective methods and devices that human beings use in dealing with 
diseases and defects are not necessarily natural. They are methods, procedures, and devices 
that have been scientifically developed to alleviate specific human challenges. We ask 
ourselves, in this context, whether contracting a disease and allowing it to cause death is more 
natural than seeking treatment against the disease, or if the contrary is true. Of course, genetic 
therapies are not natural. But this can be ascribed to almost all therapies, save for a few herbal 
drinks that some people prefer for certain minor ailments. The question is, is it morally wrong 
to prescribe and make use of unnatural remedies? It seems the argument that genetic therapies 
are not natural is an argument that may not stand close scrutiny. It seems to need a backup from 
another argument in order to credibly draw philosophical attention.  
The second naturalist argument, closely related to the foregoing one, says that genetic 
therapies interfere with how humans are constituted. In other words, it is sometimes perceived 
that genetic therapies are an affront on what I call ‘genetic authenticity’, a term by which I refer 
to the presumed genuineness of the human genetic makeup as naturally constituted, a trait that 
presumably needs to be preserved at all costs.  Any development, change, or manipulation that 
causes the genes to function differently in response to disease or harm is perceived to be a form 
of interference. The assumption is that interference of any sort is wrong and should be 
outlawed. This argument is upheld by world bodies such as UNESCO which declares the 
importance of preserving “the human genome as a common heritage of humanity” (UNESCO, 
2005).  Some thinkers fear that genetic therapies will enable human beings to “replace natural 
selection with deliberate selection, Darwinian evolution with ‘enhancement evolution’” 
(Anderson & Tollefsen, 2008, p. 79). The argument develops into two sub-themes. One sub-




genetic editing, even for the purpose of treating an illness, is thought to have the potential to 
interfere with this presumed uniqueness. Empirically, this allegation remains unproven, as long 
as research into genetic therapies has not been concluded and treatment formally launched. The 
other sub-theme holds that human nature is something that we need to sustain. But what is the 
nature of the human being for which preservation and protection is sought? Anderson and 
Tollefsen propose that this nature be understood in two parts namely descriptive and normative. 
In seeking to understand the descriptive aspect of the nature of the human being, “…human 
persons must be shown to be human animals -- bodily organisms of the species homo 
sapiens…” while the normative aspect in “…a reflective critical account of the practical 
horizons of human wellbeing, an account that grounds an understanding of human benefits, 
harms, and moral obligations” (Anderson & Tollefsen, 2008, p. 79). But this way of 
understanding the nature of the human being seems to be inadequate in considering how genetic 
therapies are an interference with human nature. The mere fact of humans belonging to a certain 
species in the animal kingdom does not necessarily give direction as to whether interfering 
with that nature is right or wrong. There have been improvements made in certain animals with 
fundamental positive changes in the bodily functioning of those animals in response to certain 
adversities such as disease, and this should apply to humans as well. This is an argument I will 
develop further in the succeeding chapter. 
The third naturalist argument points to the genetic complexity of human beings as 
another reason against genetic therapies. That human beings are genetically complex is not in 
doubt. Indeed, the human genome has only been known in science since 2003, and much is yet 
to be known. Even what is known is yet to be adequately known and described. The human 
genetic code “…consists of three billion letters (or base pairs), which is equivalent to 500 
million words, and subsequently equivalent to about 8,000 books” (Kilner, 2018, p. 5). The 
argument goes that, given the magnitude of what remains unknown on the human genetic code 
and exactly how each gene functions in relation to the others, there is a likelihood of any 
changes, or modification, or improvements, even when providing therapy against a specific 
disease like HIV-AIDS, to lead to some unknown negative effect on other genes, a state that 
may not be known until many generations later. The argument raises fear of the unknown. In 
other words, it is medically risky to carry out genetic therapies on the complex human genome, 
especially because human knowledge about it is currently limited. Costley argues that 
The danger objection points out that a few recent attempts at gene therapy in clinical trials have 
made headlines because of the tragic deaths of some of the people participating in the trials. It 
is not fully known to what extent this was due to the gene therapy itself, as opposed to pre-




have called for a stop to gene therapy until more is known. We just do not know enough about 
how gene therapy works and what could go wrong (Costley, 2018, p. 4). 
 
Based on currently inadequate knowledge on genetic therapy as well as genetic enhancement, 
naturalist arguments further raise four scientific concerns:  
…the vectors may deliver the DNA to cells other than the target cells, with unforeseen results; 
viruses as vectors may not be as innocuous as assumed and may cause disease adding new genes 
to a nucleus does not guarantee they will go where desired, with potentially disastrous results if 
they insert in the wrong place; if the changes are not integrated with other DNA already in the 
nucleus, the changes may not carry over to new cells and the person may have to undergo more 
therapy later; (and) changing reproductive cells may cause events not seen until years later, and 
undesirable effects may have already been passed on to the patient’s children (Costley, 2018, p. 
4). 
The concerns raised in this argument are strong and worthy of serious note, especially in the 
context of further research to ensure that sufficient precautions are established in order to 
ensure safety. However, the major weakness with this argument is its assumption that the 
limited human knowledge on the human genome is a permanent and unchangeable condition. 
But knowledge is a dynamic reality in which change and growth are a regular experience. 
Today we may not know much; but we may discover and know tomorrow what we do not know 
today.   
The fourth naturalist argument against genetic therapies says there is no moral 
obligation to genetically modify human beings. For an act on the human body to be morally 
obligatory, it has to necessarily possess two qualities: one, it should introduce a solution to a 
problem that is causing or supporting a harmful phenomenon (treatment of disease); and two, 
it should help the body to develop capacity to prevent harm (prevention of disease). Susan Hall 
in explaining the difference between therapy and enhancement says, “…therapy aims to 
achieve, in a particular individual, the level of functioning that would have pertained for that 
individual …in the absence of disease or disability” (Hall, 2012, p. 94). She argues that, 
although enhancement seeks to introduce capacities that make the individual function at a 
higher level than the individual’s contemporaries, there is a basic similarity between treatment 
and enhancement:  
This similarity lies in the fact that both treatment and enhancement are directed towards bringing 
about a change in the physical condition of a particular individual that is better for that individual 
than their previous condition.  In other words, both treatment and enhancement are desirable, 
from the perspective of the affected individual, because they contribute towards an increased 
level of well-being (Hall, 2012, p. 98). 
Mark Costley, however, insists on a dichotomy between the two ideas: “We use the term ‘gene 
therapy’ for efforts to bring people up to normalcy and ‘genetic engineering’ or ‘enhancement 




2018, p. 2). It appears to be the case that any interventions that are not yet understood and 
accepted to be within the ‘natural’ are to be avoided because there is no moral obligation to 
apply to them. However, an alternative analysis may support the argument that, actually, we 
are morally obligated to provide therapy, especially when we closely examine the idea of 
vaccination which is a form of enhancement. Indeed, this argument will be developed in the 
next chapter in support of genetic therapies. 
Another argument of the naturalist kind is that there is a good side of bodily weakness, 
so humans must not be overly determined to eradicate disease and bodily faults. This is an 
extension of the previous argument, especially since it seeks to have the human body retained 
naturally, with its strengths and weaknesses, without any perceived interference. Bodily 
weakness has its good side, especially in reminding the human race of its frailty, finitude, and 
limitation. It is a trait that causes us to be careful for own wellbeing and caring for fellow 
humans at the same time. The argument here is that if human weakness is genetically removed 
from human characteristics, humans may never know the true value of strength and health, 
since human weakness will have disappeared. 
The last argument I want to discuss in this section focuses on procreation which is 
supposed to be a natural process. Genetic therapy is seen as an interference with this natural 
process since genes are engineered to become resistant to one, or many, disease(s). 
Reproduction will no longer be simply a result of human gametes meeting and getting 
fertilised; it will now involve an additional procedure to ensure a scientific elimination of 
vulnerability to certain diseases. The question is whether this would be morally wrong. Already 
doctors monitor pregnancies for any vulnerability to any diseases for early diagnosis, decision 
making, and possible treatment. I doubt if genetic therapy will function differently in this 
specific scenario. Already, as has been argued earlier, vaccinations are in use to help prevent 
diseases that would otherwise be truly deadly and devastating to human populations. 
 I will review each of the preceding arguments from a utilitarian perspective and point 
out strengths and weaknesses thereof. Meanwhile, in the next section of the current chapter, I 
will proceed to a new set of arguments against genetic therapies, namely, distributive justice 
arguments. 
5.4. DISTRIBUTIVE JUSTICE ARGUMENTS 
 Some arguments advanced against genetic therapies belong to the category generally 
classified as distributive justice arguments. They are arguments that focus on the distributive 




in genetic therapies. From the start, I point out that these arguments may appeal to governments 
in Africa, including Kenya which receives special focus in this dissertation. The first argument 
in this category is an intra-health argument which appeals to better use of available resources. 
The argument presents the lower, common, and cheaper categories of health needs as worthier 
of government support than the heavier, rare, and expensive illnesses. Simply stated, the 
enormous resources that are currently being invested in research on genetic therapies 
(especially in the developed world), and the potential investment of the meagre resources 
(especially in Africa), can be used in improving general healthcare. In expressing concern about 
general healthcare needs, reference is made to the fact that numerous deaths are caused by 
malaria, TB, and water-borne diseases. These are largely preventable and curable, except that 
resources are not sufficient to meet treatment needs and preventive public health campaigns. 
Afrobarometer Policy Paper Number 31 points out that, although healthcare access has 
improved over the last decade, the reality of people’s experience points to a wide gap that still 
needs serious attention in several areas: 
In many areas, a continued absence of basic health-care facilities; Shortages of needed medical 
care experienced by almost half of all Africans; Widespread difficulties encountered in 
obtaining care, sometimes compelling patients to pay bribes; (and) Poor government 
performance, according to citizen ratings, in improving basic health services (Armah-Attoh, et 
al., 2016, p. 1). 
Research in genetic therapy is, of course, both expensive and intensive, consuming huge 
amounts of resources as well as time. In resource-scarce regions such as Africa, such research 
is viewed as “luxuries” which should not be promoted at the expense of supposedly “real” 
healthcare. This view is supported by a survey in nine sub-Saharan countries which found out 
that people were deeply concerned about such basic issues as “improving hospitals, preventing 
and treating HIV-AIDS (through ARVs), …fighting hunger, quality drinking water, infectious 
diseases, prenatal care, and childhood immunizations…” (Simmons, 2015). As long as 
healthcare in Africa is still held down with the basics, like the ones mentioned here, genetic 
therapy is still not even part of a dream. If any money becomes available, the governments 
would rather use it to take care of the basic levels of health needs than to invest it in research 
in genetic therapies. 
 The second distributive justice argument, which is closely related to the first, although 
slightly wider in scope, is a matter of choice between the developmental and educational needs 
of all the citizens on the one hand, and the healthcare needs of the sick “minority” in the 
population. It is easily understood that public funds should be used to construct and maintain 




is that economic and infrastructural development and educational institutions and systems 
benefit everyone in a country. Research, on the other hand, especially the kind carried out on 
genetic therapies, seems to benefit only a small segment of the population. The question that 
follows is, does Africa need more development than research, or does it need more research 
than development? It appears both are needed in equal measure, since research and 
development have a symbiotic relationship that makes them interdependent. To advocate for 
one without the other is to kill both. Elina Christoforou, the Coordinator of the doctoral 
programmes at the multi-campus UNICAF University, says that African countries should do 
more. She is quoted to have said,  
African countries face many challenges, which hinder the growth of research and sustainable 
development. Postgraduate education remains underdeveloped, access to it is still limited and, 
as a result, contribution to research is equally small. In spite of the fact that 15 percent of the 
global population comes from Africa, the continent only contributes a mere 2 percent of the 
world’s scientific knowledge. African countries have significantly increased investments in 
science in the last few years, but most of them still invest less than 0.5 percent of their GDP in 
research (Walker, 2018). 
If Africa, and indeed the rest of the world, is going to place emphasis on development, it has 
to, at the same time, place emphasis on research, including research in areas that currently seem 
to be of less priority, and especially research on possible genetic solutions for deadly diseases 
such as HIV-AIDS. Greater economic justice will be served better to the people in this way 
than with a narrow focus on infrastructural and educational aspects of development. 
 The third distributive justice argument says that genetic therapies are likely to 
encourage class differences among human populations. This is likely to show itself in at least 
two ways: economic power for accessing genetic treatment on the one hand, and discrimination 
based on treatment received or not received on the other hand. On the first count, it may be 
argued that only economically well-endowed people will have access to these genetic 
treatments because they are expensive. If this became a reality, genetic therapy will work 
against ideas of equality and justice in society. Any scientific development that either causes 
or enhances inequality and injustice in society is a harmful development which should be 
discouraged and discontinued. This is a strong argument against genetic therapies, given that 
they are extremely expensive to develop and to produce. In April 2018 it was reported30 that it 
had become possible to clinically treat blindness through genetic therapies, but that “…many 
people with rare diseases that could be treated in this way may never benefit from these 
therapies because they are too expensive for drug companies to develop, or too costly for the 
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patient or health service to afford,” with the cost standing at “$425,000 (£302,000) per eye” 
(Moschos, 2018). That is what middle-level professionals in African countries, outside South 
Africa and Egypt, would earn in their entire employment life. The poor majority would not 
earn that even in an entire lifetime. Definitely it would be out of question for governments to 
take over the costs of such treatment. Moschos describes a situation in which there was much 
hope when genetically engineered stem cells restored the damaged skin of a young boy. 
Genetically engineered skin stem cells restored around 80 per cent of the skin of a seven-year-
old who had suffered from blisters and open wounds from birth due to a genetic disorder. Two 
drug companies received approval for ground breaking gene therapies for childhood leukaemia 
(Moschos, 2018).  
She continues the description saying there had recently been a development of a gene therapy 
for an inherited form of blindness, and that it was now possible to edit the genome of an adult 
human being to correct genetic disorders. “The cost of these treatments, though, ranges from 
about $500,000 to $1.5m. And over a lifetime, drugs like nusinersen31 can be even more 
expensive: $750,000 in the first year followed by $375,000 a year after that – for life” 
(Moschos, 2018). This price range is the same for most genetic therapies so far successful and 
available, such as 
Kymriah, the recently-approved treatment that delivers an engineered immune system protein 
in gene therapy wrapping, is a one-time treatment for a form of leukaemia, costing 
$475,000. Yescarta, for a different blood cancer, is similarly priced. The seven-figure cap may 
come from experience with Glybera, the first gene therapy approved in Europe. Despite decades 
in development, the drug was yanked after only two patients got it, the $1 million-plus cost 
deemed excessive. The second gene therapy approved in Europe, Strimvelis, to treat an inherited 
immune deficiency, costs $665,000 (Lewis, 2017). 
From these prices, it is clear that, after years of designing a genetic drug and getting it approved 
by the relevant authorities, getting it to the market for physicians and patients is extremely 
expensive. In the end, the costs will be too high for patients to afford, resulting into extremely 
few patients. Consequently, it will not be profitable for pharmaceutical companies to 
manufacture and sell such medicines. The question, then, is how much genetic treatment should 
cost, and how such costs should be taken care of, and whether insurance companies will be 
interested in giving cover for them. One may agree with Bill Gates in his statement that 
Gene editing is generating a ton of optimism for treating and curing diseases, including some 
that our foundation works on (though we fund work on altering crops and insects, not humans). 
But the technology could make inequity worse, especially if it is available only for wealthy 
people (Gates, 2018). 
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Gates, although quite optimistic on the prospects of finding cures for certain devastating 
illnesses, points out that it will be problematic if the genetic therapies would become available 
only to rich people, and not to all who will need it.  
It seems clear that, whether individuals pay for them or insurance companies provide 
cover, genetic therapies are an expensive affair that only the super-rich in societies will be able 
to afford. But it may well be asked, is it morally wrong to manufacture treatment that only rich 
people in society can afford? The answer to this question depends on a few factors. In an ideal 
world in which the large majority are rich and able to afford anything they decide to have, the 
manufacture of such treatment would be beneficial to the majority. In other words, such action 
would bring maximum happiness to the greatest number of people. In such a case, producing 
such treatment would be morally right, at least in a utilitarian sense. But even if rich people 
were an absolute rarity, making treatment available that only rich people can afford would be 
the virtuous act to carry out. It is already the way medical treatments are done all over the world 
anyway. There are certain levels of treatment that are highly expensive and only accessible to 
the rich. As a matter of fact, society is not obliged to ensure that every critically ill patient gain 
access to a highly specialized hospital. It is simply a fact of life that certain things are only 
accessible to the rich, although certain basics are made available to everyone. But I will develop 
this argument further in the next chapter. 
 On the second count of the third distributive injustice argument is closely linked to the 
first count, and points to genetic discrimination which is likely to emerge and grow based on 
treatment received. In other words, it is likely that those who will be able to afford genetic 
therapies will be the only ones able to insulate themselves and their descendants from 
experiencing certain diseases and their devastating impact. This will make them a preferred 
class of people within the insurance industry and also among employers. Conversely, people 
who will not afford genetic therapies will face forms of discrimination based on their genetic 
inability to prevent the occurrence of disease in themselves. In the United States where people 
fear genetic tests because of the likelihood of discrimination, the Department of Health and 
Human Services has explained the occurrence of defined genetic discrimination saying, 
“Genetic discrimination occurs when people are treated differently by their employer or 
insurance company because they have a gene mutation that causes or increases the risk of an 
inherited disorder” (US National Library of Medicine, 2019). As a result, the US federal 
government as well as various state governments have enacted laws that prohibit insurance 
companies from deciding on any individual’s eligibility for cover solely on the basis of that 




on people’s suitability for employment or promotion based on genetic information. The 
discrimination is not just on people who have certain genetic conditions that make them prone 
to certain diseases; it will in future also extend to those who will not be able to genetically 
secure themselves and insulate themselves from disease. The discrimination objection to 
genetic therapies also includes people whose genetic makeup has caused them to be impaired 
physically, mentally, or emotionally.  
Such impairment can result in disablement in our society. People with disabilities are often 
discriminated against by having fewer opportunities than other people. By removing genetic 
disorders, and resulting impairment, it is true that gene therapy could contribute to removing 
one of the sources of discrimination and inequality in society. But the implicit assumption being 
made, the objection claims, is that people impaired through genetic factors need to be treated 
and made normal. The objection sees gene therapy as a form of discrimination against impaired 
people and persons with disabilities (Costley, 2018, p. 4). 
Such people will no longer appear “normal” in a society where genetic therapy, including germ-
line therapy, will have become “the new normal.” In other words, in an ideal society in which 
genetic therapies will be accessed by a large majority, such therapies will become regular, 
ordinary, or typical, and those who will not have treated themselves with the therapies will be 
sort of “abnormal” in the eyes of the many. It is such situations that the “abnormal” will 
experience discrimination in employment, in healthcare insurance, and in social life. 
5.5. ARGUMENTS FROM LACK OF CONSENT 
 An argument may be advanced that the people directly and indirectly affected by germ-
line gene therapy, such as children and future descendants, had neither agreed to nor given any 
consent to the treatment. And it could not be assumed that such agreement or consent could 
have been given on their behalf by their parents since proxy consent can only be given on 
behalf of existing persons for treatments that are actual and necessary. In other words, it is only 
normal for consent to be present and current. Consent cannot be effectual if it is only 
hypothetical. The morally problematic matter is that the individual who has a problem for 
which there is need for a solution is the existing person suffering from, say, HIV-AIDS. The 
treatment sought, however, is not only a solution to the current disease but is also providing 
the protection of a possible future person through genetic modification. The presently existing 
person assumes that the potential future person would also like to have their genetic material 
modified. But that is something that is only presumed. No one has the capacity to know for 
sure what will be the preferred method of treatment for a yet-to-be-conceived person. The 
germ-line therapy gives such descendants capacities which they simply inherit rather than 




consciously. There are various ways of understanding the consent argument in this context: 
consent as right, consent as permission, and consent as agreement.  
 Rights are civic liberties that are guaranteed to individuals and societies because they 
belong to an organised system of modern governance, such as a state or a nation, as citizens. 
Such civil liberties are normally defined and protected by the constitution of the country. 
Existence is a prerequisite for the guarantee and enjoyment of civil liberties or rights. For 
example, the Constitution of Kenya states that every person in Kenya has the right of access to 
health care (Constitution of Kenya, 2010, p. 24). The Constitution here assumes that the person 
on whom the right is conferred actually exists and is personally able to choose whether and 
how to enjoy this right. For a person to enjoy treatment, they have to have the capacity to give 
consent to forms of treatment that they understand and prefer. A presumed future person does 
not exist in reality, and does not enjoy such a right to health care as prescribed in the 
Constitution because the prescription is for present people. A future person cannot give consent 
for a present procedure because the future person is only presumed to possibly come into being 
in future. How about parental consent given on behalf of a minor? The fact is that parental 
consent is given on behalf of, and in the best interests of, an existing minor who is either 
actually physically undergoing treatment or has treatment plans being made on their behalf. 
Future persons do not exist, so they do not have rights to give consent on treatment. The 
question then is, if non-existing persons cannot make treatment decisions in the present, why 
should existing persons have the right to give consent on behalf of the non-existent ones? There 
is a close relationship between consent and rights, and consent “…can create rights as well as 
turn what would otherwise be a wrongful act into an act that is right. It can, for example, give 
another person a right to do something that would otherwise be wrong” (Gunderson, 2008, p. 
87). Consent can also be a means by which a right can be waived, or a way of leading a patient 
not to stand up for a right. In this sense, consent is a sort of “double-edged sword.” 
 There is also the idea of consent as permission as an argument that challenges the use 
of genetic therapies.  In giving consent, one gives authorisation for the treatment to be applied 
to the body, such that a physician is absolved from liability that would otherwise be applicable 
if the patient had not given such consent. The patient gives a “go-ahead”, or approval, or 
endorsement, to be treated in the manner prescribed by the doctor. One analyst explains that 
“…consent functions as way of allowing another to do what would otherwise be morally or 
legally impermissible. Consent functions to facilitate, or at least not prevent, an action” 
(Gunderson, 2008, p. 87). A future person cannot be personally present to understand the 




parent or legal guardian to give such permission. A complication arises with the reality that 
there are no legal provisions for existing persons to sign legally enforceable documents of 
consent one behalf of persons who are yet to be even conceived in the first place. In other 
words, it is not clear how a non-existent person can grant permission for any form of treatment. 
Therefore, any decision made should be considered arbitrary. Yet a counter-argument will 
respond that life is packed with arbitrary decisions, including contraception, pre-natal 
treatments, and vaccination, which are all permitted and carried out on behalf of potential as 
well as actual living persons. As such there should be no exception with regard to germ-line 
genetic therapies. 
 Finally, there is a sense in which consent is an agreement between the patient and the 
physician. It is a form of a contract or treaty which should be binding on both parties, with 
guarantees, and should be legally enforceable. For instance, in the event that a progeny of a 
genetically treated individual gets infected with HIV-AIDS after birth, they should be able to 
sue for damages. That necessitates that appropriate legal framework be put in place across 
international boundaries to take care of the nature of agreements, treatments, and any resulting 
litigation. In the context of treatment, there is no right not to receive medical treatment and 
care. For example, it is never considered wrong to provide treatment to a sick child, or to a 
mentally disabled person, or to an elderly person, even when it may not be possible to obtain 
their consent because they are not able to give it. The argument advanced by Holm is worthy 
of note:  
…it is quite usual to make decisions that have far reaching effects on one’s descendants (e.g., 
deciding what country to live in). If these decisions are not problematic, why should we regard 
germ-line engineering as a problem? …lack of consent would have to be equally problematic 
even if future generations were benefited (Holm, 2002, p. 88).  
Consent from persons unable to give it seems unnecessary even in cases where the potential 
benefits of an act are clear and non-controversial. As Gunderson points out, “…it would be 
absurd to refuse to engage in germ-line genetic engineering to prevent a person from being 
born with a devastating genetic disease such as Tay Sachs on the grounds that the future persons 
would not have consented” (Gunderson, 2008).  If we have to have consent for every good 
action that we need to take, there would be very few solutions procured for either children or 
the unborn. 
5.6. NEGATIVE THEOLOGICAL-ETHICAL ARGUMENTS 
In this section I introduce a discussion on theological-ethical arguments which I treat 




Africans in general, and Kenyans in particular. The World Factbook gives a breakdown on the 
religious diversity of Kenyans, based on the last official population census carried out in 2009: 
“Christian 83% (Protestant 47.7%, Catholic 23.4%, other Christian 11.9%), Muslim 11.2%, 
Traditionalists 1.7%, other 1.6%, none 2.4%, and unspecified at 0.2% of the population” 
(Kenya Population, 2019). These figures are supported by official records of the Kenya 
National Bureau of Statistics which place Catholics at 9,010,684, Protestants 18,307,466, Other 
Christian 4,559,584, Muslims 4,304,798, Hindu 53,393, Traditionalists 635,352, Other 
Religions 557,450, no religion 922,128, and those who do not know 61,233 (Kenya National 
Bureau of Statistics, 2013). With variations on inclinations, the religious commitment in Kenya 
is reflective of other countries in Africa. Some of the earlier mistakes made in response to HIV-
AIDS in the 1990s were based on faulty theological persuasions, which in turn informed ethics. 
An example was the false idea that AIDS was a form of punishment from God, an idea that 
was later and gradually corrected by theologians and moral philosophers. Based on the 
prevalent influence of religion, it is, therefore, important to discuss theological-ethical 
arguments that may be raised against genetic therapies. 
Arguments that appeal to the authority and sovereignty of God in relation to morality 
are classified as theological-ethical arguments, regardless of the religious persuasion in focus. 
Theological ethics are ethics that are primarily founded on religious or theological doctrines or 
principles. It is important to understand these arguments especially because religion is a 
dominant facet of human life throughout the world. Belief systems are strongly influential in 
matters of life and health, and frequently form the basis for either accepting or rejecting new 
approaches to medicine. The connection between Christianity and Western philosophy has 
been discussed in fair depth by Vincent Brümmer who argues that there are four facets of which 
Western philosophy consists, and each has its own basic theme with which it is identified.  
Christian philosophy is dominated by the biblical motive of creation, fall and redemption; Greek 
thought by the motive of form and matter; humanistic thought since the Renaissance by the 
motive of nature and freedom; and scholastic thought (that is an attempt at accommodating the 
Christian motive to one of the other motives) by the motive of nature and grace (Brümmer, 
2006, p. 41). 
In Vincent Brümmer’s argument, although the latter three motives are different from that of 
Christian thought, there is a pivotal place for Christian philosophical thought that cannot be 
ignored because religion underlies much of philosophical and scientific thought. It is important, 
then, where religious thought is prevalent, to delve into theological-ethical reflection. The 




Mbiti32 in his statement, "Africans are notoriously religious" (Mbiti, 1969, p. 1). These words 
of Mbiti remain as true today as they were 30 years ago when he wrote his classic work African 
Religions and Philosophy, in description of the dominance of religion in the life of the 
indigenous African. For the African, reality is primarily interpreted in religious terms. It is, 
therefore, highly likely that the acceptance or rejection of genetic therapies for HIV-AIDS in 
Africa will be, to a great extent, based on religious or theological perception of the new 
phenomenon, hence the importance of developing an understanding of certain theological 
arguments against genetic therapies in this section. 
The first theological-ethical argument is what is referred to in theological thought as 
the Creator-creature distinction. This is in reference to the doctrinal dichotomy between God 
as the Creator on the one hand, and human beings and the rest of the universe as creatures on 
the other hand. “The distinction between God as the Creator and everything else (the creation; 
the heavens and earth) is a fundamental Christian belief…” (Sigler, 2014), a belief that 
Christianity shares with Judaism and Islam. God is the creator of all that exists, and remains 
distinctly different from what He has created, including human beings. As humans we owe our 
existence to God who alone has neither beginning nor end. There should never be confusion 
between the Creator and His creation.  Caneday explains how humans relate to God through 
“five primary analogical relationships” namely “(1) king and subject; (2) judge and 
defendant/litigant; (3) husband and wife; (4) father and child; and (5) master and slave” 
(Caneday, 2003, p. 163). The idea is that, although God reveals Himself to humans in human 
terms, God remains incomparable to humans. We must maintain the perception that humans 
are able to create because humans are like God and are created by God in God’s own image 
and likeness. “God is the original; we are the organic image, the living copy” (Caneday, 2003, 
p. 163). This idea of creator-creature distinction has serious moral implications, especially in 
relation to the subject of genetic therapies. Firstly, it is the idea that should lead human beings 
into acknowledging finitude in all endeavours, including scientific research and medical 
practice. In other words, human beings should humbly acknowledge that God created human 
beings with a complex genome which should not be subject to human editing or modification 
of any kind for any reason. Secondly, it should bar humans from venturing into doing things 
that only God can do, the idea commonly referred to as “playing God” in ethics discourse. In 
                                                          
32 Professor John Samuel Mbiti (born on 30th November 1931; died on 6th October 2019) was a Kenyan-born, 
Cambridge-educated, Christian religious philosopher and writer. Between 1977 and 2005, Mbiti was a Professor 
of Philosophy of Religion at the University of Bern, Director of the Ecumenical Institute of the World Council of 
Churches, and an ordained Anglican parish minister to the town of Burgdorf, Switzerland. This academic and 




essence, humans must not venture into areas in which only God reserves knowledge and 
authority, and this includes genetic engineering. Any science that modifies human genes and 
the way these genes function is an affront onto the majesty and authority of God, as it blurs the 
creator-creature distinction. 
A second theological-ethical argument focuses on the given-ness of life, in which case 
the term “given-ness” implies that God is the giver of life. Both the Bible and the Quran teach 
that life comes to us from God as a gift. The first book of the Bible, Genesis Chapter 1, tells of 
how the Spirit of God (the Holy Spirit) hovered over the face of the waters and that the earth 
was formless, empty and dark (Genesis 1:2). When God miraculously spoke with His almighty 
Word and power, everything immediately came into being, including the light; the atmosphere; 
the land, water and plant life; the sun, moon and stars; the birds of the air and the fish of the 
seas; and finally, every land animal and human life. In a later book, the Bible presents a 
character named Job who, in his extreme suffering, spent time thinking more about life than 
most people would do in similar situations.  
His day seemed to pass quicker than a “weaver’s shuttle” (Job 7:6), or a single breath (Job 7:7). 
His days appeared to rush by like a courier with an urgent message (Job 9:25), as a “swift ship,” 
or like an “eagle who hastens to the prey” (Job 9:26). He saw man’s days as “few.” He was 
rather like a flower that blossoms and then quickly dies, or as a rapidly passing shadow (Job 
14:1-2). 
The prophet Jeremiah quotes God, “Before I formed you in the womb, I knew you; before you 
were born, I set you apart” (Jeremiah 1:5a). The Psalmists addresses God saying,  
For You created my inmost being; You knit me together in my mother’s womb. I praise You 
because I am fearfully and wonderfully made; Your works are wonderful; I know that full well. 
My frame was not hidden from You when I was made in the secret place. When I was woven 
together in the depths of the earth, Your eyes saw my unformed body. All the days ordained for 
me were written in Your book before one of them came to be. (Psalm 139:13-16) 
Saint Paul was once invited to speak before the philosophers of Athens, his limited opportunity 
forced him to focus on the origin of life. He confidently affirmed that it is the true God who 
“gives to all life, and breath, and all things” (Acts 17:25). Later, in a letter to a young student 
of his, St. Paul reminds Timothy that the Creator is the one who “gives life to all things” (1 
Timothy 6:13). The Quran says that there are great blessings for those “who, when a misfortune 
overtakes them, say, ‘Surely, we belong to God and to Him shall we return’” (Surat Al-Baqara, 
2016). As Suzy Ismail says in one lecture at Princeton, “Life’s fragility should remind us of 
the greatness of God, and the goodness of God’s creation should inspire us to respect life” 
(Ismail, October 6th, 2014). 
Other writings also carry the same idea. Tolstoi, in his book Anna Karenina, brings out 




before death reveal dependence on God for life itself: “‘Where am I? What am I doing? Why?’ 
She wanted to rise, to throw herself back, but something huge and implacable pushed at her 
head and dragged over her. ‘Lord, forgive me for everything!’ she said, feeling the struggle to 
be in vain’” (Tolstoi, 1886, p. 725). At the end of her life, Anna turns to God in expression of 
deeply genuine regret and repentance. In this case we may join Andrews in her lament, “It can 
be a helpless and terrifying feeling to think that one does not have the power in himself to 
change, improve, or fill his own life with meaning. What is the purpose of our lives if 
everything that eventually comes to us is a gift and is not a result of our own efforts?” 
(Andrews, 2017). She continues into a different perspective, saying,  
“But maybe that’s the wrong question. Maybe it needs to be turned on its head. If life itself is a 
gift– if our being is the gift– what if its purpose is the business of the giver and not of the gifted? 
If the changes that take place in me are a gift, then I am filled with all the more gratitude for my 
… productive energy” (Andrews, 2017).  
All of life, including suffering moments, is given to us from the Creator. Of course, we are 
responsible for our own failures in the things we are supposed to carry out. But ultimately life 
is not of our own making. It is a gift from the Creator who has its finer details that we are not 
aware of, and who brings it to an end at His will. This argument, though in support of human 
medical effort to treat diseases and assure physical comfort, views scientific effort to alter or 
modify human genetic functioning as an extremity that seeks to either introduce permanence 
of life or somehow defeat God’s decision to end it. This is viewed as morally wrong because 
human beings are raising their intellectual and creative capacity beyond what humans were 
really created to be. 
 The notion of the giftedness of life is given attention by Sandel who, while discussing 
the topic of enhancement, criticises “the drive to mastery” among humans who approach live 
as “a kind of hyperagency – a Promethean33 aspiration to remake nature, including human 
nature, to serve our purposes and satisfy our desires… And what the drive to mastery misses 
and may even destroy is an appreciation of the gifted character of human powers and 
achievements” (Sandel, 2004, p. 5). Sandel says 
To acknowledge the giftedness of life is to recognize that our talents and powers are not wholly 
our own doing, despite the effort we expend to develop and to exercise them. It is also to 
recognize that not everything in the world is open to whatever use we may desire or devise. 
Appreciating the gifted quality of life constrains the Promethean project and conduces to a 
certain humility. It is in part a religious sensibility. But its resonance reaches beyond religion 
(Sandel, 2004, p. 5). 
                                                          
33 The term Promethean describes a characteristic of “being rebelliously creative and innovative” like the ancient 
Greek demigod Prometheus who, in Greek mythology, “modeled humans from clay and taught them agriculture 





The idea that Sandel brings out is relevant to the matter of human enhancement, especially with 
regard to sports performance, height increment for children, and memory capacity, beauty, and 
other not-so-necessary aspects of enhancement. However, if we reflect upon it in connection 
with genetic therapy for devastating illnesses, then it is not fair to attribute the human struggle 
to defeat disease to “the drive to mastery”. Human beings who strive to defeat danger are not 
just seeking heroic achievements, but are naturally affirming self-preservation.  
A third theological-ethical argument is based on an evaluation of the human bodily 
endowment as given by God. The human body and the way it functions has been described by 
some as “God’s masterpiece” (Paturi, 1998). It is a precise and efficient machine, so to speak. 
Paturi marvels at the wonder that the human body is: 
The body has a chemical plant far more intricate than any plant that man has ever built. This 
plant changes the food we eat into living tissue. It causes the growth of flesh, blood, bones and 
teeth. It even repairs the body when parts are damaged by accident or disease. Power, for work 
and play, comes from the food we eat (Paturi, 1998).  
The human body, as made by God, has its God-given mechanisms for dealing with infiltration 
and disease, whose treatment should be as natural as possible. The natural way the human body 
responds to disease is through the immune system which is absolutely indispensable for human 
survival, especially “…in a world full of potentially dangerous microbes, and serious 
impairment of even one arm of this system can predispose to severe, even life-threatening, 
infections” (The College of Physicians of Philadelphia, 2019). The cells of which the immune 
system consists are found in the blood and in some internal organs of the body. God is 
understood to be the maker of this complex system for the protection of humans. From this 
perspective, treatment should only aid the body’s capacity to fight disease without any genetic 
engineering taking place. Genetic therapy is seen to be tampering with bodily mechanisms 
established by God. This argument gets weaker under close scrutiny when other human 
experiences are brought to the fore. For example, humans have invented and used vaccinations 
for decades in order to prevent disease without waiting for natural bodily responses. 
The last argument in this section is based on the idea that I have chosen to call 
“eschatological perfection” because of its focus on the future end times as taught in the 
Judaism, Christianity, and Islam, though in varying details. The key though is that the world 
and all of reality, as presently constituted, will come to an end and will be replaced by an eternal 
bliss in which human being will experience no more sickness, pain, or death. In his article 
‘Eschatology and Christian Perfection,’ CJ Barker explains that eschatology is concerned with 
“ineradicable aspirations of mankind,” in relation to time and eternity, setting forth the idea 




peace and perfection (Barker, 1944, p. 8). “It is a commonplace of the language of piety to 
contrast the temporal with the eternal” (Ibid.). The Kingdom of God is expected to usher in an 
end to all human suffering, an idea that should comfort the believer to persevere when 
contemporary solutions fail to yield expected remedies for disease and pain. Does that mean 
human beings should stop all efforts at finding treatments for harmful diseases? Of course not. 
But the endeavour to find solutions must be in the context of, at the same time, appreciating 
human limitations which frustrate final solutions, and will continue to do so, until God brings 
in a new dispensation of peace, security, and justice. The value and urgency of this 
eschatological perfection is propelled by the anonymity of the dates and times when this final 
bliss in heaven will become a reality, as stated in several portions of the Bible (Matthew 24:36-
44, 1 Thessalonians 5:1-3, 2 Peter 3:10, Revelation 3:3), as well as in the Quran (Surah 20:15 
and Surah 30:63). 
Admittedly, theological arguments against genetic therapies turn out to be the weakest 
from a purely philosophical point of view. Ironically, on the ground, especially on a continent 
like Africa in general, and in Kenya in particular where there are “more than 4,000 registered 
churches,” mainly Catholics and evangelicals, (Information Cradle, 2018), the same 
theological arguments turn out to be also the strongest arguments against genetic therapies. 
These arguments make sense to many people in various contexts that are influenced by 
religious and theological ethics. 
As stated earlier at the beginning of this section, the value of these theological-ethical 
arguments is in developing the idea that religion is held high in the lives of the majority of 
Kenyans, who happen to reflect upon issues with a religious or theological perception. The 
theological-ethical arguments discussed above are not necessarily entirely agreeable. Firstly, 
the view that there is a distinction between creatures and the Creator does not annul human 
scientific developments intended to solve human problems such as disease. Secondly, the 
notion of the given-ness of life does not prevent humans as “receivers” from creativity and 
development, especially if consistency is to be maintained together with the notion that humans 
are made in the “image and likeness” of God. Such creativity, in consistency with being in the 
“image and likeness” of God, may include genetic therapies for deadly diseases such as HIV-
AIDS. Thirdly, the complexity with which God is viewed to have made humans – a point used 
in supporting the idea of letting the human genome stay as it has always been – has never 
prevented humans from catching killer diseases. Indeed, such an argument would go against 
the science of medicine, a tendency that would be really absurd! Lastly, eschatological 




eschatological perfection is likely to benefit only those who believe, which is why Rabbi 
Abbahu said, "The day of rain is of more importance than the day of resurrection; for on the 
latter day only the righteous will arise from the dead, but rain falls for all alike, righteous and 
wicked" (Jewish Virtual Library, 2019). In other words, eschatological expectations will not 
necessarily be beneficial to all. We might as well consider the day of genetic therapies to be 
the day of rain in this context. In the third section of Chapter 7, I respond in some detail to the 
theological-ethical arguments. 
5.7. CONCLUSION 
I have discussed various possible reasons that either have been raised or may be raised 
against any research and usage of genetic therapies. I have used these arguments to establish 
that although genetic therapies may be perceived to be harmful beneficial if applied in Africa 
for the treatment of HIV-AIDS, the perceived harm should be carefully evaluated with a view 
to seeking solutions, especially since existing remedies are not a permanent solution. I have 
presented and developed arguments such as slippery slope, naturalist, distributive justice, lack 
of consent, and negative theological-ethical arguments. These arguments are challenged by the 





CHAPTER 6: ARGUMENTS IN FAVOUR OF GENETIC THERAPIES 
6.1. INTRODUCTION 
In this sixth chapter I endeavour to establish the desirability and ethical appropriateness 
of using genetic therapies. In seeking to establish the benefits of such therapies, I argue in 
support of their development and application in the treatment of HIV-AIDS in Africa. In the 
sections I present arguments from the nature of human genes, the potential of genetic therapies, 
communitarianism, theological ethics, justice, cost-based arguments, current limitations of 
treatments through ARVs and HAARTs, affirmation of good parenthood, unfounded hostility 
towards genetic therapies, and current headways in the development of genetic therapies. 
6.2. ARGUMENTS FROM THE NATURE OF HUMAN GENES 
 In this chapter, I discuss arguments in favour of genetic therapies for diseases in 
general, and for HIV-AIDS in particular. And this first section begins with two arguments from 
the nature of human genes. The first of these arguments is that the human DNA is mostly shared 
with other forms of life that exist on the planet earth, such that it is quite accurate to say that 
there is nothing special or unique about the human DNA. Curchoe summarises the idea in her 
statement that 
We share 98% of our DNA with chimpanzees, and over 50% with chickens, fruit flies, and 
bananas… some regions of our genomes are ultra-conserved and not a single letter is different 
from primitive bacteria. All of us alive today share one unbroken genetic lineage with our single 
cell ancestors from billions of years ago (Curchoe, 2018). 
This scientific statement seeks to affirm the inter-relatedness of life while at the same time 
postulating the idea that difference is a natural aspect of that shared nature of existence. 
Research has also revealed “…99.9 percent of the genetic information in DNA is common to 
all human beings. The remaining 0.01 percent is responsible for differences in hair, eye and 
skin colour, height and propensity to certain diseases” (Deziel, 2018). If it is true that humans 
share their DNA with other forms of life, especially animals, then it should follow that scientific 
or genetic tests carried out on animals such as mice, or rabbits, should have the potential of 
relatively transferable effects. In other words, the special status of human beings should not be 
over-exaggerated as to perceive any research on the human DNA as an affront that must be 
prevented at all costs. On the contrary, any beneficial genetic tests found to be successful on 
animals should be subjected to further development in order to become suitable for human 
beings. This argument is especially relevant in response to a generally prevalent idea that 
genetic tests and treatment can be effected on animals and plants, but not on human beings 




delays, or prohibition altogether, in the development of genetic therapies for devastating 
diseases, including HIV-AIDS. The argument is not against any control in the scientific 
development and testing of genetic therapies. No. There is great value in the regulatory 
frameworks established by countries such as the United Kingdom and the United States to 
prevent potential misuse of genetic therapies to select desired human characteristics for non-
medical purposes, besides ensuring that potentially harmful outcomes are avoided.34 
Internationally, UNESCO plays a general advisory and regulatory role through the 
establishment of global declarations and treaties, such as the Universal Declaration on the 
Human Genome and Human Rights, 1997. Indeed UNESCO also carries out general 
monitoring and sends out cautions from time to time, like it did on 29th November 2018 after 
a Chinese scientist, He Jiankui, had just announced success in producing two genetically edited 
babies (UNESCO, 2018). Yet in all their noble tasks and roles, these bodies must not view 
human genetic makeup as forms that must be protected from science without regard to other 
potentialities that may emerge out of rigorous scientific work. 
 The second and closely-related argument is in recognition of the fact that human genetic 
makeup mutates in response to the environment in which one lives. In other words, as 
UNESCO notes in its Article 3 of the Universal Declaration on the Human Genome and Human 
Rights,  
The human genome, which by its nature evolves, is subject to mutations. It contains 
potentialities that are expressed differently according to each individual’s natural and social 
environment, including the individual’s state of health, living conditions, nutrition and 
education (UNESCO, 1997). 
In real life, this means if someone has ever had common cold, or chickenpox, or flu, the virus 
modified that person’s genome. Similarly, the DNA of a child can be detected throughout the 
birth-mother’s body. As Curchoe briefly states it, “…a static, unchanging genome is not part 
of human nature” (Curchoe, 2018). Ellen Matloff, the President and CEO of My Gene Counsel, 
says 
Most people are born with at least 15-20 gene mutations. Some of the mutations are for very 
minor things, but some of them may be life threatening, especially those related to hereditary 
cancer. These mutations may range from things such as high blood pressure, 
hypercholesterolemia, hereditary heart conditions, to clotting disorders, and various cancers -- 
it runs the gamut (Hurst, 2015). 
                                                          
34 In the UK, the Gene Therapy Advisory Committee (GTAC) regulates the use of gene therapy, and its Research 
Ethics Committee (REC) must evaluate and approve all requests to carry out genetic therapy on humans. In the 
US National Human Genome Research Institute (NHGRI) is responsible for identifying ethical and legal issues 




This idea points out that no human being is static in so far as their genetic characteristics are 
concerned. So much change takes place in a human being’s DNA, including disease-causing 
changes, that it is no longer reasonable to attempt to protect the DNA through prohibitive policy 
framework. It would be reasonable to have a genetic diagnosis on one’s proneness to a genetic 
disease, although such a diagnosis would only force a patient into anxiety as they confront 
mortality. It would be more helpful if such diagnosis would possibly be followed by careful 
explanation of genetic treatments available. Granted that genetic therapies may be more 
aggressive in terms of the magnitude of change they may achieve in the human DNA. But even 
without these therapies, the DNA will mutate anyway; only that it will do so in a natural way 
without human influence. Therefore, genetic therapies should be perceived as a collaborative 
process between what the human body does on its own and what science does to creatively and 
efficiently manage the same or similar processes for the benefit of the human body. These 
therapies should be accepted in the same way vaccines have been accepted for strengthening 
the body’s capacity to deal with certain potentially debilitating illnesses. I suggest that, once 
the efficacy of genetic therapies is ascertained and applied on certain diseases, research should 
push further for the possibility of eliminating even the presumed small sicknesses. 
6.3. ARGUMENTS FROM THE POTENTIAL OF GENETIC THERAPIES 
 In this section I present arguments which are based on the potential of genetic therapies 
in the provision of solutions facing humanity, especially disease and related factors. From the 
arguments presented, it will be possible to assess whether the potential benefits outweigh 
potential risks. The first argument is that genetic therapy could provide cure for genetic diseases 
through the correction of disease-causing genes which are normally transmitted from one 
generation to another. Genetic therapies could lead to the saving of future generations from 
suffering, thereby leading healthy lives. Presently, diseases like cystic fibrosis, thalassaemia, 
Alzheimer’s disease, HIV-AIDS, Parkinson’s disease, Diabetes, Multiple sclerosis, Lupus, 
Asthma, Schizophrenia, and Cancer have no known effective cure, and genetic therapy would 
provide a viable solution. Some who oppose genetic therapies may suggest “…the selection of 
healthy embryos or foetuses…” as a preferable approach to genetic therapy, to which Savulescu 
responds, 
But such genetic tests require abortion or embryo destruction, which is also objectionable to 
some people. What’s more, genetic selection doesn’t benefit patients - it’s not a cure. It merely 
brings a different person, who is free from disease, into existence. Future people would be 
grateful if their disease is cured, rather than being replaced by a different healthier or non-




A common trait in human societies is the endeavour to protect future generations from 
experiencing similar problems as the present generations. The present generation is 
instinctively duty-bound to make their best effort at finding solutions so that offspring do not 
experience the same. Ancient communities who experienced drought found ways of digging 
wells or boreholes for their use and the benefit of their descendants. Others discovered 
treatments for certain killer-diseases and passed on the knowledge to the next generations. As 
Hurst advises with regard to genetic testing, 
Your life is not your own, especially when you are a parent. You owe it to yourself, to your 
children, and to the rest of your family to know whether or not you have a hereditary cancer 
syndrome. Besides, you may be saving many other lives besides your own by alerting them to 
the possibility that they may be carriers, too (Hurst, 2015). 
That idea also applies to genetic therapies, had they already been made available and 
functioning. It is not natural for a human being to experience or discover a problem, yet not 
seek a solution for that specific problem, a solution that the founder ends up passing on as 
valuable knowledge. In genetic therapies research, science seeks to provide treatments to the 
present sufferer as well as protection to the future offspring, especially of deadly diseases that 
have troubled humanity for millennia. Diseases in which many genes combine to cause ill 
health are complex and would be likely reduced, or even eliminated, through genetic therapy. 
A disease-free life would be a worthy gift to bequeath the future generations of humanity.  
 A second argument is that, since genetic editing has been proven to delay ageing in 
mice, it can be inferred that genetic therapies may eliminate age-related illnesses such as heart 
disease or cancer. “Gene editing might offer the prospect of humans living twice as long or 
perhaps even hundreds of years, without loss of memory, frailty or impotence” (Savulescu, 
2015). In other words, there is a link between ageing and certain illnesses, including HIV-
AIDS. The speed of ageing is faster in situations of poverty and disease. When genetic therapies 
reduce or eliminate such diseases, ageing will also be slowed down considerably, leading to 
longer, happier, and more fulfilling lives. There is nothing, morally or otherwise, beneficial 
from the early death of anyone. Rather, a longer life enables one to contribute to the 
development of society in a way that only that one person can.  
 The third argument is that genetic therapies are likely to benefit the most disadvantaged 
members of the human society, as part of the health care. Although an earlier argument against 
genetic therapies in the immediate previous chapter postulated that such therapies are likely to 
benefit only the wealthy members of society, a public health funding approach could make the 
treatments available for all who need them. This is the same way vaccines are availed to many 




the use of ARVs among disadvantaged populations. Savulescu uses a similar argument to point 
out that “the biological lottery – nature – has no mind to fairness” (Savulescu, 2015).  He 
reminds us that, while some people are born gifted and talented, others are born with either 
“short painful lives or severe disabilities.” As a result, interventions such as diet, education, 
and specialised care are attempts to rectify inequalities caused by nature. In the case of the 
potential use of genetic therapies for HIV-AIDS, the most disadvantaged and the most 
vulnerable populations are likely to benefit, thus reducing inequalities rather than increasing 
them. If the use of germline genetic therapies were to be scientifically validated, their safety 
guaranteed, and their availability widespread, certain genetic conditions could be eliminated 
from the population altogether. Conditions like HIV-AIDS could become diseases of the past, 
in the same way that global vaccination programmes have eradicated diseases like polio. Such 
benefits far outweigh any monetary expenditure or human capital investment that governments 
and research institutions may use in research. 
6.4. ARGUMENTS FROM COMMUNALISM 
There are arguments that emanate from the idea of communalism in order to promote 
common good. These arguments view genetic therapies as potentially resourceful solutions to 
universal communal problems, including HIV-AIDS. The first argument here is that no human 
being is an island on his or her own. Each person is involved in the life of another person. Life 
is a corporate phenomenon that gives us the obligation to live justly in the world. In the 
Christian faith, this shared nature of life is what makes us the “communion of saints” with a 
worldwide network. It causes us to acknowledge our dependence on others as it also reminds 
us of our obligation to support others, especially in situations of need. Because of the communal 
nature of human life, the individual choices we make affect other people in diverse ways, 
although those affected may have no opportunity to express their preferences, especially if they 
are not presently involved in our lives in any active and interactive way. We choose who to 
marry, and what career to follow; yet the future children born in our marriage and the future 
employers have no prior say to these choices we make. We are simply seeking satisfaction in 
life as it really is. Therefore, it is important that there be a global effort put in place for a 
potentially beneficial solution for HIV-AIDS and other diseases, for the survival of all. 
 The second argument is that any harm to one is harm to all. From a communal 
perspective, the domination of HIV-AIDS on the African continent is a form of harm to the 




solution for a major cause of harm in the global community. Even at individual levels, parents 
have a duty to seek to prevent harm from affecting their children. 
Your life is not your own, especially when you are a parent. You owe it to yourself, to your 
children, and to the rest of your family to know whether, or not, you have a hereditary cancer 
syndrome. Besides, you may be saving many other lives besides your own by alerting them to 
the possibility that they may be carriers, too (Hurst, 2015). 
From the argument presented by Hurst, genetic testing is an obligation for parents who 
necessarily need to alert their offspring who may be potential carriers of genetic diseases. Yet, 
we may ask, of what value is it for a parent to make an offspring aware of a particular genetic 
condition? Surely, it would be more beneficial to the offspring if such a parent would pass on 
a solution, rather than mere information. Unborn children, whether conceived naturally or 
artificially through IVF and germline gene therapy, are unable to make any choices about their 
genetics; they cannot decide whether they are born with or without particular conditions. It is 
better for the current generation to bequeath a solution, rather than a continuity of harm through 
disease and suffering. When genetic therapies become efficient and available for treating HIV-
AIDS in Africa, it will be of great benefit to the whole world. It is also, in this regard, important 
to note that a solution for a disease that is prevalent in Africa is not merely a favour for African 
peoples; it is a solution to a global problem. The global community will enjoy some peace and 
improved health when assured those future generations will have nothing to worry about, as 
far as HIV-AIDS is concerned. For this reason, the on-going scientific research should be 
encouraged and funded through global collaboration, in the same way other concerns have been 
addressed. 
The third argument is that we have an obligation to help our neighbours when their 
situations are dire and need our positive intervention, regardless of whether the sufferers are 
nearby or far away. Peter Singer argues this principle out in a 1972 article, “Famine, Affluence, 
and Morality”, after the catastrophic cyclone in Bangladesh in 1971. Singer rejects the common 
pre-philosophical assumption that physical proximity is a relevant factor in determining 
one’s moral obligations to others. In discussing the matter of whether people living in wealthy 
nations should be more obliged to help those near them than to contribute to famine relief in 
distant places, Singer writes: “It makes no moral difference whether the person I can help is a 
neighbour’s child ten yards from me or a Bengali whose name I shall never know, ten thousand 
miles away” (Singer, 1972, p. 229). For him the only consideration should be “whether the evil 
that may be prevented by one’s contribution outweighs whatever inconvenience or hardship 
may be involved in contributing, and for the large majority of people in affluent societies, the 




The fact that a person is physically near to us, so that we have personal contact with him, may 
make it more likely that we shall assist him, but this does not show that we ought to help him 
rather than another who happens to be further away. If we accept any principle of impartiality, 
universalizability, equality, or whatever, we cannot discriminate against someone merely 
because he is far away from us (or we are far away from him). Admittedly, it is possible that we 
are in a better position to judge what needs to be done to help a person near to us than one far 
away, and perhaps also to provide the assistance we judge to be necessary. If this were the case, 
it would be a reason for helping those near to us first. This may once have been a justification 
for being more concerned with the poor in one's town than with famine victims in India. 
Unfortunately for those who like to keep their moral responsibilities limited, instant 
communication and swift transportation have changed the situation. From the moral point of 
view, the development of the world into a "global village" has made an important, though still 
unrecognized, difference to our moral situation (Singer, 1972, p. 230). 
Singer applies the time-honoured utilitarian argument that any action becomes a duty if it will 
prevent more pain than it causes or cause more happiness than it prevents. More significantly 
in this argument is the idea of communitarian utilitarianism by which the affluent countries 
should find it justifiable to support research in genetic therapies in order to alleviate suffering 
among patients of HIV-AIDS, the majority of whom are in Africa. 
6.5. POSITIVE THEOLOGICAL-ETHICAL ARGUMENTS 
 In this section, I intend to explain four theological arguments, very much from a 
Christian perspective, in support of genetic therapies for HIV-AIDS, while responding to the 
theological-ethical arguments that I had raised earlier in Chapter 5. These arguments are 
premised on the general understanding that Africans are very religious and tend to respond to 
issues of disease and suffering with religious viewpoints, whether justifiably or not. The first 
of these arguments focuses on the concept of the image of God in humanity. It is a fundamental 
belief in Christianity, Judaism and Islam that the human being is created in the image of God, 
the imago Dei. Without engaging in theological depth, the image of God in humanity involves 
creativity and innovation in solving human problems, among other qualities. A few examples 
may be relevant to illustrate this. God created human beings and left them to think, design and 
develop houses, clothing, shoes, vehicles, medicine, working tools, weapons, and 
communication gadgets, among other life AIDS. Each of these life AIDS gets remarkably 
improved in successive generations. Understandably, the advent of every new development 
comes with a measure of surprise and resistance before people accept and learn to make good 
use of it. Of course, any new development that is proved useless or dangerous is discarded in 
the process, but the good and the useful are retained, polished up, and improved with time. The 
scientific efforts at developing genetic therapies for various diseases, including HIV-AIDS, 
should be appreciated as an extension of the functions of the imago Dei, and not as a way of 




form of miracles, God normally lets humans discover for themselves what may cure diseases 
and wisely make use of such discoveries. It is a gift from God; not a sign of rebellious 
competition with the divine. 
 The second argument is that God only tolerates defects and disease. He never embraces 
them; instead, He seeks to overcome and remove them. In biblical narratives, for example, God 
does not allow people with defects to serve as priests, prophets, or kings. He also does not 
allow animals with defects as offerings. Instead God always seeks to heal the blind, the lame, 
the crippled, and the demon-possessed. This should tell us that God prefers a life of 
completeness and wholesomeness for human beings. It follows that humans should desire 
completeness and wholesomeness, rather than tolerate defects, including genetic defects, in 
life. If there may be any way of correcting a defect or curing an illness, including the possible 
successful use of genetic therapy, it should be understood to be the will of God. Healing from 
illness is the perfect desire of God for every person. There is no theological justification at all 
for either preventing or rejecting genetic therapies. 
 The third argument is one that I have inferred from the concept of salvation in order to 
develop the idea that God’s purpose for human beings is to move them towards perfection. God 
plans to move each human being from the worst to the best; from sin to justification 
(conversion); from justification into a process of sanctification (purification); and finally from 
the process of sanctification into a final state of glorification (perfection) in eternity.  This 
divine process shows that humans are in God’s scheme of things when they engage in efforts 
that seek perfection. Human experiences through education, healthcare, enculturation, 
mentorship, religion, business, professionalism, sports, travels, and other engagements, are 
means by which humans grow and improve, reinforcing efforts towards perfection. It is not 
normal among humans to desire to remain poor, or sick, or vulnerable, or ignorant, or 
uncultured, or pagan, or primitive, or any such related states. Even in the present availability 
of ARVs for reversing some of the effects of HIV-AIDS, it remains clear that there is still no 
cure for HIV-AIDS. Our desire for the perfect should drive us into seeking a viable solution, 
such as the use of genetic therapies. Of course, that same desire for perfection should drive us 
into making great effort at ensuring the safety of these therapies, as well as eliminating faults 
and undesirable consequences on life and health. However, we must never shy away from the 
journey towards perfection. That move towards perfection may include not only treatment and 
prevention of diseases, but also genetic capacity-building so that humans may become actually 




 The fourth argument is that the creation of solutions to disease is not a challenge to 
God, but a complement to God’s work. God is portrayed as compassionate and merciful 
towards those in need, including the sick and the disabled, and consistently seeks to deliver the 
victims from such life experiences. God’s use of, or collaboration with, human agents to resolve 
human problems, is consistent with the fundamental creationist view that God created humans 
in His image and likeness. Similarly, the involvement of human beings in resolving human 
miseries, including illnesses, is one of the highest virtues in collaboration with the divine. 
Genetic therapies, if put to use to treat HIV-AIDS, are developments that God would approve, 
rather than detest, because it is not competition with the divine.  
6.6. JUSTICE ARGUMENTS 
In this section I will discuss two arguments in support of genetic therapies from the 
perspective of justice. The first of these arguments focuses on the idea of equity in the 
development and use of these therapies in view of the economic inequalities among the various 
nations of the world. Both equity and equality can be used to create fairness in a society. 
Sometimes it is thought that equal treatment automatically results into fairness, but that is not 
necessarily the case. There is need for clarity on the difference between equity and equality. 
“Equity is giving everyone what they need to be successful. Equality is treating everyone the 
same” (Sun, 2014). Although the objective of equality is to promote fairness, “it can only work 
if everyone starts from the same place and needs the same help. Equity appears unfair, but 
actively moves everyone closer to success by levelling the playing field” (Sun, 2014). Yet, in 
many aspects of life, people do not get to start from the same place, and they do not all have 
the same needs. The difference between the two concepts can be clarified a little further. For 
instance, whereas equity identifies the differences and attempts to narrow the gap between 
various groups, equality does not regard the differences between the groups. Through equity 
people get what they need, while through equality everyone gets what others within the group 
gets, even if that is not their need. 
Equity is realistically achievable; equality is not, and remains a pipe dream for all 
human societies. The fear that genetic therapies may create inequality in societies is unfounded. 
Inequality is already a real human phenomenon to which no society is a stranger. It is an 
experience humans have through education, income levels, economic strength, bodily strength 
or beauty, intellectual ability, family size, spiritual experience, and professional life. 
Experiences vary as much as outcomes of these common life ventures. While some people 




manage the lowest levels available. In contemporary healthcare, while some people afford 
available cancer treatment options, others die of undiagnosed cancers. Similarly, when genetic 
therapies will become available, some people will find them affordable, while others will not 
afford them. The idea of affordability for everyone should not be a key factor influencing 
whether the therapies should be researched and developed or not. As the potentially high cost 
of a new highly efficient model of a car or a plane does not necessarily prevent the development 
of the new model, so the possible high cost of potentially highly effective genetic therapies 
should not be a reason to prohibit the research and development of those therapies. No one ever 
stopped the development of either the Mercedes Benz or the Rolls Royce for the reason that 
only a few people would drive it. Instead, with regard to genetic therapies, modalities of 
equitable distribution should be discussed, agreed upon, and implemented after the therapies 
will have been successfully developed. The rich may become generous in donating funding for 
the universal treatment of everyone; governments may take up the responsibility of 
implementation among citizens; religious organisations may engage in charitable support to 
the effort; world organisations may mobilise for a unified global approach; insurance agencies 
may develop affordable schemes for these therapies; researchers may end up developing 
affordable genetic therapies in the long run; and other options may just turn up.  The 
concept of distributive justice becomes relevant and applicable only once something good has 
been developed and availed. For instance, once genetic therapies will have been fully 
developed, tested, and availed, then discussions about distribution and matters of equity will 
arise. How do we know or not know if, when genetic therapies become standardized, the 
presumed wealthy nations will not assist the poor in the developing world in order to make the 
treatment available and affordable? Besides, the fact that genetic therapies will be expensive 
does not necessarily dictate that poor people will never have access to them. When ARVs were 
first developed, they were, and still are, expensive. But governments and world organisations 
developed creative ways of ensuring distribution and treatment access. In any case, we should 
not stop the development of a good thing only because we fear it may be expensive. We cannot 
reasonably instruct a child to stop studying hard in school merely because we think the parents 
may not afford subsequent university fees, for what if the child wins a generous scholarship? 
The point here is that equitable access should be the focus, rather than seeking equal access for 
everyone. In the end, what everyone needs is a fair chance of accessing the genetic therapies 
once they become reliably available. 
Questions may arise, such as: What if the poor are not able to afford genetic therapies? 




conditions cause poverty among people? And what actions are necessary to alleviate these 
conditions? It is very much possible that the poor, who are also the worst affected by HIV-
AIDS, may not afford genetic therapies when those therapies become available for patients. 
Empirical research has led to conclusions that certain social and economic conditions make 
people poor and complicate their access to healthcare, and this should be of concern in relation 
to a possible lack of access to genetic therapies as well. Loignon, et al, in a study carried out in 
Canada, report that  
Persons living in poverty (PLPs) are at greater risk for deterioration in health status, chronic 
illnesses, and premature death than are affluent persons. Yet there is a growing body of evidence 
indicating that PLPs receive the least amount of healthcare (known as the inverse care law). 
PLPs are less likely to have a family physician and to obtain preventive and secondary care, and 
more likely to report negative experiences of care (Loignon, et al., 2015, p. 2). 
Poverty causes people to either avoid or cease the use of various health services because the 
poor perceive that healthcare service providers “do not listen to them or are rude, judgmental, 
or controlling” (Loignon, et al., 2015, p. 3). The poor also believe “their poverty affects the 
quality of care they receive and that they are mistreated, marginalized, and discriminated 
against because of their financial situation” (Ibid.). Given that Canada, where the study was 
carried out, is a developed country with fairly advanced healthcare systems, the situation can 
only be worse in African countries such as Kenya. A similar research in Nigeria and Uganda 
revealed that poverty-stricken women were unable “to prioritize accessing fistula treatment 
over household expenditures” and recommended “innovative approaches to financial 
assistance, transport, information of the available repair centres, rehabilitation, and 
reintegration in overcoming cost barriers” (Keya, et al., 2018). It is, therefore, necessary to 
address poverty if HIV-AIDS patients – and indeed other patients – are to gain access to 
healthcare, especially when genetic therapies become a reality. Loignon, et al, propose a five-
point approach to changing how healthcare should be provided among the poor:  
“…compensation models for health equity practices (which) should be tested, implemented, and 
evaluated for effectiveness before being scaled up; …more resources to support 
interdisciplinary healthcare teams in underserved areas and to modify primary care practice 
guidelines to incorporate social and economic factors; …the need to develop effective training 
that integrates evidence on the social inequalities of health and poverty to provide the 
knowledge and tools required to help healthcare professionals avoid stigmatizing and 
developing negative attitudes towards the poor; …the need to close the equity gap in healthcare 
systems by better addressing the social determinants of health, such as poverty, poor housing, 
and food insecurity; (and) …the need to alter the law that mandates physicians to determine 
whether or not patients are fit for work, hence determining the amount of social assistance they 
receive and consequently the living conditions that impact their health and healthcare” 
(Loignon, et al., 2015, p. 9).  
Income levels are generally inadequate in low-income countries in Africa, including Kenya, 




Priority will need to be given to factors that make poverty such a prevalent experience in many 
households in Africa. Governments will need to initiate policy changes so as to remove barriers 
to healthcare access, especially for the poor. The concern about poverty and healthcare grows 
deeper as far as HIV-AIDS is concerned: 
There are strong bi-directional linkages between HIV-AIDS and poverty in resource-poor 
settings. HIV-AIDS is both a manifestation of poverty conditions that exist, taking hold where 
livelihoods are unsustainable, and the result of the unmitigated impact of the epidemic on social 
and economic conditions. HIV-AIDS is at the same time a cause and an outcome of poverty, 
and poverty is both a cause and an outcome of HIV-AIDS (ILO AIDS, 2005). 
In other words, as AIDS impoverishes people, it also slows down economic growth and enables 
poverty to, in turn, expose more people to HIV-AIDS, thereby sustaining the deadly cycle of 
cause and effect. Strengthening economic performance at both national and household levels 
will have to be a top priority of the Kenya government if the citizens have to benefit from the 
emerging genetic therapies. The ten main causes of poverty in Kenya, as in many parts of 
Africa, are inadequate access to clean water and nutritious food, little or no access to 
livelihoods or jobs, conflict, inequality, poor education, climate change, lack of 
infrastructure, limited capacity of the government, lack of reserves, and mismanagement 
of public resources through corruption. These are the issues to be addressed by the 
government, if poverty is to be effectively alleviated, especially as it affects healthcare.  
The second argument is that the geographical location of the scientific base of the 
development of genetic therapies should not necessarily affect distribution and access. This 
argument responds to such fears as the possibility of the developed world producing the 
therapies by themselves and for their own people, leaving out the majority sufferers of HIV-
AIDS who live in Africa. Going by previous experience, medical products developed and 
produced in developed nations are distributed all over the world, including Africa and other 
developing areas of the globe. If genetic therapy will be first successful in the developed world, 
there is nothing morally wrong with that. Development must practically begin from 
somewhere, before it spreads or benefits the rest of the world. Airplanes are still manufactured 
in the developed world, yet Africans buy them and use them for transport. What needs to be 
encouraged is a network of collaborative approach to the research so that, rather than individual 
scientists from various institutions in diverse jurisdictions carrying out individualised research 
on genetic therapies, there should be deliberate inclusion of scientists from Africa too, as well 
as formalised collaboration with research universities in the continent. The point here is that 
there should be no fear that, just because much of the on-going research into genetic therapies 




and other developing nations. Since other scientific products have been previously developed 
and distributed from the developed world before, there is no sound basis for any fear that things 
will be different when it comes to genetic therapies. 
For research collaboration35 to turn out well it will need to be structured or restructured 
to involve scientists and institutions in the developed countries like the United States, China, 
the United Kingdom, and Australia, where significant strides have been made in genetic 
research, on the one hand, and countries in Africa, especially Kenya, South Africa, Nigeria, 
and other African countries, where HIV-AIDS continues to infect and affect large populations. 
Such partnerships will require input in terms of resources, finances, and personnel, for them to 
fully fledge out. Western research institutions have a long-standing tradition of scientific 
engagement that has resulted in the developments currently being reported in genetic therapies 
research. In contrast, with the exception of only a few top universities in South Africa, the 
continent of Africa lacks research capacity, generally arising from a serious lack of research 
funding for universities. Consequently, Africa will not successfully engage in meaningful 
genetic research on its own due to the lack of sufficient resources to dedicate to the process. 
But the West, and China, will also not go far enough in genetic research, especially in relation 
to HIV-AIDS, without collaborating with Africa where the disease has had the most impact. 
Africa-based scientists may be faced with strong impediments such as prejudice against Africa 
generally by well-endowed western-based researchers, together with the prevalent economic 
hardships in which Africa-based scientists operate. But these should not be barriers against 
collaboration. South African research universities such as University of Cape Town and 
University of Stellenbosch have spearheaded scientific and technological research in certain 
areas, including in more recent times, the first successful penile transplant36 done at the 
University of Stellenbosch on 11th December 2014, besides previous success in nuclear science 
and other technological developments. Such achievements by a research university in Africa 
should be positively viewed as clear signs of strong capacity to engage in new frontiers such 
as genetic therapies, and should encourage collaboration. Kenya is not too far behind with its 
leading role in technological advancement, especially in money transfer systems, which has 
been borrowed by other settings, including western countries. Although it is not directly 
                                                          
35 The exact details of how such collaboration may be initiated and how it may work are beyond the scope of this 
dissertation, and should be the subject of a research that focuses on a topic like, say, “Potential Collaboration 
between Africa and the West in Research in Genetic Therapies for Prominent African Diseases.”  




relevant to medical science, the country holds much potential for growth in research in such 
serious laboratories as the Kenya Medical Research Institute (KEMRI).    
6.7. COST-BASED ARGUMENTS 
There is a cluster of arguments that I generally refer to as cost-based arguments because 
they present the matter of costs either against or in support of genetic therapies. In a previous 
presentation of an argument against genetic therapies, there was an argument that genetic 
therapies will be extremely expensive and unaffordable to the poor majority who are also the 
sufferers of HIV-AIDS, particularly in Africa. However, in this section, I present a contrary 
argument. If successfully developed, and if all risks are identified and resolved, germline 
therapy has the potential to remove HIV-AIDS completely from the population. This will, in 
turn, reduce or even remove the long term healthcare costs of treating the disease. 
Consequently, the costs of providing genetic therapies for HIV-AIDS patients will now be a 
cheaper option than the combined future costs of providing a lifetime of conventional treatment 
for the same patients and their descendants. If governments can consider this option, if 
approved, overall spending on healthcare will be slashed significantly. This possibility should 
justify making genetic therapies available through public funding in each country.   
6.8. THE PRESENT LIMITATIONS OF ARV AND HAART 
Patients of HIV-AIDS the world over have had their lives extended and their mortality 
reduced through the use of contemporary treatment using highly active antiretroviral therapy 
(HAART). At times, and in some contexts, this may have led to a misconception that HIV-
AIDS has a cure, a misconception that is quite unhelpful in the fight against the HIV-AIDS 
pandemic.  
…in fact, as soon as the therapy is interrupted viral load inevitably resumes from cellular and 
anatomical reservoirs and CD4+ T cells level declines again. Thus life-long administration of 
the drugs, which requires a complex and cumbersome dosing regimens, is needed to contain 
viral rebounds after drug interruption. Unfortunately HAART is costly and leads to cardio-
metabolic complications, cumulative toxicities and development of viral-escape mutants. 
Therefore, the unavoidable therapy failure and the side effects outbreak make necessary sooner 
or later treatment interruption and multiple changes of different cocktail regimens over the life-
span of an AIDS subject (Bovolenta, et al., 2013). 
A cure for HIV-AIDS remains a medical mirage. Experts have known for a while that 
antiretroviral treatment is not curative. 
Despite the tremendous advances in antiretroviral combination therapy over the last decade, 
eradication of HIV from the infected organism is still an elusive goal. Lifelong therapy is 
associated with potential long-term toxicity, adherence problems, and development of drug 
resistance. Thus, gene therapy approaches targeting viral eradication are still attractive (van 




Furthermore, “…despite the progress in medical and behavioural approaches to control HIV 
infection, a cure for AIDS is far from being available because eradication of cryptic cellular 
reservoirs is not achievable with existing therapies” (Bovolenta, et al., 2013). It is clear that 
HAART treatments are only partial, as it has been observed that “…viral load rapidly rebounds 
after HAART cessation since there are inadequate HIV-specific immune responses generated 
by classical HIV drug therapy regardless of the drug combination used” (van Lunzen, et al., 
2011, p. 78). In other words, the availability of ARVs or HAART has not provided a cure for 
HIV-AIDS, despite alleviation of much physical suffering and extension of life. These current 
treatments are severely limited in terms of providing a cure. The statement is not judgmental 
on the HAART, since they were not developed as a cure in the first place. My argument here 
is that the availability of ARVs and HAART should not lead to complacency against the search 
for a cure. It is in this context that genetic therapies are proposed as a potentially viable 
alternative approach for the treatment of AIDS. A study published in 2012 showed that 
Highly active antiretroviral therapy dramatically improves survival in HIV-infected patients. 
However, persistence of HIV in reservoirs has necessitated lifelong treatment that can be 
complicated by cumulative toxicities, incomplete immune restoration, and the emergence of 
drug-resistant escape mutants. Cell and gene therapies offer the promise of preventing 
progressive HIV infection by interfering with HIV replication in the absence of chronic antiviral 
therapy (Hoxie & June, 2012, p. 1). 
Recent studies revealed that babies born to mothers with HIV face higher risks even though 
they had been born HIV negative. “HIV-uninfected children born to mothers with HIV are 
prone to infections that are more severe, are at almost two times greater risk of dying before 
their first birthday, and are more likely to be born prematurely than children born to mothers 
without HIV” (Slogrove, et al., 2018). Mortality persists among HIV-exposed infants, “even 
with maternal antiretroviral therapy.” This is confirmed among mothers who are on ARVs 
before and during pregnancy, and after the birth of the children. It affirms that, rather than 
providing protection against HIV-AIDS, these treatments leave the new-borns more vulnerable 
to other infections. This situation calls for not just somatic treatment of HIV-AIDS, but also 
for germline gene therapies which will effectively prevent babies from inheriting the 
devastating illness from their mothers. Even if all other arguments were to be rendered 
unworthy, this is the one argument for genetic therapies that should receive serious attention. 
It is agonising for a mother to pass on a serious illness to her child, in full knowledge that 
nothing can be done to reverse the baby’s condition permanently for the baby’s sake. 
Conversely, it gives much satisfaction for parents and medics to know that they can bring HIV-




6.9. AFFIRMATION OF GOOD PARENTHOOD 
The argument in this section is developed from Janet Malek who, taking note of 
objections to genetic technologies on the grounds that such technologies are not supportive of 
“the unconditional acceptance that lies at the heart of praiseworthy parental attitudes,” argues 
that “it is possible for a parent to exhibit unconditional acceptance of the child herself without 
accepting each of that child’s traits” (Malik, 2013, p. 59). Given that it is now possible for 
parents to become aware of the risks of a genetic disease to which their future children may be 
at risk, medical science employs genetic diagnosis to help parents avoid the birth of a child 
with such a genetic illness. The idea that Malik argues against is summarised as follows: 
Some scholars have argued that potential parents who use RGTs to reduce the likelihood that 
their future child will have a disabling genetic condition demonstrate an inappropriate attitude 
toward parenthood. More specifically, they claim that this choice reflects conditional 
acceptance of the child, an attitude that is antithetical to what it is to be a good parent (Malik, 
2013, p. 59). 
It is assumed that good parenting involves taking care of a child as received at birth, inclusive 
of any defects, disabilities, without turning the child into what they are not, thereby focusing 
on the parent-child relationship rather than the child’s traits. The idea is that a potential parent 
should simply welcome the child, and not spend time evaluating a child’s suitability based on 
potential for disability and illness. This is the idea that Malik objects to as she points out the 
fact that cultural variations in the concept of good parenting makes it impossible for people to 
agree on what really constitutes good parenting. She argues that parental love does not mean 
neglecting to correct deficiencies which could be corrected before the birth of a child. She 
further argues that “…the idea that parents should do what they can to make their future 
children better off is not part of the obligation of unconditional love but rather is a distinct 
duty” (Malik, 2013, p. 61). An important point is raised to give clarity to the necessary 
distinction between a person and a person’s traits, with the emphasis that “…if a person were 
identical to his traits, any change in that person’s traits would bring about a change in that 
person’s identity” (Ibid.).  
If a future child is not identical to his traits or characteristics, it is possible for a potential parent 
to accept one and not the other. That is, a parent can show an attitude of unconditional 
acceptance for the child himself, but not take that same attitude toward each of the child’s traits. 
When a potential parent’s attitudes toward the future child are distinguished from her attitudes 
toward the future child’s traits, it becomes clear that a potential parent can use RGTs37 with the 
intention of determining the traits of her future child in a way that is not inconsistent with 
praiseworthy parental attitudes (Ibid.).  
                                                          
37 RGTs are reproductive genetic technologies (RGTs) over which there arise some ethical concerns. In the context 




Malik’s idea makes much sense in logic, for the reason that accepting a child as a gift is not the 
same as accepting the disease that troubles the child. Accepting, tolerating, and sustaining 
debilitating defects would be irresponsible of a parent if a solution may be within reach. The 
validity of this argument is in the idea that a normal parent should possess the capacity to give 
good things to their offspring. Parents who desire good traits, including good health, for their 
children are affirmed as good parents. Conversely any parent who knows an offspring’s 
potential to be born with a correctable defect, and knowingly avoids correcting the defect 
should lay no claim to good parenthood. A parent whose child has a disability of any kind is a 
good parent if she seeks to help the child live better despite the challenges. Although they 
unconditionally accept, love and appreciate their children, good parents exemplify proper 
parenting by working to improve the lives of those children. A parent who has HIV-AIDS 
should normally make effort to deflect the disease from her offspring, as people generally do 
through the use of ARVs. In a context where genetic therapies will provide a permanent 
solution for HIV-AIDS, future children will have benefited from the wise choices made by 
their parents for their sake. As such, these therapies should be accepted as an affirmation of 
good parenthood. And good parenthood among the majority sufferers of HIV in Africa will be 
good for humanity globally. 
6.10. UNFOUNDED HOSTILITY TOWARDS GENETIC ENGINEERING 
 There appears to be a generally prevalent hostility towards genetic engineering, 
especially in relation to either genetic therapies or human enhancement, or both. This hostility 
is propagated by regulatory bodies and civil organisations whose mandate is to safeguard 
human interests in relation to scientific research and medical progress. For the most part, the 
hostility comes out of genuine concerns for human safety and a suspicion that rogue scientists 
could take advantage of any available loophole to push forward a scientific agenda without due 
regard to human safety and ethical concerns. In many instances there is a clash of perception 
between policy-makers and medical scientists, each side claiming a measure of control over 
the other. As Curchoe points out, 
Policy-makers the world over typically do not have a background in medical sciences, genetics, 
or medical ethics but they are tasked with making the policy that governs these concerns. Often, 
science moves more quickly than policy and it is up to the scientific societies to display a 
modicum of self-governance, as with the voluntary, worldwide moratorium first on transgenic 
organisms, then later on human cloning (Curchoe, 2018). 
In many cases, the hostility emerges from within scientific professionals, either out of valid 
scientific concerns or perhaps out of what appears to be professional rivalry. An example is 




(alipogene tiparvovec) for “…approval for the treatment of lipoprotein lipase deficiency 
(LPLD). Patients with this disorder of triglyceride metabolism experience severe acute 
pancreatitis attacks that can be fatal” (Boudes, 2014, p. 33). This led to the European 
Commission approval in November 2012, and Glybera® became the first gene therapy 
approved in the Western world, and gene therapy became a reality. What is not commonly 
known is that the approval had been preceded by a lengthy process after the original submission 
had been made in January 2010, but had been turned down by the EMA, and a re-examination 
was only done when the sponsor, Amsterdam Molecular Therapeutics, repeatedly requested it. 
Between October 2011 and November 2012 there were tests, repeated tests, a falling out of the 
sponsor leading to a takeover by a new sponsor, additional analysis, re-examinations, and 
numerous committee reviews (Boudes, 2014, p. 34). On the one hand, this process can be 
acclaimed as a mark of thoroughness, leaving nothing to chance, which is absolutely 
commendable. On the other hand, one can perceive underlying hostility towards genetic 
therapies in this case, leading even bodies that normally would depend on the judgment of 
EMA to also demand independent scientific verification procedures before making further 
recommendations. The common legal doctrine in criminal justice that “a crime suspect is 
innocent until proven guilty in a court of law” may be applied in reverse: genetic therapies are 
guilty until proven innocent in an extremely rigorous scientific verification process. I perceive 
this to be a form of unfounded hostility towards genetic therapies. 
 In March 2019 a group of specialists called for “a global moratorium on all clinical uses 
of human germline editing”. They asked governments to commit themselves to not approving 
any germline editing unless certain conditions are met. The time would allow for the 
establishment of an international framework before further research is done on human germline 
editing (Lander, et al., 2019). The call for a moratorium was specifically with regard to “all 
clinical uses of human germline editing — that is, changing heritable DNA (in sperm, eggs or 
embryos) to make genetically modified children.”  
By ‘global moratorium’, we do not mean a permanent ban. Rather, we call for the establishment 
of an international framework in which nations, while retaining the right to make their own 
decisions, voluntarily commit to not approve any use of clinical germline editing unless certain 
conditions are met (Lander, et al., 2019). 
This call was made after a Chinese biophysicist He Jiankui reportedly edited embryos to create 
two babies, and it was suspected that a number of scientists had been apparently aware of this 
work but had not made any attempts to stop it. This was in the context of perceived “growing 
interest in proposals for genetic enhancement of humans” (Lander, et al., 2019, p. 165). One 




new ethical dimensions as foundational to the call. But in the end the reasons were the same 
old ones, quite similar to the kind already discussed in Chapter 5 of this dissertation. The 
reasons advanced include the need for broad societal consensus, the fear that the results may 
backfire, the fear of potential stigmatization, the possibility of commercialisation of 
enhancement, the possibility of psychologically negative experiences of children, the fear that 
humans may fundamentally become different from who they really are, unequal access to the 
technology, and the possibility of genetic harm to other species (Lander, et al., 2019, p. 167). 
This is another sign of unfounded hostility towards genetic therapies. Recently, Chinese state-
run news agency Xinhua reported that “He Jiankui, the researcher responsible for creating the 
world’s first gene-edited babies, had been sentenced to three years in prison on the charge of 
illegally practicing medicine” (Houser, 2019, p. para 1). Earlier, China had condemned He’s 
research soon after the birth of the twin babies out of his experiment. The same news agency 
also reported that, in addition to the two babies announced earlier, “a third gene-edited baby 
has officially been born” (Houser, 2019, p. para 3). It appears that the severe opposition to He’s 
research is fired up by what Scherz calls “the issue of enhancement or making people better 
than well” (Scherz, 2019, p. 28). Scherz argues that “…the He case was especially worrisome 
since his goal was not to cure a genetic illness in a person with a specific mutation, but to 
protect against HIV by introducing a mutation” (Scherz, 2019, p. 28). This argument against 
He does not provide any moral difference between curing an illness in a patient and protecting 
a healthy person from contracting a deadly disease. It would appear that, for Scherz, it would 
be morally right – perhaps even obligatory – to use a genetic therapy to cure a patient of HIV, 
but absolutely wrong to use the same therapy to prevent a healthy person from contracting HIV. 
But such an argument would be invalid because protection from harm is just as important as 
cure from a harmful disease. Otherwise, if Scherz’s argument were to stand, then medical 
science would concentrate on treating the sick while totally ignoring vaccinations and public 
health education and regulations whose aim is to protect the healthy. A careful reading of the 
report reveals a general attitude of fear and hostility towards genetic research as the more 
obvious basis for the severe punishment accorded to Jiankui, whereas it would be prudent, at 
this stage, for the scientific community to seek to appreciate efforts made, correct any mistakes 
– real or imagined – in the research protocols, and develop new and useful guidelines for further 
research.  
 The argument against unfounded hostility towards genetic therapies is not intended to 
discard regulatory oversight over new and emerging genetic technologies. Indeed, research 




be ensured to be safe and effective” (Hughes, 2019, p. 112). In addition, there is need for 
regulatory agencies “to enforce cultural norms, protect against hypothetical social harms, or 
ensure that the human genome remains unchanged” (Hughes, 2019, p. 112). However, 
regulation is not the same concept as prohibition. Regulation should provide for rational 
guidelines, as in the case of the Nuffield Council on Bioethics which, while taking note of the 
prevailing illegality of genetic therapies in Britain, “…cautions against a rush to ban such 
therapies without extensive public debate, and urges research on their safety and efficacy” 
(Hughes, 2019, p. 112). Their advice is that there be a careful assessment of the risks of adverse 
results, after which the genetic therapies should be approved for clinical use. 
The argument that I am developing here is that there has been unfounded hostility 
towards genetic engineering in general and genetic therapies in particular. Such hostility is not 
based on any grounded philosophical foundations. Instead, they are based on fear-mongering 
and die-hard comfort with status quo science. Yet if humans had been fearful of making 
attempts at treating disease, death would have probably wiped out the human race through the 
previous plagues. Human beings must remain in a forward match towards liberation from 
disease, indignity, and pain, and must remain unhindered by those whose desire is to remain 
within familiar science territories. People who are generally hostile towards genetic therapies 
must not prevent scientific work whose intention is to bring an end to human suffering and pain 
through such illnesses at HIV-AIDS. Instead, the points of concern need to be raised with a 
view to seeking proper solutions in the overall context of assurance of safety in health care. 
6.11. CURRENT HEADWAYS IN GENETIC THERAPIES 
This last section presents arguments based on the phenomenal headways that are being 
achieved in research in genetic therapies a factor that has not received attention from those who 
oppose these therapies and any related research. The argument is that when a new development 
emerges that seeks to solve a human problem, then, although it may show signs of being 
problematic in some ways, the society needs to find ways of resolving its problematic aspects 
and then move forward with its implementation, rather than merely reject the new approaches 
in whole. A substantial amount of work has been done, and new developments have emerged 
in the last three years or so, including successful clinical trials. These new developments cannot 
be ignored by rational human beings who seek solutions to such challenges as HIV-AIDS, 
cancer, diabetes, and TB. 
In March 2019 a patient in Britain was cured of the HIV infection “after he received a 




that a cure for AIDS will successfully be developed soon, in agreement with the comment from 
Anton Pozniak, the President of the International AIDS Society: “Although this is not a viable 
large-scale strategy for a cure, it does represent a critical moment. The hope is that this will 
eventually lead to a safe, cost-effective and easy strategy… using gene technology or antibody 
techniques” (Reuters, 2019). In June 2019, reports emerged that a gel had been developed in 
Kenya “that can kill the AIDS-causing virus” (Nation Media Group, 2019). “If the human trials 
are successful, Kenya could be the first country in the world to put an effective anti-HIV 
microbicide38 in the market.” If this were to become a reality soon, it would bring significant 
progress in the search for a cure for HIV. In July 2019 researchers published a report saying 
they had gotten closer to finding cure for HIV after they had used CRISPR technology to 
eliminate disease in live mice for the first time (Dash, et al., 2019). The scientists, based at 
Temple University and the University of Nebraska, had used a combination of CRSPR gene-
editing technology and a therapeutic treatment called LASER ART, and succeeded in erasing 
HIV DNA from the genes of the mice. Dr. Kamel Khalili39 who co-authored the study 
commented, “We think this study is a major breakthrough because it for the first time 
demonstrates after 40 years of the AIDS epidemic that the HIV disease is a curable disease” 
(Turner, 2019). Of course, not all that works well in mice necessarily works well in humans. 
And, of course, the absolute safety and efficiency of the procedure has to be ascertained. But 
the study gives hope that genetic therapies have capacity to cure patients of HIV-AIDS in the 
near future. 
The argument here is that, with so much progress already made in scientific research, 
with strong indications of possible success, save for necessary improvements and appropriate 
further tests, it is more prudent to proceed with the development of genetic therapies than to 
create hurdles and push backwards. There seems to be too much positive progress to allow for 
a reversal of the efforts made in recent times. If ever the invested funds were to go to waste, it 
would be better to “waste” the funds making progress towards perfecting these milestones than 
to waste the same by a halt of any activities due to the fear of the unknown. The current 
headways in genetic therapies provide much hope on the perhaps imminent development of 
genetic therapies against HIV-AIDS, especially for Africa which bears the greatest burden of 
the disease. 
                                                          
38 “A microbicide, according to the World Health Organisation, is a substance applied inside the vagina or rectum 
to reduce the transmission of sexually transmitted infections, including HIV… It works by lowering and stabilising 
the environment at levels that are too acidic for HIV to survive” (Nation Media Group, 2019). 
39 Dr. Kamel Khalili is the chair of the Department of Neuroscience and Director of the Center for Neurovirology 





I have established the desirability and ethical appropriateness of the proposed use of 
genetic therapies. To establish the benefits of such therapies, I have argued in support of the 
necessity to develop and apply them in the treatment of HIV-AIDS in Africa. I have presented 
arguments from the nature of human genes, the potential of genetic therapies, 
communitarianism, theological ethics, justice, cost-based arguments, current limitations of 
treatments through ARVs and HAARTs, affirmation of good parenthood, unfounded hostility 
towards genetic therapies, and current headways in the development of genetic therapies, all to 






CHAPTER 7: EVALUATION AND RECOMMENDATIONS 
7.1. INTRODUCTION 
In this final chapter I provide an evaluation of the arguments against and in favour of 
genetic enhancement therapies in order to determine their relevance and their ethical 
implications on the health situation in Kenya. As part of the discourse, I evaluate the magnitude 
of HIV-AIDS in Africa, especially Kenya, as well as the necessity and suitability of genetic 
therapies as solutions to the problem. I also give a utilitarian assessment of the challenges of 
genetic therapies and an appraisal of the same therapies for HIV-AIDS, before making 
recommendations. 
7.2. MAGNITUDE OF HIV-AIDS IN AFRICA, ESPECIALLY IN KENYA 
The extent to which HIV-AIDS has impacted Africa in general, and Kenya in particular, 
is the subject under discussion in Chapter 1 of this dissertation, although a brief recollection 
may be useful here. While the population of Kenya in 2016 was 48.46 million, the estimated 
prevalence of HIV among people of ages 15 to 49 was 6.9%, resulting into about 31,000 deaths 
and 840,000 orphans from AIDS in the same year. It was also reported that about 940,000 
people were receiving antiretroviral therapy (ART) (CDC, 2019). By 2018 it was estimated 
that there were 1,493,382 Kenyans living with HIV, with new infections standing at 52,767, 
and deaths at 28,214 in that year (Oketch & Kilonzo, 2018). The rest of the world has not done 
any better. “In 2017 an estimated 36.9 million people were living with HIV (including 1.8 
million children) – with a global HIV prevalence of 0.8% among adults. Around 25% of these 
same people do not know that they have the virus.” It was reported that the vast majority of 
people living with HIV are “...located in low- and middle- income countries, with an estimated 
66% living in sub-Saharan Africa. Among this group 19.6 million are living in East and 
Southern Africa which saw 800,000 new HIV infections in 2017” (Sidibé, 2018).  These 
statistics continue to confirm that Africa bears a large and disproportionate burden of the HIV-
AIDS scourge. All cadres are directly or indirectly affected by the disease. It remains of 
concern that in sub-Saharan Africa, “...three in four new infections are among girls aged 15–
19 years and young women aged 15–24 years are twice as likely to be living with HIV than 
men” (Sidibé, 2018). 
Whether one is studying the general situation in Africa of the specific situation in 
Kenya, the likely observation is that HIV-AIDS remains a formidable health challenge in both 




AIDS. It continues to kill millions who leave destitute dependants behind. It also continues to 
affect the economic capacity of the population to produce and engage in development. Kenya 
is, specifically, of concern because, together with Mozambique and Uganda, it shares the 
position of being the fourth largest bearer of the HIV-AIDS epidemic burden in the world. The 
human resource capacity in Kenya, and further on in Africa, continues to suffer from the impact 
of HIV-AIDS. The illness is an issue that cannot be simply wished away. It is also quite clear 
that ARVs or HAART are only a temporal means for quelling the illness while leaving the 
problem alive and unhindered. In reality, therefore, there is no cure for HIV-AIDS. 
The situation is getting worse, rather than better, with recent reports indicating that “an 
alarming surge in resistance to crucial HIV drugs” had been observed. 
Surveys by the World Health Organization (WHO) reveal that, in the past 4 years, 12 countries 
in Africa, Asia and the Americas have surpassed acceptable levels of drug resistance against 
two drugs that constitute the backbone of HIV treatment: efavirenz and nevirapine. People 
living with HIV are routinely treated with a cocktail of drugs, known as antiretroviral therapy, 
but the virus can mutate into a resistant form (Mega, 2019). 
 
The WHO carried out the surveys from 2014 to 2018 in selected clinics in 18 countries, and 
concluded that “…more than 10% of adults with the virus have developed resistance to these 
drugs in 12 nations” (Mega, 2019). The organisation now says it is “not considered safe to 
prescribe the same HIV medicines to the rest of the population, because resistance could 
increase” (Mega, 2019). In those surveys, sub-Saharan Africa showed the highest level of 
resistance in infants with HIV. This report reinforces the notion that the magnitude of the HIV-
AIDS scourge remains alarming and in need of a more effective solution than currently 
available. 
It is clear that the magnitude of the HIV scourge is devastating, especially in the context 
of drugs that neither cure nor remove the disease from the human community. In this situation, 
what kind of solutions should scientific medical research endeavour to provide for Africa? It 
is imperative for governments in Africa to prioritise the problem of HIV-AIDS and seek 
solutions in the same way European nations had to put plans in place in fighting against Black 
Death and other plagues, actions that led to the saving of European populations at the time. 
There is renewed need to remind Sub-Saharan governments that millions of the population are 
sick with HIV-AIDS, for which there is actually no cure. In addition, workers are incapacitated 
and many die; economic challenges affect families and cause poverty; the cost of doing 
business increases and affects the economy; poverty and hunger continues to ravage the 
continent; child and maternal mortality in relation to HIV-AIDS continues; AIDS continues to 




and the economies of African nations, including Kenya, continue to experience the effects of 
the disease. It is not possible to talk about health among African populations without reflecting 
on HIV-AIDS. The magnitude of the problem is huge, and cannot be ignored. It cannot be 
assumed any more that ARVs and HAARTs will solve the problem, or that the problem will 
somehow simply go away. With Africa carrying 70% of the HIV-AIDS burden, and with 
Kenya being among the leading countries with infected and affected populations, the country 
needs to take serious note of the problem and put plans in place to not just reduce the infections 
but actually eliminate the disease. 
An understanding of the magnitude of the disease should lead to the conclusion that a 
continuation of the disease in infecting the people is a serious form of harm. Furthermore, it is 
also important to consider if the use of ARVs and HAART, which help patients to manage their 
lives and enable them to live active lives, but without actually providing a cure, is also a form 
of harm. If both are a form of harm, then there is need to deal with HIV-AIDS beyond the 
provision of ARVs and HAART. In the first instance, HIV-AIDS is harmful to the people in 
many ways, as already previously discussed. I hasten to add that additional harm occurs as 
governments simply express satisfaction with providing ARTs to the people, and no longer 
seek to eliminate the disease. Although the government is not responsible for causing the initial 
harm, since the government does not promote infection, and although the government acts 
benevolently by providing ARTs and HAART to the sick, failure to draft any plans for the 
elimination of such a highly devastating illness is a serious form of harm to the citizens. 
Furthermore, a good idea always gets overtaken by a better idea that emerges, especially where 
the magnitude of the problem clearly calls for a better idea. 
The other question that needs attention is that of whether the magnitude of HIV-AIDS 
in Africa in general, and Kenya in particular, is of such significance as to warrant attention in 
a utilitarian understanding. Granted that not all health problems necessarily affect the majority 
in a given population, and certainly HIV-AIDS is not affecting everybody in Africa in any 
direct way. However, a health challenge, especially a devastating illness, draws the attention 
of a utilitarian philosopher due to the effects of the disease on the people. A solution to the 
scourge of HIV-AIDS will definitely bring much happiness to the infected people and their 
families, besides giving them relief from pain, discomfort, and anxiety, while at the same time, 
causing no additional harm to the people. Indeed, it can be said with certainty that no African 
nation will be left out of the resultant happiness and fulfilment when a lasting solution will be 




is primarily felt in Africa should be worthy of attention, planning, and investment by African 
governments. That will be an excellent utilitarian achievement. 
7.3. NECESSITY AND SUITABILITY OF A GENETIC THERAPY SOLUTION 
For an idea or a thing or an experience to be necessary, it has to be vital for certain 
events or conditions to continue or to thrive. It is essential, obligatory and basic. An example 
would be the way life would not continue without food. Hence food is a necessity to life. Water 
and air belong to the same category, and are necessities. In logic, the term necessity would refer 
to three ideas: a proposition which, if denied, would lead to a self-contradiction; an inference 
or an argument whose conclusion cannot be false if its supporting premises are true; and a 
condition which “must exist if a given event is to occur or a given thing is to exist” (Blackburn, 
2008, p. 71). It is in this third sense that I make reference to the term necessity with regard to 
genetic therapies as solutions to the HIV-AIDS pandemic in Africa. I will argue that the 
development and realisation of genetic therapies is a condition that needs to exist if the world, 
especially Africa, is to become completely free of HIV-AIDS. For now, it is also necessary to 
clarify that suitability refers to something deemed appropriate for meeting a need or resolving 
a problem. It is right and befitting for the purpose for which it is intended; something that is 
correct and befits the situation. The idea also has the connotation of timeliness and 
convenience. I will further develop this idea in arguing that genetic therapies are suitable for 
resolving the HIV-AIDS disease. 
It is a necessity for genetic therapies to be brought into reality and functionality in the 
world in general and in Africa in particular, if HIV-AIDS is to be stamped out and good health 
is to be realised. In other words, genetic therapies are not merely an idea that people should 
imagine or wish for; it is not a concept that belongs to the domain of science fiction any more. 
Rather, it is a necessity. It may have actually become an absolute necessity, without which 
human life can no longer proceed as we know it. Since Africa is home to 15% of the world’s 
population, it is necessary to pay attention to any health challenges facing the continent. 
Resolving the HIV-AIDS disease in Africa relieves a significant percentage of humanity of a 
huge threat to human survival and well-being. And since Africa bears 70% of the world’s HIV-
AIDS burden, eradicating the disease from Africa relieves the world population of one of the 
worst health challenges the world has ever faced in modern world. Surely, it makes utilitarian 
sense for genetic therapies to be applied into ensuring that 70% of those who are infected by 
HIV-AIDS get cured, and possibly their descendants will never have to get infected. Already 




regard to CRISPR, with significant investments in terms of time, money, and human resource 
capacity. The scientific community cannot be going to such great lengths only for the sake of 
the 30% sufferers in the rest of the world, although even the suffering of the 30%, for sure, 
deserves attention. From a utilitarian perspective, the substantial scientific and technological 
investment in genetic therapies will lead to the greatest happiness for the greatest number of 
HIV-AIDS patients when it applies to Africa. 
Genetic therapies are suitable for resolving the problem of HIV-AIDS in Africa and 
meeting the health needs of a fairly large segment of the population. The suitability of genetic 
therapies is strategic in the context of previous and existing attempts at dealing with the 
problem. Such attempts include the promotion of abstinence from premarital and extramarital 
sex, the building up of faithfulness as a virtue in marital relationships, the use of condoms to 
prevent HIV infections, and the use of ARVs to sustain the lives of those already infected with 
the virus. Yet it has to be noted that if these attempts had been successful in dealing with HIV-
AIDS there would have been significant decline in the number of infections. Indeed the 
problem would have been solved decades ago, especially when ARVs were introduced. 
Mother-to-child infections should not be happening any more. Abstinence and faithfulness are 
excellent ideas if self-control were an enduring virtue in all African peoples. But I would be 
stretching my imaginations too far if I ever claimed that African peoples were paragons of 
virtue. Therefore, both abstinence and faithfulness can be classified as ideal and suitable but 
only rarely effective for HIV-AIDS. They cannot be relied on to provide cure. In theory, if 
abstinence and faithfulness were efficiently practised, it would be possible for all the infected 
people to die in a given span of time, and leave a population devoid of the illness. But this is 
an impractical theory that remains largely ineffective. They are not befitting for the purpose 
for which they are intended, as they do not help the majority. Condoms, too, should be a great 
solution under the assumption that they are used properly in all sexual engagements. But it has 
been said that some people even recycle them; and some men even wash them and pass them 
on to their friends, a clear illustration that the correct use of these items is still far from 
becoming reality. Where they have been used well, they have helped in the reduction of 
sexually transmitted diseases as well as unplanned pregnancies. But their use as a prevention 
against HIV has not resulted into a significant reduction in new infections. To claim that 
condoms are truly effective would be a stretch of human imagination. The last category of 
attempted alleviations come from ARVs which boost bodily functioning without providing a 





Although the development of genetic therapies for HIV-AIDS is still far from 
conclusive reality, the potential for both somatic and germline treatments gives hope that is 
otherwise lacking in all prevailing attempts at dealing with the disease efficiently and 
conclusively. Somatic genetic therapies, as discussed in detail earlier, will eliminate HIV-AIDS 
in the patient, although without insulating the future generations from infections. But even with 
that comes a clear possibility of actually eliminating the disease from the population. If 
governments in Africa will join in funding the on-going research, and later engage in 
supporting the production and distribution of the resulting somatic genetic therapies, it is 
possible for all the people currently infected with HIV to get cured completely. I must add that 
germline genetic therapies will only make it better by ensuring that future generations will not 
get infected because they will have not inherent capacity to get infected. Of course, there are 
still numerous scientific challenges to be resolved before these therapies can become a medical 
reality. But for a virus such as HIV which continually mutates and defeats the development of 
conventional medicines for treatment, genetic therapies are the right and befitting solution 
which will also be most convenient. And for the sufferers and their families, genetic therapies 
will also be timely.  
7.4. A UTILITARIAN ASSESSMENT OF THE CHALLENGES OF GENETIC 
THERAPIES 
In this section I do not intend to recount or narrate the arguments raised against genetic 
therapies, a task already carried out in Chapter 5 of this dissertation. Rather, I intend to develop 
a utilitarian assessment of the challenges in order to make rational conclusions on their validity 
or otherwise, based on the three basic tenets of utilitarianism: that happiness is the only idea 
that has intrinsic value; that actions are right when they promote happiness and wrong when 
they cause pain; and that everyone’s happiness counts equally. From this perspective, 
challenges posed by genetic therapies should be considered valid if they prove that genetic 
therapies work against these three principles of utilitarianism. If pleasure is to be sought after, 
pain is to be avoided.  Firstly, to say that pleasure is the only thing that has intrinsic value is to 
say that pleasure is good in itself, and that a world in which pleasure exists is a better world 
than a world without pleasure. Secondly, to say that right actions are those that lead to 
happiness and wrong actions are those that cause pain is to place emphasis on consequences of 
actions. An act that causes greater happiness among a greater number is better than an act that 
causes happiness in just one person. When the focus is on only one person then the right act is 




pain in the same person. But it is not only the consequences of an act that counts, but the 
motives of the agent as well. In this case, generosity motivated by compassion is much better 
in a utilitarian context than a similar act motivated by desire for popularity for the giver. 
Thirdly, if everyone’s happiness counts in equal measure, the life of one person is not more 
important than the life of another person. In other words, the life of a king is as important as 
the life of a peasant. For example, a good utilitarian health policy is the one that will provide 
for health services to the citizens without regard to social or economic status of anyone 
involved. 
This understanding should lead to the question of whether the challenges posed by 
genetic therapies cause pain and harm, thereby acting against the pleasure of the many. I will 
now assess arguments raised against genetic therapies, such as slippery slope arguments, 
naturalistic arguments, economic justice arguments, arguments from lack of consent, and 
theological-ethical arguments, all of which are discussed in Chapter 5 of this dissertation. These 
clusters of arguments postulate on the challenges, real or imagined, of genetic therapies. 
   Slippery slope arguments hold the idea that accepting a form of genetic therapy will 
cause temptation to initiate other forms of therapy that are morally much more dubious. If 
genetic therapies are accepted for the treatment of HIV-AIDS, the same therapies may be 
sought after to resolve other challenges in human life. Fear is an important tool of trade in 
slippery slope arguments: the fear of making improved or superior human beings, the fear of 
re-introducing eugenics, and the fear of opening up new frontiers in medicine. These fear 
factors need closer examination before a conclusion is reached on the validity of the arguments. 
Firstly, there is fear that success in treating HIV-AIDS using genetic therapies will lead to 
attempts to improve human life through, for instance, curing baldness, suppressing obesity, 
eliminating poor eyesight, improving physical and intellectual performance, and 
technologically enhancing the human race in other areas. The glaring failure of most slippery 
slope arguments is in not showing what harm is caused by such envisioned improvements. For 
example, if genetic therapies will be used to cure poor eyesight, it is extremely difficult for a 
rational person to explain how such an act could be harmful, against all obvious indications 
that the act would cause happiness to the recipients of such genetic treatment. Similarly, if the 
use of genetic therapies were to tempt humans on a slippery slope into improving intellectual 
capacity, humans would only be happier to develop higher capacity to solve their problems. 
This, in turn, would cause greater happiness among those who would receive such capacity. It 




happiness to the entire human race. Secondly, there is the fear of re-introducing eugenics, like 
in the Nazi days, through genetic science, a fear that has no reliable basis at present. 
In Nazi Germany, there was “the frightening series of coerced medical experiments and 
the severe violations of human rights, not only in relation to Jews, gypsies and ‘people of 
colour’, but, particularly, in relation to people living with disabilities... there are alarming signs 
that old-style eugenics is apparently still looked upon favourably by even some modern-day 
policy-makers such as those in Singapore, Malaysia and even China” (Van Niekerk, 2018, p. 
35). If the utilitarian goal of genetic science is to cause happiness through elimination of 
suffering and enhancement of positive traits, the same genetic science would not at the same 
time seek to cause painful human experiences motivated by racism. In any case, given the 
challenges from past experience, it is now easier to mobilise world governments to legislate to 
control genetic therapies so that they are not turned into enhancement experiments with racial 
undertones. Thirdly, there is the general fear of getting into new frontiers in medicine. This is 
exemplified by the slow acceptance of somatic gene therapy by regulatory committees due to 
perceived relative safety, while holding off on germline therapy due to perceived greater risk. 
However, medicine is a discipline that continues to evolve and grow on the basis of new ideas 
and developments. Indeed, the history of medical science is lined up with encounters of 
resistance to new advancements that were feared at introduction because very little was known 
about them. But later, with more knowledge and widespread use, the same medical 
technologies gained acceptance, and are today taken for granted. Newness is always greeted 
with hesitation and scepticism. I conclude that slippery slope arguments are mostly speculative 
and do not give evidence of harm likely to occur if genetic therapies are developed and 
implemented to cure and eliminate HIV-AIDS. The arguments themselves seem to be more 
harmful in seeking to prevent the use of genetic therapies to solve a human problem and cause 
happiness to a significant population. 
The next cluster of arguments against genetic therapies is naturalistic arguments which 
hold to the following key ideas: that genetic therapies are not natural; that genetic therapies 
interfere with how humans are constituted; that human beings are genetically complex; that 
there is no moral obligation to genetically modify human beings; that there is a good side to 
human bodily weakness; and that procreation is supposed to be a natural process. These 
arguments do not forecast beyond the natural, and may appear to promote the maintenance of 
the status quo with regard to how human beings deal with problems. To argue that genetic 
therapies are not natural is to put forward assumptions that only the natural is good, and that 




natural is good is to assume that nothing good is obtainable from the artificial which is not true, 
given the numerous artificial machines, vehicles, equipment, and facilities that human beings 
have become so dependent on for efficient functioning. These artificial developments have 
caused much happiness in human life. To imagine that the natural is always good is to ignore 
the devastating turbulence and destruction that natural calamities visit on human beings from 
time to time. Nature has sometimes been a source of great pain to human beings. An item or 
an idea does not have to be natural to be of such value or quality as to cause great happiness to 
human beings. 
There are two examples of how nature has previously caused misery, pain, and death to 
human beings. The first example is the Tuskegee syphilis experiment that was conducted from 
1932 to 1972 by the US Public Health Service. It was an observational study of the natural 
progression of untreated syphilis among Africa-American men while, all along the men were 
lied to that they were recipients of free treatment from the government (Nix, 2017). Although 
penicillin was already an available form of treatment for syphilis, nature was left to take its full 
course in this research as a result of which many participants died while others went blind or 
insane. The Tuskegee story is a sad one that warns us of the terrifying dangers of a let-nature-
take-its-course attitude towards disease. The second example is that of the influenza pandemic 
– also known as the Spanish flu – that infected about 500 million people around the world 
between January 1918 and December 1920, killing about 50 million. This was a disease that 
broke out from unknown quarters and progressed naturally as people made contact with others 
through sneezes and coughs. The situation was made worse by the on-going world war at the 
time (CDC, 2019). The Spanish flu was a terrifying disease that wiped out populations without 
much warning, and exposed the helplessness of humans when confronted with strange 
debilitating illnesses. 
The argument that genetic therapies interfere with how humans are constituted is a valid 
one in the sense of pointing out a fact. In other words, genetic therapies affect and alter the 
normal bodily functioning of a human being. This argument goes together well with the 
subsequent two arguments: first, that human beings are genetically complex and secondly, that 
there is no moral obligation to genetically modify human beings. It is admissible that any effect 
on the body that leads to deformation or disability or mental degradation or failure of bodily 
organs would be wrong. Furthermore, if the genetic therapy would change the formation of 
what is known as human, it would be wrong too. For instance, if in an extreme case of bodily 
malfunction someone were to develop an additional eye and a third leg, that sort of genetic 




in discussing about genetic therapies, the focus is not on changing the way humans look or 
function. Rather, the focus is on correcting the genetic structure in order to develop capacity to 
evade certain diseases, such as HIV-AIDS. This is an intention that is likely to cause greater 
happiness among those who have experienced the devastating impact of incurable life-
threatening illnesses quite in the same way as vaccines have helped reduce or eliminate certain 
diseases. Of course, there is a good side to human bodily weakness; but bodily weakness should 
never be a desirable state of life. Bodily weakness should be something that catches up with 
us, rather than something we seek after. Human beings should naturally seek to remain healthy, 
be able to work, and be able to function in a regular way in order to remain fulfilled and happy. 
Any scientific procedure that gives an assurance of that should receive requisite approval. It is 
agreeable that, in an ideal world, procreation is supposed to be a natural process. However, 
modern medical science has developed fairly adequate technological interventions, such as in 
vitro fertilisation, artificial insemination, and surrogacy that have resolved human infertility in 
modern times in unprecedented proportions. As van Niekerk has suggested, although care and 
responsibility must be taken seriously, it is not proper that “science and technology could or 
should be stopped in its tracks…” (Van Niekerk, 2018, p. 35). Despite the moral challenges 
associated with some procedures in some specific contexts, these procedures have largely 
reduced the pain of childlessness, while at the same time increasing happiness in families. 
Human beings can no longer consistently argue against artificial interventions in an age in 
which transport, medicine, education, commerce, agriculture, housing, and numerous other 
aspects of human life are run by sophisticated technology. 
Distributive justice arguments focus on challenges that are likely to come with the 
introduction of genetic therapies in a Sub-Saharan country like Kenya where there is 
understandable need to prioritise on less costly but common health needs, rather than the long-
term and costly ones. In Kenya, like in other countries in Africa, numerous deaths still occur 
from malaria, TB, and water-borne diseases. Although these diseases are curable and 
preventable, resources for treatment and prevention campaigns are not sufficient. Research in 
genetic therapies is, therefore, viewed as an unaffordable luxury and a dream. Available 
resources would rather be spent on infrastructural development. However, the government of 
Kenya and other African governments should view this matter differently in order to cause the 
greatest happiness possible for the people. Rather than attempt to prioritise the more affordable 
health concerns at the neglect of research into genetic therapies, it is possible to invest 
comprehensively in all the concerns, including research in genetic therapies for HIV-AIDS. It 




and preventing the common tropical diseases, only for the same people to continue to suffer 
from the effects of HIV-AIDS, which would be a case of replacing one form of pain with 
another. The priority choices should be between comprehensive health policy that includes 
supporting research in genetic therapies, rather than between affordable health concerns and 
expensive ones. 
A continuation of the challenges related to economic justice will raise the twin points 
of economic power as a means for gaining genetic treatment on the one hand, and resultant 
discrimination between treatment recipients and non-recipients on the other hand. As discussed 
earlier in Chapter 5, genetic therapies are expensive to develop and produce; once made 
available in the market, they will be expensive to administer too. This means only wealthy 
people will afford them, which is a form of economic injustice. However, it may be argued that 
all human life is lived on the basis of affording or not affording certain things. Good things 
should not be kept away from the market just because some people will not afford them. 
Governments do not stop constructing roads because some people will not drive on them. 
Similarly, hospitals are built, equipped, and staffed, even if some people will never fall sick. 
In any case, the Kenya government should be encouraged to classify the treatments and develop 
cost-sharing mechanisms. For example, the government can undertake to provide government-
funded treatment to everyone who has HIV infection using somatic genetic therapies, but leave 
germline genetic therapies to individuals who desire them and can afford them. In this way, the 
choice to eliminate HIV-AIDS from the people will be a government responsibility, while the 
choice to eliminate the potential of one’s children to contract HIV will be the choice of the 
individuals. Public funding for the somatic treatment can be sourced from taxes, insurance, and 
donor aid. If the government funds somatic genetic therapies, then there will be no inequality 
in the access to the treatment, and discrimination will not arise against those who will have not 
been treated with the same technology. Individuals who will elect to go the extra mile and take 
up germline therapies will be simply perceived to be seeking something better that they can 
afford. In this way, the utilitarian calculus will have been fairly applied, and the majority will 
be happy. 
The challenge of lack of consent from future descendants is one that can only be 
hypothetical and speculative, and does not address reality. It is possible to approximate that 
what makes existing humans happy will make future generations happy too, if all other life 
factors will remain the same. Parents may save resources for their unborn children without 
having to worry that the assets will not please the children. If it is agreeable that disease is a 




AIDS is a good act whose results should result into great happiness among the future 
generations. In the present generation, people make choices that lead to the elimination of 
certain disease-causing traits, and no child complains after birth that they had been denied 
opportunity to have a bad experience. In any case, it is not right to subject the existing 
generation to such a serious illness as HIV-AIDS only for the reason of respecting the future 
generation’s supposed right to consent. If for some strange reason, the world were to come to 
an apocalyptic end before the future generation were born, surely the existing generation should 
have a happy ending for themselves, such as ending the scourge of HIV-AIDS. The future is 
planned for by those who exist now; those who are yet to exist are beneficiaries of decisions 
and developments brought about by those who live now. Surely no one would be counted as 
reasonable for withdrawing from Law School on the account of lack of assurance in knowing 
whether it would be in the best interest of future children to be born into a family of practising 
lawyers. No one really knows for sure what the preferences of future generations will be, so 
decisions made that affect them are on the basis of the experiences and preferences of the 
existing parents. It should also be understood that consent is a contract agreement that has to 
be withdrawable if its terms and conditions are violated by either party involved. If genetic 
therapy works against the interests of an unborn person, that unborn person should be able to 
seek legal redress in a valid court of law. If the unborn will not sue on their own, those who 
sue on their behalf do so in their own interests and not those of the unborn. It is a complication 
that is realistically unnecessary.    
The Creator-creature distinction that forms an integral part of the theological-ethical 
arguments against genetic therapies is an essential belief in the monotheistic faiths of Judaism, 
Christianity, and Islam. The emphasis is placed on the incomparable difference between God 
as the Creator and humans as the creatures. It is a doctrine that subdues humans into finitude 
in knowledge and science, while at the same time barring humans from attempting to do what 
only God can allegedly do. Human activity must never undermine the authority of God, and 
humans must not “play God” in scientific efforts like genetic therapies. As a person who 
believes in God, I agree with this idea fully. However, it is reasonable to rationally conclude 
that God has endowed human beings with a creative capacity that is not found in other 
creatures. The creative capacity in humans is evident in science, architecture, art, music, 
technology, engineering, education, and medicine. Indeed, human capacity for creativity has 
caused much development and progress in the modern world. For example, instead of creating 
roads for us, God gives us engineering and technological capacity – through education and 




for entertainment, God enables us to create music and drama for ourselves. And rather than 
preventing diseases from attacking us, God allows them to attack but also gives us medical 
knowledge to treat them.  
The idea that God seeks the happiness of humans has been linked with utilitarianism in 
an argument developed by Bentham who thought that the faithful would endorse the utilitarian 
standpoint if only they viewed God as benevolent” (Rachels & Rachels, 2012, pp. 100-101). 
Bentham decried the small number of believers who were truly consistent in their belief in 
God’s benevolence, and went further to appeal to the faithful to not only talk about God’s 
benevolent character but to actually emulate the same in their own lives (Rachels & Rachels, 
2012, p. 101). John Stuart Mill also said 
If it be a true belief that God desires, above all things, the happiness of his creatures, and that 
this was his purpose in their creation, utility is not only not a godless doctrine, but more 
profoundly religious than any other. If it be meant that utilitarianism does not recognize the 
revealed will of God as the supreme law of morals, I answer that a utilitarian who believes in 
the perfect goodness and wisdom of God necessarily believes that whatever God has thought fit 
to reveal on the subject of morals must fulfil the requirements of utility in a supreme degree 
(Mill, 1979, p. 21). 
For Mill, subscribing to utilitarian ethics is not necessarily equivalent to being anti-religion, 
and utilitarianism should not be a threat to religion. As Rachels & Rachels point out, “…the 
classical utilitarians did not think they were advocating an atheistic or antireligious philosophy. 
God, in His benevolence, wants His creatures to be happy, so He acts towards them to promote 
their happiness. This may mean that those who act in ways that bring happiness to other people 
act in God’s interest. In the context of this dissertation, acting in God’s interest would be to 
develop genetic interventions for HIV-AIDS and make them available for the treatment of 
patients. Allowing an illness to prevail and cause pain and death under the guise of refraining 
from “playing God” would be the height of religious hypocrisy. Ending a disease like HIV-
AIDS through genetic therapy would not only please human beneficiaries but also please God 
who created humans and endowed them with knowledge to do so.   
7.5. A UTILITARIAN APPRAISAL OF GENETIC THERAPIES FOR HIV-AIDS 
In this section I review and give an appraisal of genetic therapies for HIV-AIDS using, 
as in the previous section, the three foundational principles of utilitarianism: that happiness is 
the only idea that has intrinsic value; that actions are right when they promote happiness and 
wrong when they cause pain; and that everyone’s happiness counts equally. In this context, 
arguments in favour of genetic therapies for HIV-AIDS should enable us to appreciate such 




Firstly, the similarities that exist in the genetic makeup of humans and other living 
things should assure humans that the safety of new medical technology, once proven on certain 
living organisms and animals, can be tested for efficacy on humans without extraordinary risk. 
The role of regulatory bodies is to provide a framework that will lead to proper development 
of safe genetic therapies and supervised clinical trials in order to assure the human population 
of the validity and safety of these new technologies. If the objective of the genetic science is to 
eliminate pain and suffering, and to ensure that more people live long, healthy, and happy lives, 
that is the greater good and is what governments and regulatory bodies should work to promote. 
In any case, since the human genome evolves and is subject to mutations, it is not the duty of 
governments and regulatory committees to protect the DNA, as genetic therapies are only an 
enhanced version of what the body already does naturally. 
Secondly, the possibility is there for genetic therapies to provide cure for illnesses for 
which there is no known cure, such as HIV-AIDS. While some people may think that stem cell 
treatments and bone marrow transplants for certain specific illnesses may be the better way to 
go, there is need to remember that such alternatives are individualised and are beneficial to 
only singular patients. It should be preferable to develop genetic therapies which have the 
potential for benefitting the entire country of Kenya, the continent of Africa, and the world at 
large, by eliminating HIV-AIDS and protecting future generations from it, thus causing longer, 
happier, and satisfying lives.   
Thirdly, genetic therapies for HIV-AIDS have the potential for enhancing the 
communal nature of human beings. The deadly virus causes harm to individuals, an impact 
which ends up affecting the community and the world as well. A permanent cure for HIV-
AIDS will enhance global peace and good health. Future generations will be disappointed to 
learn that the present generation were on the verge of developing genetic solutions to the HIV-
AIDS complication but fell short of doing so because of fears that were possible to resolve. 
Therefore, Kenya should collaborate with other countries in funding research and involving its 
scientists in order to develop, test, and eventually implement genetic solutions. 
7.6. RECOMMENDATIONS 
This dissertation comes to an end with seven recommendations in which I propose a 
way forward with regard to the relevance of genetic therapies for HIV-AIDS in Africa:  
7.6.1. Developing a Revised View of Facts about HIV-AIDS Treatment 
The first recommendation is the need for a revised view of facts about HIV-AIDS 




patient’s body low enough for the patient to remain strong, the viral load resumes as soon as 
the patient stops taking medication. This is currently the best available treatment for the 
disease, and it is admissible that ‘the best’ is not good enough because it does not provide an 
actual cure from the virus. Given the reports that any failure to adhere to the treatment regime 
results into a relapse which sometimes turns fatal, there is need to re-educate the public in 
general and HIV-AIDS patients in particular about the treatment facts, as well as the risks 
involved in non-adherence to the medication pattern established. It cannot be assumed that it 
is the patients who are either careless or undisciplined. Additionally, apart from re-educating 
patients on following a strict medication regime, there is need to clearly explain to people that 
ARVs are not a cure for HIV-AIDS, while acknowledging the important role they play in 
alleviating the symptoms and lengthening life. Such a situation calls for fast-tracking research 
in genetic therapies which will not only provide cure but also possibly protect future 
generations from HIV-AIDS. 
7.6.2. Propagating a Positive View of Genetic Therapies 
The second recommendation is for the governments of the world to propagate a positive 
view of genetic therapies. Currently, there is general negativity against genetic therapies, 
apparently and mainly because of the uncertainty and mistakes still prevailing in the science 
and research. Governments and regulatory bodies should not, at this stage, make conclusive 
judgements on the efficiency and efficacy of genetic therapies. The mistakes that have occurred 
so far are developmental mistakes which are bound to happen in any new and progressive 
technology that is new to human societies. Reports emanating from researchers are progress 
reports that update the global community on the stages of research. Therefore, the lack of 
polished and conclusive work should not be a basis for propagating fear of genetic therapies. 
Regulatory committees should begin to perceive themselves as helpful monitors of progress, 
rather than as research police whose work is to issue warnings and moratoria.  A positive view 
will help collate much-needed socio-economic support for the on-going research, with the hope 
of properly concluded studies and tests that end up producing reliable therapeutic procedures. 
A positive view will inspire hope and confidence in the scientific processes currently going on, 
and honest mistakes will be corrected as part of a good process. 
7.6.3. Call to Continue with Research and Development of Technologies 
The third recommendation, closely related to the second one previously discussed, is a 
call to the scientific community to continue with research as well as the development of 
technologies that already exist. Continuation of research in technologies such as CRISPR will 




and enhance a desire for perfecting what has already been developed, while also giving hope 
to affected populations. Despite the negative branding of scientists who have made efforts at 
genetic modification of embryos in an attempt to develop genetic therapies for HIV-AIDS, the 
role of science must remain forward looking in order to discover and develop solutions to 
devastating illnesses. With valid caution and monitoring from the relevant committees, it is 
important that research scientists remain focused on the final objective of developing genetic 
therapies into trustworthy methods of treating HIV-AIDS and other debilitating illnesses. 
Continuation will require persistence and focus in order to achieve the desired objective of 
developing a lasting solution for deadly diseases. 
7.6.4. Collaboration in Funding and Doing Research 
The fourth recommendation is for inter-governmental, multi-sectoral, and international 
collaboration in funding the research in genetic therapies. Governments in Africa are prone to 
responding by simply stating that they do not have money for collaborating in such 
sophisticated and expensive research. But it can be argued that African governments can save 
significant financial resources by simply minimising corruption and properly managing public 
finance. Of course, recovered resources from corruption alone may not be enough, but it will 
be significant enough to demonstrate seriousness in desire to eliminate HIV-AIDS from the 
peoples of Africa. Such demonstrated effort is likely to attract global attention, resulting in 
significant if not adequate funding for the research into genetic therapies. Furthermore, I think 
the funds should go to recognised research universities and institutes with demonstrated history 
of achievement in pioneer and cutting edge research, both in the West and in Africa, in 
collaborative arrangements, if genetic therapies are to be made directly focused and relevant 
for the treatment of HIV-AIDS. The collaboration called for here should not be limited to 
funding and international aid for research in Africa, but should be extended to include 
cooperation in research. There is much to be gained in a cooperative approach among scientific 
researchers, including the acceptance and trust that comes as a result of mutual engagement. 
International collaboration will also help remove the perception that Africa could only be 
relevant at the later stage of mass clinical trials. 
7.6.5. Inter-Governmental Commitment Treaties 
The fifth recommendation is for governments to hold inter-governmental meetings 
under the guidance of experts in order to discuss and sign agreements committing themselves 
to use the newly developed genetic therapies for HIV-AIDS in order to bring the pandemic to 
an end in the world. A commitment to usage agreement will ensure justice and equity in the 




available. This recommendation is both preparatory and anticipatory. It is preparatory in the 
sense that inter-governmental discussions and agreements on the usage of the anticipated 
genetic therapies will prepare the people positively for the results of the on-going research into 
genetic therapies. It is also anticipatory in the sense that such discussions re-position 
governments from passive waiting to expectant planners for the use of what research is moving 
the world into with regard to human health, that is, a new state in which humans will no longer 
live in fear of contracting HIV-AIDS because genetic therapies will have eliminated the 
disease. In the same way governments collaborate to deal with diseases like yellow fever and 
polio through vaccination policies that are implemented across borders, they need to cooperate 
to use genetic therapies when they are finally developed and availed.  
7.6.6. Public Education Campaigns on Genetic Therapies 
The sixth recommendation is for governments and non-governmental organisations to 
get actively involved in public education campaigns in order to help people know about genetic 
therapies in simple language. In the process, this approach is likely to aid the therapies into 
gaining acceptance. This can be modelled very much along the same lines as family planning 
and vaccination campaigns that have gone on for decades through public health educators. 
Currently, it appears only a few are even aware that research is going on in genetic therapies 
for certain kinds of diseases. The updates are restricted to academic and scientific journals 
whose content are best appreciated by scientists and interested philosophers. The regular media 
rarely reports on the progress and the challenges, hence the general lack of public awareness. 
It is strategic for governments, non-governmental organisation, universities, communications 
establishments, and international agencies to develop systems and resources for educating 
people in appropriate stages regarding the developments going on in the field of genetic 
therapies. Since the research is currently moving fast, public education needs to begin to 
prepare people now in manageable doses.   
7.6.7. Taking Responsibility in Cases of Failure 
The seventh recommendation is to encourage the scientific community, research 
universities, institutions, and governments, to take responsibility for failure that may arise from 
the implementation of newly developed genetic therapies for HIV-AIDS. If failure will be 
noticed, there will be need for clear explanations on what went wrong and how it may be 
prevented in future. Where appropriate, due compensation needs to be undertaken. This is the 
stage at which health financing policies will need to be re-drafted to take care of expenses 
arising from the need for compensation. It may be advisable to engage with insurance 




help reinforce public confidence in the therapies and will assure people that there are no secret 
cards hidden under the table. I need to clarify that the final responsibility for the genetic 
therapies for HIV-AIDS should rest with the governments of each country, separately and 
corporately. In order to get ready to take such responsibility, it is important that experts and 
policy makers begin to discuss various aspects of the therapies, not necessarily to arrive at 
conclusions, which would be premature as of now, but to begin to think and plan for what is 
coming and how certain aspects may need government intervention and responsibility. In this 





CHAPTER 8: CONCLUSION 
This research set out to establish the appropriateness of genetic therapies for the 
treatment of HIV-AIDS and alleviating the burden created by the disease in order to encourage 
the Kenya government and other African governments, together with their partners from the 
developed world, to carry out research on these technologies and develop them for the benefit 
of the majority of Africans. This objective was motivated by the present reality of having no 
known cure for HIV-AIDS in the whole world. A review of the health crisis in Kenya in 
Chapter 2 provides clarity on basic facts about the country’s healthcare system, especially in 
relation to the problem of HIV-AIDS, including some on-going research. 
In the third chapter there is a comprehensive review of genetic therapies which are 
necessary because any available treatment for HIV-AIDS is only temporal and does not cure 
the illness. A distinction is made between somatic and germline genetic therapies as different 
but potentially effective cures for the illness. Special attention has been given to CRISPR Cas9 
because, so far, it is the only technology close to providing real treatment for HIV-AIDS 
although there is need for caution and further development.  
The ethics theory of utilitarianism was chosen for addressing the problem because there 
was need to evaluate if genetic therapies would have justifiable benefit-sharing for the people, 
with minimum negative consequences. The motivation behind this choice was the desire by 
research scientists to turn misery into good health, pain into happiness, and shame into dignity. 
Given the magnitude of the problem and how it affects a large portion of the African 
population, and given the potential that the results of any genetic therapies will affect many 
either positively or negatively, a utilitarian evaluation was taken as the most suitable. 
From a utilitarian perspective, when (not if) genetic therapies will be made available 
for the treatment of HIV-AIDS, three utilitarian benefits will be realized: the patient will be 
cured; the descendants of the patient will be prevented from inheriting the disease; and future 
societies will be saved from a devastating disease burden. 
Although Chapter 5 enumerates a few arguments advanced against genetic therapies, 
the succeeding Chapter 6 presents valid arguments in support of the therapies, in addition to 
later assessments in Chapter 7 which give weight to the necessity of the therapies from a 
utilitarian perspective. The dissertation argues and concludes that genetic therapies will lead to 
elimination of misery and pain caused by HIV-AIDS, thereby causing greater happiness in 
Kenya, in Africa, and in the world. Therefore, there is sufficient justification in investing both 




The dissertation ends with recommendations that call on governments, research 
universities, research institutions, and regulatory agencies to seek collaborative arrangements 
in order to support on-going research into genetic therapies, propagate a positive view of the 
developing genetic therapies, continue with the research to the best possible standards, to enter 
into agreements supporting the use of the therapies once fully developed, to get involved in 
educating the public about genetic therapies, and to take final responsibility in case certain 
aspects of these treatments do not turn out as expected. In view of these recommendations, 
research into genetic therapies is viewed as the most viable solution to the effects of HIV-AIDS 
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